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Abstract 
Peptide-based therapeutics have been an active area of research for a number of 
years. They have been found applications as drug-delivery agents, anticancer 
therapies and as antibiotics, the latter of which is particularly notable when set against 
a present-day backdrop of the increasing problem of antibiotic resistance. However, the 
use of peptides is still limited as they suffer from poor bioavailability as a result of their 
vulnerability to proteolytic degradation. Peptoids are a class of peptidomimetics which 
represent a potential proteolytically stable alternative to peptides. Chapter 1 introduces 
peptoids, common methods of their synthesis and their potential therapeutic 
applications. The challenges associated with controlling peptoid secondary structure 
are also discussed, along with commonly seen methods of imposing conformational 
rigidity. Chapter 2 details our attempts to address this problem by synthesising a library 
of biaryl-containing cyclic peptoids which represent novel peptoid scaffolds. In Chapter 
3, we synthesise the active domain (p15) of the known anticancer peptide CIGB-300 
along with three stapled analogues on which binding assays can be carried out. In 
Chapter 4, we synthesise six cell-penetrating peptoids (CPPos) which have previously 
been reported to localise in mitochondria. Onto these peptoids we conjugated the 
known anticancer peptide D-KLA and show the ability of these peptoids to increase 
proapoptotic activity. Flow cytometry and confocal microscopy is then used to 
demonstrate mitochondrial localisation of the most active peptide-peptoid hybrid, KLA-
CPPo6. Having shown the ability of CPPos to transport biologically active cargo, we 
then conjugate the p15 peptide, previously introduced in Chapter 3, to the six CPPos in 
preparation for the evaluation of their anticancer activity. 
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Chapter 1 
Introduction  
1.1 Peptoids vs Peptides 
N-Substituted glycines, or peptoids are a class of peptidomimetic where the side chain 
is located on the nitrogen of the amide bond rather than the α-carbon (Figure 1.1).1 
 
 
 
 
Figure 1.1 Comparison of the structure of peptides and peptoids.  
As with peptides, peptoids are oligomeric and contain side chains which may comprise 
a variety of functional groups. However, the presence of the side-chain on the nitrogen 
precludes the backbone hydrogen bonding which is responsible for the secondary 
structures seen in peptides.2 The result of this is a number of differences in the physical 
and biological properties of peptides and peptoids. For instance, peptoids are highly 
resistant to enzymatic degradation; a significant problem in the application of peptide 
therapeutics.3, 4 However, the lack of inherent defined secondary structure in peptoids 
results in a lack of conformational rigidity with cis/trans isomerism of the amide bonds 
(Figure 1.2) a particular challenge to control.5-9  
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Figure 1.2 Cis/trans isomerism around the peptoid backbone amide bonds. 
 
1.2 Synthesis of Peptoids 
 
The first peptoids were synthesised using standard peptide coupling methods via 
Fmoc-protected N-substituted glycine monomers (Scheme 1.1). This monomer method 
of peptoid synthesis requires prior synthesis of N-substituted glycine monomers which 
is both labour-intensive and time consuming.  
 
Scheme 1.1 Solid phase peptoid synthesis using N-substituted glycine monomers. 
In 1992 the synthesis of peptoids via the sub-monomer method was reported (Scheme 
1.2).10 Synthesis is carried out on resin and involves two steps: acylation with a 
haloacetic acid followed displacement of the halogen by an amine.   
 
Scheme 1.2 The sub-monomer method of peptoid synthesis.  
cis  trans  
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The sub-monomer method allows for the incorporation of many different functional 
groups on the side chain via >300 commercially available primary amines, as well as 
various novel sub-monomers that can be synthesised. This method also does not 
require the use of protecting groups, other than on the side chains, and, as with solid 
phase peptide synthesis, enables easy purification as excess reagents may be washed 
away after each addition. Once cleaved from the resin, the crude peptoid may then 
undergo final purification via HPLC. Finally, this method is automatable on 
commercially available synthesisers, making synthesis facile. The sub-monomer 
method remains the most frequently used method of peptoid synthesis. 
There are also several methods of making peptoids in solution. The bromoacetyl 
bromide method is a sub-monomeric method where bromoacetyl bromide is added to a 
secondary amine in a solution-phase acylation. Following filtration and evaporation, a 
primary amine is then added in a solution-phase substitution and the resulting peptoid 
is purified by flash column chromatography before the next acylation and substitution 
cycle (Scheme 1.3).11 The need for purification between each cycle means that this 
method is far more time-consuming than the solid-phase sub-monomer method.  
RHN
Br
Br
O
acylation
N
R
Br
O
H2N R'
displacement
N
R
N
OR'
H
purification by flash column chromatography  
Scheme 1.3 Solution phase peptoid synthesis using the bromoacetylbromide method. 
An efficient method of synthesising a dipeptoid backbone is the Ugi four-component 
reaction (Ugi-4CR, Scheme 1.4). This process is a one-pot solution phase reaction 
between a primary amine, an oxo compound, a carboxylic acid and an isocyanide.12  
 
R1
O
R2 N C
R3 OH
O
R4 NH2
NR3
N
R2
O
R4 O
H
-H2O
R1
 
Scheme 1.4 Synthesis of a dipeptoid by Ugi-4CR. 
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The Ugi-4CR is a useful reaction that has previously been used to form peptoid 
macrocycles, cryptands and cages13, 14 and will be further discussed as a method of 
forming cyclic peptoids.  
 
1.3 Potential Therapeutic applications of peptoids 
Over the past decade, developing medical applications for peptides has, and continues 
to be a highly active area of research. At present there are over 60 peptide-based 
drugs on the market which have been approved by the US Food and Drug 
Administration and more than 140 in clinical trials.15 This interest in peptide-based 
therapeutics arises from their biocompatibility and ability to form defined secondary and 
tertiary structures, resulting in high selectivity. However, there are significant difficulties 
in the development of peptide-based therapeutics; namely that they are readily 
metabolised in vivo, resulting in short half-lives. As previously mentioned, the 
movement of the side chain from the α-carbon to the backbone amide nitrogen in 
peptoids confers resistance to enzymatic degradation and thus peptoids are seen as 
attractive candidates for therapeutics.3,4  
 
1.3.1 Cell-penetrating peptoids 
A major barrier to using many promising drugs and imaging probes is their inability to 
pass through eukaryotic cell membranes, resulting in poor bioavailability. The side 
chain functionality of peptides, however, enables various cargo (such as biologically 
active molecules) to be attached. Cell-penetrating peptides (CPPs) are 
characteristically no longer than 30 amino acids in length, amphiphilic16, 17 and have an 
overall positive charge at physiological pH.18-21 They enter the cell by mechanisms that 
require no energy and may or may not be receptor mediated.  
CPPs have previously been synthesised and successfully internalised in a variety of 
cells in vitro, for example rat brain and spinal cord,22 calf aorta,23 porcine and human 
umbilical vein endothelium,16 in osteoclast culture24 as well as a variety of cell lines, 
such as HeLa.25-27 
More recently, CPPs have been internalised in cancerous cells such as acute myeloid 
leukaemia.28 Such studies have utilised cell-penetrating peptides to transport cytotoxic 
or imaging moieties.29-31  
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Although some CPPs are now being used for in vivo experiments (Table 1.1),31, 32 there 
remain inherent problems. The aforementioned fragility of short peptides in biological 
systems where they are rapidly metabolised means that the CPP would have to be 
injected very close to the site of interest which may not be feasible. Failure to do this 
could lead to early release of the cargo being carried, negating selectivity with 
potentially disastrous consequences if the cargo is toxic. Whilst various solutions to this 
fundamental problem are under investigation,33-36 peptoids offer a potential solution.37 
 
Table 1.1 Commonly used CPPs for in vivo experiments. 
Name Sequence Origin References 
TAT (48 – 60) GRKKRRQRRRPPQ Human 
immunodeficiency 
virus 1 (HIV 1) 
38-41 
Polyarginine Rn (n = 6-9)  42-44 
Transportan/TP10 GWTLNS/AGYLLGKINLKALAALAKKIL galanin-Lys-
mastoparan 
45 
pVec LLIILRRRIRKQAHAHSK VE-cadherin 46, 47 
Pep-1 KETWWETWWTEWSQPKKKRKV NLS from Simian Virus 
40 large T antigen and 
reverse transcriptase 
of HIV-1 
48-50 
Penetratin RQIKIWFQNRRMKWKK Drosophila 
Antennapedia 
homeodomain 
38, 41, 51 
 
Various cell-penetrating peptoids (CPPos) have been synthesised and investigated. As 
with cell-penetrating peptides, CPPos are short (~12 residues) and amphiphilic. 
Furthermore, a study showed that peptoids are anywhere between 3 – 30 times more 
permeable than the analogous peptide.52 In this study, the compounds were 
conjugated to a dexamethasone derivative. This triggered the activation of the Gal4-
responsive luciferase upon entry into living cells and the level of luciferase expression 
was used as a measure of the cell permeability of the compound. It is thought that the 
reason for the increased permeability of peptoids relative to peptides is due to the lack 
of backbone-NH protons in peptoids resulting in greater lipophilicity.  
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CPPos are still in the early stages of research, but even so, several have already been 
synthesised that show promising cell permeability and, in some cases, the ability to 
localise in different organelle.53-56 CPPos will be discussed in more detail in Chapter 4.  
 
1.3.2 Bioactive Peptoids 
Antimicrobial peptides (AMPs) have been an active area of research for decades; 
many such peptides will kill bacteria whilst showing low cytotoxicity to mammalian cells. 
This is explained by the difference between cell membranes of bacteria and 
mammalian cells. Similar to the motifs found in cell-penetrating peptides and peptoids, 
AMPs feature segregated cationic and hyrdrophobic regions. The cationic regions bind 
to anionic bacterial cell membranes and the hydrophobic regions cause 
permeabilisation leading to leakage and eventually death.57 Because mammalian cell 
membranes are largely zwitterionic, the effect of AMPs is different and gives some 
selectivity. The exact mechanism for the action of AMPs on bacterial cell membranes is 
not well defined with several possibilities such as the carpet,57 barrel-stave pore,57 
torroidal pore58 and aggregate models.59 In addition to this, some AMPs have also 
shown activity against a broad spectrum of cancers.60-64 The reason for selectivity 
between cancerous cells and non-cancerous cells is not known, although it has been 
hypothesised that membranes of cancerous cells are in some way different to those of 
healthy cell, perhaps more negatively charged or with higher transmembrane 
potentials.60-64 Furthermore, AMPs appear to be able to overcome multidrug resistance 
seen in some cancer cells.65-67 However, in spite of promising results against bacteria 
and, in one case, comparable results to doxorubicin in mouse ovarian cancer, AMPs 
have yet to be involved in widespread trials; they suffer from the same problems as 
cell-penetrating peptides, notably lack of stability in vivo resulting in poor bioavailability.  
As is the case for cell-penetrating peptides, peptoids are seen as a potential alternative 
to peptides in the field of drug discovery. Peptoids may be used as selective delivery 
agents for biologically active molecules, or the cell-penetrating peptoids themselves 
may be biologically active. For instance, some of the peptoids investigated have also 
demonstrated some antimicrobial and anti-cancer activity.55, 68 In fact, it has been found 
that anti-microbial peptoids are analogous to AMPs in many ways, for instance in the 
relationship between structure and function. X-ray reflectivity studies showed that 
peptoid 1, which also shows anti-microbial activity (see Section 1.3.2.1), is membrane 
active and forms a stable membrane-bound orientation, similar to that of AMPs 
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pexiganan  and LL-37. This shows that the similarity to behaviour of AMPs extends to 
the molecular level.69  
 
 
 
 
1.3.2.1 Antimicrobial peptoids 
As is the case with AMPs, antimicrobial peptoids appear to work primarily by 
membrane permeabilisation and disruption.70, 71 Peptoids active against a range of 
bacteria, such as Escherichia coli,72 Bacillus subtilis,69 Pseudomonas aeruginosa 
biofilms73 and Mycobacterium tuberculosis74 have been synthesised. In 2008 the 
Barron group investigated the structure-activity relationship of helical peptoids 
designed to mimic the α-helical structure of AMP magainin-2.69 Amongst the peptoids 
investigated was one with the sequence H-(NLys-Nspe-Nspe)4-NH2 (1). Peptoid helices 
have a periodicity of three residues per turn, so the peptoid structure comprised two 
Nspe residues, which are both hydrophobic and helix-inducing, with NLys 
incoroporated every third residue to provide a cationic face.  
Peptoid 1 was found to have low micromolar MICs for both E. coli and B. subtilis (3.5 
μM and 0.88 μM respectively) and a selectivity ratio of 6.0 between the E. coli and 
human erythrocytes (measured by the quotient of the 10% haemolytic dose and the 
MIC against E. coli). To compare, the selectivity ratio of pexiganan, a peptide 
considered to have low cytotoxicity, is 24. However, an analogue of 1 where the Nspe 
residue in position six is replaced by L-proline (sequence H-NLys-Nspe-Nspe-NLys-N-
spe-L-Pro-(NLys-Nspe-Nspe)2-NH2, 2) was also tested and found to retain the helical 
structure of 1 whilst having similar MICs, but with a selectivity ratio of 20.  
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Peptoids have also been shown to be active against other pathogens. Work within this 
group has demonstrated the activity of peptoids against the parasite Leishmania 
mexicana.75, 76 Leishmaniasis is a neglected tropical disease with an estimated 12 
million people currently infected and more than 350 million more at risk of infection.77 
There is no vaccine available and current treatments are expensive, require parenteral 
administration and carry the risk of severe side-effects.78, 79 
A library of over 30 peptoids was synthesised and their activity against both the 
promastigote and amastigote forms of the L. mexicana parasite, the causative agent of 
cutaneous leishmaniasis was investigated.80 Peptoids synthesised followed four motifs: 
NxNyNy, where Nx is a lysine type side chain of varying chain lengths and Ny is an 
uncharged, hydrophobic aromatic or aliphatic side chain; NxNyNz where Nz is a different 
uncharged, hydrophobic aromatic or aliphatic side chain; (NxNyNy)(NxNzNz)-type co-
block sequence; and sequences where one or two of the NLys side chains is replaced 
by the uncharged Namy side chain (Figure 1.3). 
The group found that peptoids with fluorinated or chlorinated side chains showed 
increased activity against axenic amastigotes (whilst maintaining activity against 
promastigotes) when compared to peptoids with only non-chlorinated or fluorinated 
side chains, but that the most active analogues contained both the Npfb and Nspe side 
chains. The presence of aromatic side chains also appeared necessary with peptoids 
containing the aliphatic side chains showing very little activity against either form of the 
parasite. Finally, hydrophobicity increased biological activity and replacement of one or 
two of the NLys side chains with Namy greatly increasing activity against amastigotes 
and having micromolar ED50 values.  
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Figure 1.3 The structure of the anti-leishmanial peptoids investigated and the side chains used. 
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Following testing against axenic amastigotes, four peptoids (Figure 1.4), three ‘hit’ 
compounds (3, 4 and 5) and a negative control (6), were chosen for testing against the 
clinically relevant L. mexicana infected murine macrophages. It was found that activity 
against axenic amastigotes did not necessarily indicate activity against intra-
macrophage amastigotes. Furthermore, all three peptoids which showed activity 
against intra-macrophage amastigotes were equivalently (5) or more cytotoxic (3 and 
4) to host macrophages. This is consistent with earlier work76 and shows that the 
balance between biological activity and cytotoxicity must be finely tuned.  
 
Figure 1.4 The structure of the anti-leishmanial peptoids tested against L. mexicana infected 
murine macrophages. Peptoid 6 is the negative control and showed no activity against 
amastigotes. The structures are colour-coded according to the motifs shown in Figure 1.3. 
Amphotericin B was used as a positive control (ED50 = 0.195 μM against intracellular 
amastigotes). 
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The anti-fungal activity of peptoids has also been tested in a 2016 paper by Luo et al. 
where their efficacy against Candida albicans biofilms was investigated.81 Biofilm 
formation is thought to be linked to antimicrobial resistance, in part due to their 
polymicrobial nature and propensity for metabolic inactivity.82 Further, C. albicans-
containing biofilms are associated with infections of both biotic and abiotic surfaces, 
including surgical implants.83, 84 In 2016 Luo et al. published work in which 18 peptoids 
were tested against single species biofilms of C. albicans, E. coli, and Staphylococcus 
aureus.81 The three most effective peptoids (Figure 1.5) were then tested against 
mixed species biofilms containing C. albicans and either E. coli or S. aureus.  
 
 
Figure 1.5 The structure of the three most effective peptoids tested against C. albicans biofilms.  
All three follow the NxNyNy motif (motif 1 in Figure 1.3). Positively charged side-chains are 
coloured orange and the hydrophobic side chains are coloured blue. 
All peptoids tested were of the motif NxNyNy where Nx is a positively charged side chain 
of either NLys, Nae or Nah and Ny is either the achiral aromatic Nphe or the chiral 
aromatic Nspe side chain. For each combination, the sequence was repeated two, 
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three or four times to test the effect of peptoid length on activity. Generally, it was found 
that the twelve-residue peptoids were the most active, except against single species 
biofilms of S. aureus where the nine-residue peptoids were most active. Against single 
species biofilms of E. coli the twelve-residue peptoids were the most active unless Nx 
was Nah, in which case the nine-residue peptoids were most active. In all cases, the 
six-residue peptoids were mostly inactive.  
For sequences of the same length, Nae-containing peptoids (ie peptoids containing the 
shortest cationic side-chain length) were more active than peptoids containing the 
longer cationic side-chains (NLys and Nah). For the most part, Nah-containing peptoids 
tended to be less active than peptoids containing NLys or Nae, with the exception of 
the sequence (NahNspeNspe)3 (7). The authors of the paper speculated that the 
reason for the reduced activity of NahNyNy peptoids is due to greater flexibility arising 
from the longer aminohexane side chain. Finally, chirality made a difference to the 
activity in peptoids containing NLys or Nah with Nspe-containing peptoids being more 
active than Nphe-containing peptoids. In the case of Nae-containing peptoids, the 
presence of chiral side chains made little difference. Three of the 18 peptoids, 
considered the most active across all three single-species biofilms (Figure 1.5), were 
taken forward for testing against polymicrobial biofilms (Figure 1.6): (NLysNspeNspe)3 
(8) , (NaeNpheNphe)4 (6) and (NahNspeNspe)3 (7). Against mixed-species biofilms of 
C. albicans and E. coli peptoid 7 was the most active, but against mixed-species 
biofilms of C. albicans and S. aureus peptoid 8 showed the most reduction in S. 
aureus, whilst peptoid 6 showed the most reduction in C. albicans. The presence of S. 
aureus in the biofilm appeared to make C. albicans less susceptible to peptoid 7. The 
primary mode of action of these peptoids against all three species is thought to be via 
cell-membrane permeabilisation, which is consistent with results of assays carried out 
by Luo et al, although possible secondary intracellular targets were not investigated.81 
This proposed mode of action is similar to that of antimicrobial peptides, i.e. disruption 
of prokaryotic cell membranes.57  
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Figure 1.6 PMA-qPCR quantification of cell numbers following treatment by 100 μm peptoid 
treatment of polymicrobial biofilms of C. albicans with either S. aureus or E. coli: Cell numbers 
of A) C. albicans and B) S. aureus within the same biofilm following treatment with peptoids, 
and C) C. albicans and D) E. coli within the same biofilm following treatment with peptoids 
(**p<0.01, ****p<0.0001; mean_SD, n=3). 
 
1.3.2.2 Anticancer Peptoids 
Like AMPs, some antimicrobial peptoids have also proven to be active against cancer 
and also like AMPs, the peptoids do not show decreased toxicity to multidrug resistant 
lines of cancer cells in comparison to the non-resistant lines.55, 68 This appears to be 
because the main cytotoxic activity towards cancer cells involves damaging the cell 
membrane; peptoids translocate into the cells and upon translocation appear to 
damage the cell membrane causing lysis. It is also possible that the peptoids also have 
targets within the cell since increased cell death was also observed after longer 
incubation with the peptoids in some concentration ranges. It was observed that at low 
   8  6  7  8  6  7 
 8  6  7  8  6  7 
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concentrations, peptoids are able to cross cell membranes with no or reparable 
damage to the membrane, but may then target organelle.68 At high concentrations, the 
peptoids interact with membranes in such a way that they are damaged irreparably. 
However, the main issue with peptoids as anti-cancer agents is selectivity between 
healthy cells and cancer cells with some of the peptoids tested reporting haemolysis at 
high concentrations.55 In fact, some peptoids showed little or no selectivity between 
cancerous cells and healthy cells.  
 
However the amphipathic cell penetrating peptoid, H-(Nlys-Nspe-Nspe)4-NH2 (9), was 
tested on a mouse with implanted human breast cancer cells and it was found that this 
peptoid significantly inhibited tumour growth whilst causing no other observable toxicity 
at the therapeutic dose.68 It should, however, be emphasised that this in vivo 
experiment was only a preliminary study and toxicity of these compounds needs to be 
thoroughly investigated in conjunction with any possible biological application. 
More recently, a library of triazine-bridged cyclic peptoids was synthesised with the aim 
of targeting the Skp2/p300 interaction.85 The Skp2 receptor has been shown to be 
overexpressed in many cancers and downregulates tumour suppressor proteins, 
thereby promoting tumour progression and metastasis.86-89 p300 acetylates p53, an 
important protein involved in tumour suppression and sometimes referred to as 
“guardian of the genome” due to its role in preventing genome mutation. Acetylation of 
p53 is necessary for its stability and activation, so by binding p300, Skp2 inhibits the 
function of p53 by blocking acetylation.90, 91 
In 2016, Oh et al. synthesised a library of peptoid macrocycles with the aim of targeting 
the Skp2/p300 interaction.85 The features and methods of synthesising cyclic peptoids 
will be covered more extensively further on, but in this study, peptoid macrocycles were 
used as larger molecules capable of covering large protein interfaces. The peptoid 
library was generated by split-mix synthesis using eleven different amines for the 
displacement steps until a series of pentameric linear peptoids was produced. The 
peptoids were then capped with cyanuric chloride (10) and cyclisation was achieved by 
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deprotection of a cysteine incorporated as the first residue on each peptoid followed by 
subsequent base-mediated substitution. Finally, to remove the final chloride, the 
peptoid was treated with methoxyethylamine (Scheme 1.5). This produced a library of 
triazine-bridged cyclic peptoids with theoretical diversity of 161,051. The library of 
peptoids was subjected to an affinity-based on-bead screen to identify peptoids which 
bound to the target protein. From this peptoid 11 was identified and the binding affinity 
determined by fluorescence anisotropy. Peptoid 11 was then used to treat both HeLa 
cells and WS-1 normal human fibroblast cells at various concentrations and apoptotic 
activity tested. It was found that peptoid 11 triggered apoptosis in the HeLa cells but 
had no effect on the WS-1 cells, indicating possible selectivity between healthy and 
malignant cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.5 Synthesis of peptoid macrocycles for targeting the Skp2/p300 interaction and the 
structure of the key peptoid isolated. 
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1.4 Obstacles to the use of peptoids as therapeutics: cis/trans isomerism 
and a lack of defined secondary structure 
Whilst peptoids appear to show a lot of promise as therapeutic agents, there are still 
some significant obstacles to their use. One of the biggest challenges is to overcome a 
lack of defined secondary structure. In order to design drugs that interact with a specific 
target, conformational rigidity can be important. As well as increasing the affinity of the 
compound to the target,92 conformational rigidity reduces the likelihood and severity of 
off-target effects due to lack of specificity.93 Limiting off-target effects is particularly 
difficult whilst treating certain diseases; the side-effects that commonly occur during 
current cancer treatments are well documented.94  
In peptides inter- and intra-chain hydrogen bonding involving the amide proton enables 
formation stable secondary structures. Peptide secondary structures can broadly be 
split into three main conformations: α-helices, β-sheets and random coil. The α-helix 
conformation in naturally occurring peptides is a right handed coil with 3.6 residues per 
turn (Figure 1.7a). Hydrogen bonding between the oxygen carbonyl of residue i and 
the backbone amide hydrogen of residue i + 4 stabilises the α-helix conformation. 
Peptide α-helices are directional with backbone carbonyls pointing towards the C-
terminal end of the peptide (Figure 1.7b).95  
 
 
 
 
 
 
 
 
Figure 1.7 Peptide secondary structures with side-chains omitted for clarity: a) Ribbon drawing 
of an α-helix; b) The α-helix backbone showing hydrogen bonding between carbonyl oxygens 
and amide hydrogens; c) Peptide backbone showing an antiparallel β-sheet conformation with 
inter-chain hydrogen bonding. 
a) b) c) 
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The β-sheet conformation comprises peptide strands which are lined up in either a 
parallel or antiparallel fashion and stabilised by backbone hydrogen bonding between 
neighbouring strands (Figure 1.7c).96  
Peptide secondary structures can be defined by the allowed dihedral angles (φ and ψ, 
Figure 1.8) of the constituent amino acids.  
 
Figure 1.8 The dihedral angles of amino acids in a peptide backbone. The angle between N 
and Cα is φ and the angle between Cα and the carbonyl carbon is ψ. 
The allowed combination of φ and ψ can be plotted on a Ramachandran plot (Figure 
1.9). The allowed regions are characteristic of particular secondary structures.97, 98  
 
 
 
 
 
 
Figure 1.9 Experimentally observed Ramachandran plots of allowed dihedral angles (φ and ψ). 
The plot is colour coded according to the percentage of total amino acids in each area, i.e 10% 
of all amino acids are in the dark red areas, which make them the most densly populated. The 
white area typically takes up about 80 – 90% of the total area but only contains 10% of all amino 
acids: a) Observed regions for alanine. The region in the lower left quadrant is characteristic of 
the α-helical conformation. The region in the upper left quadrant contains two maxima and is the 
β-sheet region; b) Observed regions for glycine. Glycine has more allowed regions as a result of 
its lack of side-chain. This results in fewer steric clashes with neighbouring groups and hence 
can adopt a wider range of conformations; c) Observed regions for proline. Proline is a five 
membered ring about the backbone amide which restricts φ to about -65° resulting in fewer 
favourable conformations. Ramachandran plots obtained from Hovmӧller et al., Acta Cryst. D., 
(2002), 58, 768-776. Reproduced with permission of the International Union of Crystallography, 
https://journals.iucr.org 
φ 
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In peptoids, the side-chain is moved from the α-carbon to the nitrogen in the amide 
bond, forming a tertiary amide. The movement of the side-chains and subsequent lack 
of amide proton means that the backbones of peptoids are more flexible than their 
peptide counterparts. The amide backbones of peptoids are able to adopt cis- or trans- 
conformations (Figure 1.2) and they are able to occpy regions of Ramachandran plots 
that are typically disallowed for peptides.99 Furthermore, whilst peptide secondary 
structure is controlled by backbone hydrogen bonding, this is absent in peptoids 
meaning that any secondary structure is purely due to steric and electronic 
interactions.10, 100  
 
1.4.1 Peptoid secondary structures: helices 
The most studied peptoid secondary structure is the peptoid helix with such well-
established chemistry that the rational synthesis of such structures is possible.69, 101, 102 
Peptoid helices commonly adopt a polyproline type one (PP1) structure with all-cis 
stereochemistry along the backbone (Figure 1.10). Peptoid helices contain three 
residues per turn with a pitch of about 6 Å. Whilst the peptoid backbone is intrinsically 
flexible and achiral, the incorporation of bulky side chains in the Nα positions can 
significantly restrict movement, and if the side chain is also chiral, this can induce chiral 
helices (Figure 1.11 shows some commonly used bulky, chiral groups).103-105  
Helical peptoids are studied using circular dichroism (CD) spectroscopy. In CD 
spectroscopy, the sample is exposed to circularly polarised light at different 
wavelengths and the absorption measured. Typically, peptoids adopting a helical 
secondary structure have a characteristic double minimum at 202 nm and 218 nm, 
similar to peptide helices, suggesting a structure similar to PP1 helices. Helical 
handedness is controlled by the chirality of the α-chiral side-chain and peptoids with 
side-chains of opposite chirality will give mirror image CD spectra. Inclusion of bulky, 
chiral side-chains adjacent to the backbone nitrogens can induce helicity in peptoids as 
short as five residues. However, in general, shorter peptoids are more likely to show 
interconversion between cis and trans conformations and therefore less defined 
secondary structure.103 CD spectra of peptoids will show greater helicity if there is an 
aromatic side-chain at i and i + 3, however, stable peptoid helices can be formed if at 
least 50% of the monomers are chiral.106 Helical peptoids have been synthesised that 
are stable to 75 °C and 8 M urea. The stability of helical peptoids, especially to heat, is 
consistent with the dominant role of steric interactions in structural stabilisation.107 
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Figure 1.10 Polyproline type 1 peptoid helix. The structure was generated using molecular 
mechanics. Image reproduced in part from Fowler and Blackwell, Org. Biomol. Chem., (2009), 
with permission from The Royal Society of Chemistry.100 
 
 
 
 
 
Figure 1.11 Bulky, chiral side-chains commonly used to induce helicity in peptoids. 
More recently, polyproline type 2 (PP2) peptoid helices where the amide bonds are all 
trans have also been synthesised using multiple N-aryl glycine monomers108 (Figure 
1.12). Cis/trans isomerism in peptoids is influenced by electronic effects due to n → π* 
interactions between backbone carbonyls and side-chains, favouring cis conformations, 
or between carbonyl groups, favouring the trans configuration. Inclusion of electron 
deficient side chains lowers the HOMO - (n) LUMO (π*) gap between backbone 
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carbonyl and side-chain groups, favouring cis configurations. Conversely, electron rich 
side-chains destabilise this interaction in relation to the n → π* between adjacent 
backbone carbonyl groups (Figure 1.13).7, 109 Therefore, whilst N-aryl glycine 
monomers favour trans configuration, a highly electron deficient polyfluorobenzyl side 
chain (Figure 1.12) favours a cis conformation.6 
 
 
 
 
Figure 1.12 N-aryl glycine (Nary) side chain and pentafluorobenzyl (Npfe) side chain. 
 
 
 
 
 
 
 
 
Figure 1.13 n → π* interactions between a) backbone amide carbonyls stabilising the trans 
conformation and b) backbone amide carbonyl and side chain stabilising the cis conformation. 
Oxygen is shown in red and nitrogen is blue. Adapted with permission from B. C. Gorske, B. L. 
Bastian, G. D. Geske and H. E. Blackwell, J. Am. Chem. Soc., 2007, 129, 8928-8929. Copyright 
2007 American Chemical Society.6 
 
 
 
a) b) 
a) b) 
trans-amide 
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1.4.2 Other peptoid secondary structures: turn structures and nanosheets 
Other peptoid secondary structures have also been achieved, although the chemistry 
for these is in its infancy compared to that of helical secondary structures.  
N
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Figure 1.14 a) The x-ray crystal structure of an example macrocyclic peptoid hexamer with a 
turn structure b) the peptoid backbone with type I (left) and type III (right) peptide, both in grey 
c) chemical structure of macrocyclic peptoid hexamer (12). Image reproduced from Fowler and 
Blackwell, Org. Biomol. Chem., (2009), with permission from The Royal Society of Chemistry.100 
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Figure 1.15 a) The NMR structure of the turn induced by an included triazole group with the 
backbone in green b) the structure of the example peptoid with the triazole highlighted in red. 
Image reproduced Fowler and Blackwell, Org. Biomol. Chem., (2009), with permission from The 
Royal Society of Chemistry.100 
Peptoid turns have so far been induced by two methods: macrocyclisation110 (which is 
discussed in greater detail in Section 1.6) and by the inclusion of heterocyclic 
monomers whose geometry mimics that of a turn.111-113 Head-to-tail macrocyclisation 
(further discussed in Section 1.6.1) of linear peptoids containing alternating aromatic 
and alkyl side-chains form amphiphilic structures whereby hydrophobic residues are on 
one face and hydrophilic residues are on another. For hexamers (e.g. peptoid 12) and 
octamers of this type, the structure resembles type I and type III β-turns with two amide 
a) b) c) 
a) b) 
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bonds in the turn region adopting a cis configuration while the rest of the amide bonds 
are trans100, 110, 114 (Figure 1.14). 
Alternatively, a monomer may be incorporated which mimics the turn structure. An 
example of this is the triazole monomer (13, Figure 1.15 as an example). The triazole 
is a conformationally rigid structure that forms a tight turn. Inclusion of bulky α-chiral 
groups next to the triazole further stabilise this structure.111  
Recently, peptoids have been designed that self-assemble into nanosheets: flat, 2D, 
planar bilayers of only 2.7 nm thickness, but that extend for many tens of microns in 
width and length115 (Figure 1.16). Peptoid nanosheets are considered mimics of 
peptide β-sheets, however, unlike peptide β-sheets which have an inherent twist 
arising from the backbone chirality of peptides, peptoid nanosheets are completely flat. 
The first reported synthesis of a peptoid nanosheet was by the Zuckermann group in 
2010 and consisted of two 36 residue peptoids of opposing charge: (NaeNpe)18 (14)  
and (NceNpe)18 (15).   
Nanosheet self-assembly was dependent on the constituent peptoids having 
alternating polar and non-polar, aromatic monomers and was dependent on periodicity: 
repeating units of two sub-monomers were necessary and having repeating units of 
three or four monomers did not result in nanosheet formation. The peptoids dissolved 
in concentrations of >50% acetonitrile but were stable to a range of pHs and 
temperatures.115, 116 
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Figure 1.16 a) Peptoid nanosheet structure as obtained via molecular modelling. Oxygen is red, 
nitrogen is blue and carbon is yellow; b) Structures of positively charged peptoid (NaeNpe)18 
(14) and negatively charged peptoid (NceNpe)18 (15). Image reprinted with permission from 
Springer Nature, Nat. Mater., “Free-floating ultrathin two-dimensional crystals from sequence-
specific peptoid polymers,” Nam et al., copyright 2010 Nature Publishing Group.115  
a) b) 
Chapter 1: Introduction 
 
23 
 
Later work by the Zuckermann group reported the synthesis of single peptoids capable 
of nanosheet self-assembly. Two peptoids were made using the same design 
principles from the two peptoid nanosheet, i.e. containing positively and negatively 
charged monomers with two-fold periodicity of alternating polar and non-polar aromatic 
residues. The first peptoid had a block charge copolymer-type structure of 
(NaeNpe)9(NceNpe)9 and the second alternated positively and negatively charged 
monomers, (NaeNpeNceNpe)18. Both formed nanosheets, but the block copolymer 
structure was the most stable towards changes in pH and temperature.117 
 
1.5 Attempts to rigidify peptoid secondary structure: cyclisation 
In nature, one of the ways in which conformational rigidity is achieved is by  forming 
covalent bonds that effectively ‘staple’ the three dimensional structure in place. For 
instance, small cyclic peptides exhibit strong antibacterial properties118-121 and di-
sulphide bridges are common in cysteine-containing peptides to constrain side 
chains.122-124 In novel synthetic peptides, cyclisation can also lead to resistance to 
proteolysis and greater cell penetration.110, 125, 126 
As with peptides, cyclic peptoids have been shown in several cases to improve cell 
penetration and also to enhance antimicrobial activity when compared to their linear 
precursors.127 Cyclisation of linear peptoids restricts the movement of the peptoid, 
increasing rigidity and reducing the number of possible conformations.  
 
1.6 Methods of cyclising peptoids 
(Note: Parts of the below content can also be found in the minireview ‘Recent Advances in the 
Synthesis of Peptoid Macrocycles’ in Chemistry- A European Journal.128 Reproduced with 
permission). 
 
Recent cyclisation methods have been split into three broad techniques: head-to-tail, 
side chain- to-side chain and side chain-to-tail cyclisation and these will be discussed 
in the context of their possible applications. 
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1.6.1 Head-to-tail cyclisation 
In 2007 the Kirschenbaum group reported the synthesis of peptoid macrocycles.110 The 
technique used was head-to-tail cyclisation, carried out in the solution phase as a 
condensation reaction between the N-terminus and the carboxylic acid terminus 
(yielded by cleavage from 2-chlorotrityl resin, Scheme 1.6). 
We have already briefly seen a cyclic peptoid hexamer (12) as an example of a peptoid 
turn structure (Figure 1.14). This peptoid was synthesised via efficient head to tail 
cyclisation from the linear precursor (16, Scheme 1.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.6 Head to tail cyclisation of a linear peptoid (16) hexamer to form a cyclohexamer 
(12). 
This methodology was more widely applied and chains up to 20-mer lengths underwent 
rapid room temperature cyclisations giving up to 90% yields after 5 minutes at room 
temperature at moderate dilutions (0.6 – 3.0 mM). Cyclisation of the peptoid octamer 
was also found to proceed with little accumulation of the intermolecular reaction 
products at concentrations ranging from 0.3 to 78 mM. Conversely, ring strain meant 
that the tetramer only cyclised with a 12% yield after 5 minutes. Notably, Shin et al. 
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managed to crystallise the cyclic hexamer (12) and the resulting crystal structure 
showed the hydrophobic phenyl side chains oriented on one face and the hydrophilic 
methoxy ethyl side chains oriented on the other face. This has implications for the 
future design of peptoid oligomers; it may be possible to design more complex peptoids 
which cyclise to form an ordered, amphiphilic structure.110  
This method of head-to-tail cyclisation was more recently used to make a cyclic peptoid 
octamer (17, Scheme 1.7)  which assembles to form a nanotubular structure (Figure 
1.17), capable of reversibly sequestering water.129   
 
 
 
 
 
 
 
 
 
Scheme 1.7 Formation of a cyclic peptoid (17) from linear peptoid (18) which assembles into a 
nanotubular structure and is capable of reversibly sequestering water. 
The linear parent peptoid (18) was designed to incorporate side chains that would 
impose a sequence of cis (c) and trans (t) amide bond configurations that corresponds 
to ccttcctt; a sequence observed in many peptoid macrocycles.110 N-aryl glycine 
monomer units (Figure 1.12) have been shown to exhibit a strong preference for a 
trans conformation, as described previously in Section 1.4.1,  whilst some N-alkyl 
monomer units show a preference for cis conformation.108 This principle was used to 
select the side chains in the synthesis of the linear parent peptoid (18); the aryl groups 
enforced the trans conformation about the amide bonds whilst the methoxy groups 
were included to improve water solubility and the propargyl groups allow for possible 
further modification. The resulting macrocyle conformation was as predicted with the 
Chapter 1: Introduction 
 
26 
 
alkyl groups allowing a cis-conformation of associated amide bonds and the aryl 
groups enforcing trans-conformations.    
 
 
 
 
 
 
 
 
 
Figure 1.17 Crystal structure of water-sequestering peptoid macrocycle: (17), a) crystal 
structure of single molecule with oxygen in red and, nitrogen in blue and hydrogen in white; b) 
top view of three stacked peptoid macrocycles showing the cavity in which water (red) is 
sequestered; c) side view of three stacked peptoid macrocycles. Hydrogen is omitted (except 
for the water molecules) for clarity.  
1.6.1.2 Small head-to-tail macrocyclic alpha peptoids 
Since 2007, efforts have been made to synthesise smaller (3- to 5- mer) cyclic 
peptoids, but until recently, the yields obtained were often relatively low , particularly for 
the trimers (< 20%) or conditions were not optimised.130-133 They are desirable targets 
since small cyclic tetrapeptides may act as histone deacetylase inhibitors (HDIs).134, 135 
HDIs have long been used as mood stabilisers and anti-epileptics, but are now also 
attracting interest as possible treatments for inflammatory136 and parasitic diseases,137 
as well as cancers.138 In 2012, Olsen et al. reported the synthesis of cyclotetrameric 
peptoid-peptide hybrids which inhibited class 1 histone deacetylases.139 Hoping to 
provide the tools to eventually make entirely peptoid-based HDIs, in 2014, Culf et al. 
successfully synthesised cyclic tri-, tetra- and pentapeptoids in high yield (Scheme 
1.8).140  
The reactions were carried out in solution using a variety of activators and bases and 
found that a mixture of 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1-
a) 
b) 
c) 
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Hydroxy-7-azabenzotriazole (HOAt) and triethylamine (TEA) resulted in the best yields. 
When n = 1 or 3 the reported yields after overnight, room temperature incubation were 
90% and 97% respectively. Under the same conditions, when n = 2, the reported yield 
was 38%, but when EDC and TEA were replaced with 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) and diisopropyl ethylamine (DIPEA), and the reaction 
was carried out at 50 oC overnight, the reported yield rose to 80%. 
 
 
 
Scheme 1.8 Head-to-tail synthesis of short cyclic peptoids. 
The authors did not elaborate on why the cyclisation of n = 2 was such a challenge, 
however they speculated that an increase in temperature improved the yield because 
of an increased rate of cis-trans isomerisation about the amide bonds.  
 
1.6.1.3 Macrocyclic arylopeptoids 
An interesting variation of head-to-tail cyclisation was reported in 2014 by Hjelmgaard 
et al. where arylopeptoids are cyclised and form nanotubular structures.141  
 
 
 
 
 
 
Figure 1.18 Comparison of the repeating units of N-alkylated para-cyclophanamides and 
arylopeptoids. 
Meta-arylopeptoid 
Ortho-arylopeptoid 
Para-arylopeptoid 
N-alkylated para-cyclophanamide  
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Arylopeptoids, which are considered a subclass of peptoids whereby the backbone is 
extended by a phenyl ring at each residue, are closely related to N-alkylated para-
cyclophanamides (Figure 1.18). Macrocyclic N-alkylated para-cyclophanamides, if the 
R group is a long, hydrophobic chain, form a hydrophobic cavity and thus, these 
compounds show potential as selective hosts and artificial enzymes. Arylopeptoids can 
be efficiently synthesised, based on the sub-monomer method, and can readily 
undergo head-to-tail macrocyclisation (Scheme 1.9) to form rigid, well-defined 
structures, similar to N-alkylated para-cyclophanamides. 
 
Scheme 1.9 Head-to-tail macrocyclisation of arylopeptoids. 
The reactions in Scheme 1.9 were carried out on ortho-, meta- and para-arylopeptoids. 
Para-arylopeptoids have a rigid backbone which means that head-to-tail cyclisation is 
challenging. Thus the resulting macrocycles were cyclohexamers (n=4, e.g. 19) rather 
than cyclotrimers (n=1). Formation of the cyclotrimer (20) or cyclohexamer (21) from 
the ortho-arylopeptoid is dependent on the side chain; the substituents around the ring 
are more hindered, so a bulky side chain will favour formation of the cyclohexamer. 
Conversely, the meta-arylopeptoid favours the cyclotrimer (e.g. 22), even with a bulky 
isopropyl side chain.  
Crystal structures of some of the macrocycles showed the formation of tubular 
structures. In the case of the ortho-arylopeptoid the cyclohexamer (21) formed when 
the side chain is an isopropyl group contains one acetonitrile molecule (from the 
crystallisation solvent) in an interior cavity (Figure 1.19). These cyclohexamers stack to 
form a tubular array, even in the absence of any hydrogen bonding. It is speculated 
that a water molecule which bridges two consecutive rings may further stabilise the 
supramolecular assembly. Importantly, the presence of the acetonitrile molecule 
indicates that the interior cavity of this tubular array is large enough to accommodate a 
molecule, and thus the system has potential to be a selective host. 
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Figure 1.19 Crystal structure of orthoarylopeptoid cyclohexamer (21): a) crystal structure of 
single molecule with oxygen in red and, nitrogen in blue and hydrogen in white; b) top view of 
three stacked arylopeptoid macrocycles showing the cavity containing water (red) and 
acetonitrile (yellow); c) side view of three stacked peptoid macrocycles. Hydrogen is omitted 
(except for the water and acetonitrile molecules) for clarity. 
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1.6.1.4 Consecutive Ugi reactions 
The Ugi 4-component reaction (U-4CR) is a multi-component reaction (MCR) which 
involves a ketone or aldehyde, an isocyanide and a carboxylic acid (Scheme 1.10).142 
 
 
  
 
Scheme 1.10 General example of the Ugi 4-component reaction. 
The U-4CR is used to synthesise large libraries of compounds, thanks to the ready 
availability of a wide range of suitable building blocks. Whilst there are many reports of 
U-4CRs being used to make peptoids and peptoid hybrids,13, 143-146 U-4CRs have also 
been used to make and cyclise peptoids. In 2008, Vercillo et al. reported the syntheses 
of peptoid macrocycles using consecutive U-4CRs as a way to generate peptoid-RGD 
motifs.14 The peptide-RGD is the tripeptide L-arginine-glycine-L-aspartate and peptoid-
RGD is the corresponding peptoid sequence (i.e. with the side chains moved from the 
α-carbons to the backbone amide nitrogens). RGD is common to many peptides 
involved in cellular recognition147 and the RGD loop is recognised by nearly half of all 
known integrins. Integrins are a family of cell-adhesion molecules and have key roles in 
various processes, including thrombosis, metastasis and osteoporosis.147 Hence, 
integrins are attractive therapeutic targets and Vercillo et al. hoped that their peptoid-
RGD-containing macrocycles could be used in this way. In order to achieve this, three 
consecutive Ugi reactions were carried out; the first two, U-4CRs, yielded the acyclic 
parent peptoid (28) and the third, an Ugi three-component 4-centre reaction, cyclised 
the parent peptoid to form peptoid-RGD-containing macrocycle 29 (Scheme 1.11).14 
Many RGD peptide macrocycles and nonpeptidic mimics have been shown to be highly 
active antagonists for a range of integrins.148-151  These RGD peptide macrocycles and 
nonpeptidic mimics are also selective for particular integrins, due to the conformational 
rigidity imposed by cyclisation. However, studies of the activity and selectivity of 29 in 
comparison with the macrocyclic peptide analogue are not yet available. 
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Scheme 1.11 Synthesis of peptoid-RGD-containing macrocycle (29) by consecutive Ugi 
reactions. 
 
1.6.2 Side chain cyclisation 
1.6.2.1 Grubbs’ Ring-Closing metathesis 
Olefin metathesis is a widely applied method of carbon-carbon bond formation using 
ruthenium alkylidene catalysts. Ring-closing metathesis (RCM, Figure 1.20) can be 
used to form large macrocycles.152  
 
Figure 1.20 Representative Ring-Closing Metathesis (RCM). 
RCM has many features that make it attractive for use in the formation of cyclic 
peptoids; the catalysts are tolerant of a wide variety of functional groups, allowing 
variation in the side chain groups. The catalysts are easily handled, not requiring the 
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use of glove boxes, and the reaction is clean, producing few by-products, making 
purification straightforward. RCM is usually carried out in solution phase, and, as seen 
above, cyclisation of peptoids can also be carried out in solution. However, particularly 
when transition metal catalysts are used, solid phase synthesis is preferred; carrying 
out the reaction with the peptoid on resin allows removal of any non-resin-bound by-
products and unreacted starting materials by simply washing the resin. This also 
simplifies recovery of the catalyst. The solid phase synthesis of cyclic peptoids by RCM 
(Scheme 1.12) was reported by Khan et al. in 2011.153 
 
Scheme 1.12 Grubbs Ring Closing Metathesis reaction on resin to form cyclic peptoids as 
reported by Khan et al.  
Initially, the double bonds in the side chain were included by the use of allylamine for 
the substitution step of peptoid synthesis, but this produced the corresponding cyclic 
peptoids in very low yields (10 – 20%). The parent peptoid structure was subsequently 
altered to extend the length of the alkene-containing side chain by swapping allylamine 
for 3-buten-1-amine in the corresponding substitution step.  
 
Various catalysts were tested, but the most effective one was phosphine free (30), 
giving a yield of 80% compared to 20% of the next best catalyst when reacted with a 
model peptoid. The reaction was carried out both under microwave conditions and at 
40 oC on a shaker, with the latter conditions being slightly more efficient, particularly in 
minimising formation of dimers.  
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1.6.2.2 Thiol-ene 
The thiol-ene reaction (Scheme 1.13) is considered a type of ‘click chemistry’ due to 
high yields, stereoselectivity and rates.154, 155 There are two mechanisms by which the 
thiol-ene reaction may proceed; either by radical addition or Michael addition, catalysed 
by either a base or a nucleophile. 
 
  
Scheme 1.13 The thiol-ene reaction. 
The thiol-ene reaction has been used to cyclise peptides, using a maleimide (31) as the 
source of the double bond.156 Non-protected maleimides can only be incorporated at 
the end of the chain since they are labile to the nucleophilic bases that are used in 
peptide/peptoid synthesis. 2,5-Dimethylfuran (32) can be used to protect maleimides 
(Scheme 1.14); 2,5-dimethylfuran (32) reacts with the maleimide (31) by Diels-Alder 
cycloaddition. The protected maleimide (33) can be deprotected by heating.  
 
Scheme 1.14 Protection of maleimides by Diels-Alder reaction with 2,5-dimethylfuran. 
In principle, protection of the maleimide in this way allows it to be incorporated at any 
place in a peptide/peptoid chain; however, in the paper, maleimido group inclusion was 
at the N-terminus only (34). After cleavage from the resin, the maleimide was 
deprotected and cyclisation occurred in the same step to give cyclic peptoid 35 
(Scheme 1.15).  
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Scheme 1.15 Peptoid cyclisation by a thiol-ene reaction. 
In the paper by Elduque et al. the cyclised peptoid (35) was then used to attach a 
nucleoside, 2’,3’-dideoxy-3’-azidothymidine (AZT, 36),  via Huisgen reaction to form 
peptoid-AZT conjugate 37 (Scheme 1.16).156  
AZT (36) is an anti-retroviral drug used to treat HIV/AIDS.157 At high doses, AZT is 
associated with side effects such as anaemia, neutropenia, hepatotoxicity, 
cardiomyopathy and myopathy. This limits the dose that can be given to patients, and 
this means that some HIV replication still occurs. This allows resistance to develop so 
that, ultimately, the progression of the disease is only slowed.158 Development of 
resistance is slowed by combining AZT with other anti-retroviral medicines. 
Conjugation of AZT to cyclic peptoids is of interest to see whether cell uptake and 
subsequent interaction with components of the cell is improved, or different. 
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Scheme 1.16 Conjugation of a nucleoside to a cyclic peptoid by Huisgen condensation to form 
and AZT-containing cyclic peptoid (37). 
 
1.6.2.3 Copper(I)-Catalysed Azide-Alkyne Cycloaddition (CuAAC) 
Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) refers to a 1,3 dipolar 
cycloaddition between an azide and an alkyne to give a 1,2,3-triazole (Scheme 1.17). 
CuAAC is considered a ‘click’ reaction, and is catalysed by a Cu(I) compound in the 
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presence of a non-nucleophilic base.159 It is a high yielding and versatile reaction since 
the required functional groups are easily incorporated into a variety of compounds. 
 
Scheme 1.17 Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC). 
CuAAC as a method to cyclise peptoids was first reported in 2007 by the Kirshenbaum 
group (Scheme 1.18).160 This on-resin reaction was used as a way to ‘staple’ helical 
peptoid chains in order to rigidify the structure.  
 
 
 
 
Scheme 1.18 CuAAC to form a cyclic peptoid. 
In 2012, the Kirshenbaum group used CuAAC in the solution phase to form a bicyclic 
peptoid (Scheme 1.19).161 A linear peptoid containing both an azide and an alkyne 
group side chain (38) was first synthesised, cleaved from the resin and then cyclised by 
head to tail condensation between the N-terminus and the carboxylic acid-terminus to 
form the a monocyclic peptoid (39). Bicyclic peptoid 40 was then formed by CuAAC 
between the side chain alkyne and azide groups. This intramolecular reaction was the 
major reaction pathway under dilute conditions, giving a yield of 27% but formation of 
the homodimeric, doubly crosslinked peptoid (41) with a yield of 4% was also 
observed. Crystal structures of 40 and 41 were obtained (Figure 1.21). Whilst 40 
appeared to exist in only one configuration, bicyclic peptoid 41 was found to be a 
mixture of two backbone conformations and further investigation determined the 
conformation of the monocyclic peptoid to be the main factor contributing to the 
conformation of the resulting bicyclic peptoid. The formation of bicyclic peptoids by the 
use of the efficient and versatile CuAAC has the potential to unlock more complex, 
constrained peptoid conformations.  
 
Chapter 1: Introduction 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.19 Formation of a bicyclic peptoid (40, major product) using CuAAC, and the 
homodimeric, doubly crosslinked peptoid (41, minor product). 
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Figure 1.21. Crystal structures of bicyclic peptoid cyclooctamer (40) and the homodimeric, 
doubly crosslinked peptoid (41): a) crystal structure of cyclooctamer (40) with oxygen in red and, 
nitrogen in blue and hydrogen in white; b) crystal structure of 40 highlighting the triazole and 
bridging side-chains (purple) and the original cyclic peptoid structure obtained via head-to-tail 
macrocyclisation (green); c) crystal structure of the homodimeric, doubly crosslinked peptoid 
(41) with oxygen in red and, nitrogen in blue and hydrogen in white; b) crystal structure of 41 
highlighting the triazole and bridging side-chains (purple) and the original cyclic peptoid 
structures obtained via head-to-tail macrocyclisation (green). Non-bridging side-chains and all 
hydrogen atoms are omitted for clarity. 
 
1.6.3 Side chain-to-tail cyclisation 
1.6.3.1 Nucleophilic substitution 
In 2015, Kaniraj and Maayan reported a high yielding side-chain-to-tail method of cyclic 
peptoid synthesis. The linear parent peptoid includes a chloride side chain that reacts 
with a secondary amine at the terminus of the peptoid chain by substitution under basic 
conditions (Scheme 1.20).162 The cyclisation reaction was carried out whilst the peptoid 
was still on resin, meaning that protecting groups on any side chain functional groups 
could be removed at the same time as the peptoid was cleaved from the resin. This 
allowed for the inclusion of a wide range of functional groups in the peptoid chain.  
a) b) 
c) d) 
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Cyclisation occured with the propyl chloride side chain in various positions on the 
peptoid chain to form ring sizes as small as 4 and as large as 19.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.20 Side chain to tail formation of a cyclic peptoid by halide substitution.  
We have already seen head-to-tail macrolactamisation but macrolactamisation can 
also be used in a side chain-to-tail cyclisation (Scheme 1.21).163 However, unlike in the 
head-to-tail method, the side chain-to-tail method is carried out whilst the peptoid is still 
on resin. 
The sequences chosen for the peptoids were based on linear and cyclic sequences 
seen to inhibit the interaction between apolipoprotein E and amyloid-β; a cause of 
Alzheimer’s disease, though whether the cyclic peptoids actually interacted with either 
compound was not confirmed.  
 
Scheme 1.21 Side chain to tail macrolactamisation.   
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The sequencing of peptoids is problematic; something that is a major barrier to their 
utility. In 2014, the successful sequencing of peptoids was achieved by first cyclising a 
modified linear peptoid on resin (Scheme 1.22). 
 
 
Scheme 1.22 Synthesis of a cyclic peptoid precursor (45) to a sequenceable linear peptoid.  
A homocysteine residue was incorporated into the sequence as the first residue giving 
42. The peptoid (43) is then synthesised by the sub-monomer method and the N-
terminus is chloroacetylated (44). Subsequent deprotection of the homocysteine sulfur 
and base-mediated cyclisation gave a cyclic peptoid (45) which, when cleaved from the 
resin, gave a linear peptoid that was tagged at each end. The incorporation of two 
different end groups enabled sequencing by tandem mass spec. The thioether could be 
oxidised by mCPBA to yield the linear peptoid. However, due the strong oxidising 
ability of mCPBA, other functional groups in the peptoid were affected. In order to 
prevent side reactions with other functional groups, the peptoid is synthesised on 
Tentagel S NH2 resin and CNBr can be used to cleave the peptoid and open the ring 
(Scheme 1.23), giving the tagged linear peptoid (46).164 
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Scheme 1.23 Cleavage of cyclic peptoid (45) to give the tagged linear peptoid (46). 
 
1.7 Conclusions and Project Overview 
Numerous studies have shown that peptoids have huge potential as novel therapeutic 
agents, with their resistance to proteolytic degradation of particular interest. Their 
potential applications are wide ranging, from anti-infective agents, to anticancer drugs, 
to imaging probes, to transporters for other therapeutic agents. However, peptoid 
therapeutics are not without their own drawbacks, mainly arising from cis/trans 
isomerism of the amide bonds and the lack of backbone hydrogen bonding resulting in 
poorly defined secondary structures. A lack of conformational rigidity presents a 
serious problem for certain therapeutic applications, as this is often linked to good 
selectivity and binding affinity for a specific target. Poor selectivity and binding affinity 
can result in reduced effectiveness of the drug and increase the chance of off-target 
effects  
Chapter 2 looks at boronic acid-containing peptoids. The first part of Chapter 2 details 
attempts to make a novel protected boronic-acid building block that may be 
incorporated anywhere in a peptoid sequence. Boronic acids are synthetically and 
therapeutically useful functionalities but their application in peptoids is thus far limited. 
The ability to incorporate boronic acids at any point in a peptoid chain using the sub-
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monomer method is therefore beneficial. The second part of Chapter 2 looks to 
synthesise a library of novel cyclic peptoids via Suzuki-Miyaura cross-coupling 
(Scheme 1.24). In doing so, we hope to report novel peptoid scaffolds that impose 
conformational rigidity. A further feature of these peptoids the presence of the biaryl 
group which is a motif seen in many therapeutics and which is discussed further in 
Chapter 2.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.24 Proposed Suzuki-Miyaura cross-coupling to form a cyclic peptoid.  
Chapter 3 reports the synthesis of the nucleophosmin-binding segment of the 
anticancer peptide CIGB300 and three stapled analogues in order to carry out binding 
assays. The ultimate aim is making a more stable analogue of the whole peptide. This 
is done in two ways, summarised in Figure 1.22. The first way is by making minor 
alterations to the structure of the active peptide via different stapling methods, for 
example by replacing the existing disulphide bridge with a C-C linked bridge. The 
second way to stabilise the peptide is, by replacing the attached peptidic transporting 
unit with a series of short cell-penetrating peptoids, and this is the theme of Chapter 4.   
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Figure 1.22 Strategy for stabilising an existing anticancer peptide 
Chapter 4 describes the use of a series of short cell-penetrating peptoids to deliver 
bioactive peptides to their targets. The first peptide sequence this is applied to is the 
anticancer KLA peptide sequence (D-(KLAKKLAK)2). The resulting peptoid-KLA 
peptide hybrids are shown to be toxic to HeLa cells whilst the unmodified KLA peptide 
shows little toxicity. The second peptide sequence is the nucleophosmin-binding part of 
CIGB-300, synthesised in Chapter 3. The resulting chimeras will then be conjugated to 
a luminescent probe.  
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Chapter 2 
Boronic Acid-Containing Peptoids 
2.1 Background 
2.1.1 Boronic acids as synthetic building blocks 
Boronic acids are synthetically useful building blocks, providing access to many novel 
compounds. They can undergo functional group conversion to generate halides1-4 
(Scheme 2.1), alcohols5 (Scheme 2.2), esters6 (Scheme 2.3) and various amino 
groups7-11 (Figure 2.1).  Boronic acids are also useful for generating carbon-
heteroatom bonds12-14 (Figure 2.2). However, our main interests in the inclusion of 
boronic acids in peptoids are firstly, their use in the formation of carbon-carbon bonds, 
specifically the synthesis of biaryl groups via Suzuki-Miyaura cross-coupling15 
(Scheme 2.4). 
 
 
 
 
 
Scheme 2.1 Example of stereoselective halodeboronation of alkenylboronic acids.4 
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Scheme 2.2 Stereospecific oxygenation of boronic esters to generate an alcohol.5 
 
 
 
 
Scheme 2.3 Stereoselective oxygenation of boronic esters to generate an ester.6 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2.1 Examples of amination reactions starting from boronic acids and esters. 
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Figure 2.2 Generating carbon-heteroatom bonds from boronate-containing compounds (via 
Chan-Lam coupling reactions). 
 
 
 
 
Scheme 2.4 General example of a Suzuki-Miyaura cross- coupling reaction. 
 
2.1.2 Carbon-carbon bond formation  
C-C bond formation reactions using boronic acid building blocks are particularly useful 
and this was recognised in 2010 when Suzuki was one of the recipients of the Nobel 
Prize for Chemistry for his eponymous coupling reactions involving boronic acid 
building blocks (Scheme 2.4).15 The Suzuki-Miyaura coupling reaction reacts a boronic 
acid, 47, with a halide, 48 using Pd(0) as a catalyst and a base to form a new C-C 
bond, forming a biaryl group, 49. These reactions are of particular interest in peptoid 
chemistry as they provide a potential route towards cyclic and stapled peptoids. Cyclic 
peptoids are a desirable target because they may show greater activity against 
pathogens and may be more specific for certain targets16 and has been discussed in 
detail in Chapter 1. Various attempts have already been made towards stapling and 
cyclising peptoids (see Chapter 1), but boron cross-coupling reactions have so far not 
been attempted as a way to achieve this. 
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Whilst the example in Scheme 2.4 shows an aromatic boronic acid, 47, Suzuki-
Miyaura coupling also extends to heteroaromatic and alkenyl boronic acids. It should 
also be noted that there are many other similar cross-coupling reactions and insertions 
(including Heck-type and Sonagashira-type coupling reactions) and using other metal 
catalysts, such as iridium,17 nickel18 and rhodium19, 20 but Suzuki-Miyaura coupling is 
the most relevant to this project and the other reactions will not be discussed here. 
 
2.1.2.1 The biaryl group 
The biaryl group, for example, 49, Scheme 2.4, is of particular interest for peptides and 
peptoids. Not only do they provide a route to cyclic peptides21-28 and peptoids, but the 
biaryl group has attracted interest from the pharmaceutical industry as it shows activity 
across a wide range of therapeutic classes, including anti-inflammatory, anti-fungal, 
anti-tumour, anti-hypertensive and anti-rheumatic agents29, 30 (two examples are shown 
in Figure 2.3). Furthermore, it is also possibly useful as an infertility treatment since it 
is an agonist for follicle stimulating hormone (FSH) receptors.31   
Biaryls interact with hydrophobic aromatic residues in peptides and proteins, but also 
show favourable interactions with the more polar amide and hydroxide groups and 
positively charged moieties. This means that the biaryl group can potentially interact 
with a wide range of receptors.32 In fact, statistical analysis of NMR-derived binding 
data performed on 11 protein targets showed that compounds containing biphenyl 
substructures bound preferentially to the proteins with a high level of specificity (>250 
fold).32 
 
 
Figure 2.3 Biaryl containing drugs: 50, Fenbufen, is used to treat arthritis,33 51, Valsartan is an 
antihypertensive drug.34  
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Biaryl scaffolds are considered privileged structures by the pharmaceutical industry.30, 
32 Privileged structures are used to describe molecular frameworks that are capable of 
binding to a diverse array of receptors. So ubiquitous is the biaryl motif, that in a 2003 
review, it was stated that 4.3% of all known drugs contained a biphenyl.30, 32  
 
2.1.2.2 Biaryls in antibacterial compounds 
Some biaryl-containing compounds show anti-bacterial activity against both Gram-
positive and Gram-negative bacteria.35, 36 A notable study by Jefferson et al. in 2004 
carried out lead optimisation of a compound (52, Figure 2.4) that had been shown to 
bind to bacterial 23S RNA and inhibit bacterial protein synthesis in a cell-free system 
(IC50 = 14 μM) but lacked antibacterial activity in MIC assays with E. coli and S. 
aureus.36  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Structure of and comparison of activities of three compounds investigated in lead 
optimisation studies by Jefferson et al. Substituted substructures are in red. Compound 52 is 
the original hit compound which inhibits bacterial protein synthesis (IC50 = 14 μM) but showed 
no activity against E. coli or S. aureus. Compound 53 contained the biaryl group and was most 
effective against E. coli and S. aureus (MICs = 6 – 13 μM and 3 – 6 μM respectively, IC50 in the 
cell-free system = 9 μM). Compound 54 is the phenyl substituted compound which was inactive 
against E. coli and S. aureus (IC50 in the cell-free system = 40 μM).  
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The authors suggested that this lack of activity was down to poor cell penetration 
and/or the action of efflux pumps, resulting in inadequate compound availability inside 
the cell. Their most effective compound (53, Figure 2.4) contained a biphenyl group 
and was active against E. coli and S. aureus (MICs were 6 – 13 μM and 3 – 6 μM 
respectively) as well as against multi-drug resistant S. aureus (MIC 13 – 25 μM). 
Furthermore, compound 53 was found to have a 4-fold greater in vitro activity 
compared to the phenyl substituted compound, 54 (IC50 = 9 μM and 40 μM 
respectively) which showed no activity up to 100 μM in assays against S. aureus and 
E. coli. This suggests that the biphenyl group is critical for antibacterial activity, at least 
in the compounds investigated. 
The biaryl motif is also found in various biologically active peptides, for example 
vancomycin (55, Figure 2.5) which is widely used as an intravenous antibiotic and is 
used to treat conditions such as meningitis caused by methicillin-resistant S. aureus.37, 
38 The biphenomycins are a family of tripeptide macrocycles linked by a biaryl group.27 
Biphenomycin A (56, Figure 2.7) and biphenomycin B (57, Figure 2.7) have both been 
the target of total synthesis projects due to their observed activity against Gram-
positive and β-lactamase resistant bacteria.24, 27, 39-41 Furthermore, biphenomycin A (10) 
was found to be effective against bacterial infections in mice, even exceeding 
expectations from the in vitro studies.42  
 
 
 
 
 
 
 
 
 
Figure 2.5 Antibacterial cyclic peptides containing biaryl linkages. 55 is vancomycin, 56 is 
biphenomycin A, 57 is biphenomycin B. The biaryl motifs are highlighted in red.  
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2.1.2.3 Other biologically active biaryl-containing compounds 
RP 66453 (58, Figure 2.6) binds selectively to the neurotensin receptor in guinea pigs 
(IC50 = 30 μg/mL).23, 43, 44 Neurotensin is a 13-amino acid peptide which is found 
throughout the central nervous system as well as in enteroendocrine cells in the small 
intestine where it is involved in smooth muscle contraction.45 Neurotensin is implicated 
in many biological pathways: it appears to be involved with dopamine signalling,46 is a 
mitogen for pancreatic and colorectal cancers47-49 and neurotensin-deficient mice are 
less prone to obesity.50 Structural modifications of RP 66453 (leaving the biaryl linkage 
intact) have produced neurotensin antagonists that are claimed to be useful in the 
treatment of various illnesses, such as depression, anxiety disorders, irritable bowel 
syndrome and pancreatitis.51 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Biologically active cyclic peptides containing biaryl linkages. Compound 58 is 
RP66453, a neurotensin antagonist. Compound 59 is TMC-95A which shows anti-tumour 
activity. Compound 60 is complestatin (of chloropeptin II) which inhibits HIV-1 induced 
cytopathicity.  
TMC-95A (59, Figure 2.6) is another tripeptide, cyclised by a biaryl linkage, similar to 
the biphenomycins. It was isolated from the fermentation broth of Apiospora montagnei 
and shows reversible, non-covalent 20S proteasome inhibition.52, 53 Proteasomal 
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degradation of a variety of cellular proteins is essential for many intracellular 
processes, including cell-cycle progression, apoptosis and regulation of metabolic 
pathways.54 Hence, proteasome inhibitors attract interest as potential drug targets.55 
TMC-95A showed activity against HCT-116 human colon carcinoma cells (IC50 = 4.4 
μM) and HC-60 human promyelocytic leukaemia cells (IC50 = 9.8 μM).53 More recently, 
TMC-95A was shown to promote neurite outgrowth in PC12 rat pheochromocytoma 
cells, activity that may be applicable to repairing damaged neurons and hence are of 
interest in the development of drugs to treat conditions such as Parknson’s disease.56 
Finally, complestatin (60, Figure 2.6) is a cyclic peptide containing a biaryl linkage 
isolated from Streptomyces lavendulae and inhibits HIV cytopathicity and HIV-1 antigen 
expression in MT-4 cells with no observable toxicity to the cells up to 400 μM 
concentrations.28, 57 When the MT-4 cells were pretreated with complestatin prior to 
exposure to HIV-1, HIV-1 induced cytopathicity was inhibited. However, pretreatment of 
the HIV-1 with complestatin had no effect. This indicates that complestatin’s primary 
mode of action is via interaction with the cells, inhibiting viral adsorption to the cell 
surface.37  
 
2.1.3 Previously synthesised boron-containing peptoids 
In spite of the obvious synthetic utility of boronic acids, there are at present few 
literature examples of boronic acids being incorporated into peptoids. Furthermore, the 
methods in the literature have limitations. 
The first method involved the synthesis of a boronic acid pinacol ester-containing 
amine, 61 via functional group conversion of an alcohol, 62, (Scheme 2.5). This was 
then made into a short peptoid, 64 (generic structure 63), via a 4-component Ugi 
reaction (Scheme 2.6).58  
 
 
 
 
Scheme 2.5 Synthesis of the amine building block 62.  
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Following synthesis, the peptoid was reacted further in a Suzuk-Miyaura cross-coupling 
reaction (example in Scheme 2.7).58  
Whilst this set of reactions gives moderate yields, it is limited in scope. For the 
synthesis of longer peptoids, the submonomer method is superior; it is less time 
consuming and purification between additions is more straightforward. However, no 
attempt was made to use boronic acid pinacol ester building block in a submonomer 
synthesis. 
 
 
 
Scheme 2.6 4-component Ugi reaction for the formation of a boronic acid-containing peptoid, 
63 from a boronic acid pinacol ester, 62. 
 
 
 
 
Scheme 2.7 A Suzuki-Miyaura cross-coupling reaction on a short peptoid, 64. 
The second method uses a copper mediated 1,3-cycloaddition reaction to incorporate a 
boronic acid at the end of a longer peptoid chain to form boronic acid-containing 
peptoid 65 (Scheme 2.8). Boronic acid-containing peptoid 65 was then cyclised by 
coupling with a hexose at the other end of the chain to form cyclic peptoid 66 (Scheme 
2.9).59 The obvious downside to this method is the necessity of the formation of the 
triazole in the reaction. It has already been seen that such peptoids may still penetrate 
cells, but whilst the triazole is an amide bond mimic, it would be useful to be able to 
include boronic acids without the need to also include a triazole. 
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Scheme 2.8 Incorporation of a boronic acid into a peptoid using a copper-mediated 1, 3 
cycloaddition. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.9 Cyclisation of a boronic acid-containing peptoid, 65, via coupling of a boronic acid 
with a hexose side chain to form cyclic peptoid 66. 
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2.1.4 Aims 
Boronic acids are undoubtedly highly useful synthetic building blocks in various fields of 
organic chemistry but with regards to peptoids they have been considerably under 
used. Part of this is due to the difficulty in incorporating boronic acids into peptoids. 
Boronic acids have so far only been incorporated onto the end of peptoids,58,59 
although the CuAAC method59 (Scheme 2.8) could feasibly be used to incorporate 
boronic acids elsewhere in the peptoid chain via post-translational modification. 
However, this is a lengthy process involving overnight reaction times. Additionally, the 
azidomethyl phenylboronic acids need to be synthesised. Ideally, we would like to be 
able to incorporate boronic acids directly via the submonomer method. 3- and 4- 
(aminomethyl)phenylboronic acid pinacol esters (67 and 68) are commercially available 
and could be used in the submonomer method. However, direct conversion from the 
pinacol ester to the boronic acid frequently results in partial deprotection, even after 
using harsh conditions, long reaction times. It can also be difficult to separate the 
boronic acid from the free diol without reforming the ester.60-62 An alternative protecting 
group is the MIDA group. MIDA boronates (e.g. 69) are benchtop stable and 
deprotection is much more straightforward than for pinacol esters.63,64 The boronic acid 
is protected by N-methyliminodiacetic acid (70, MIDA) which can be removed under 
aqueous basic conditions. MIDA-protected boronic acids were chosen because they 
are air stable and compatible with a wide variety of synthetic conditions. Additionally, 
previous work within the group had demonstrated their stability toward amide coupling 
conditions.65 However, there are no commercially available MIDA boronates which can 
be used directly in submonomer peptoid synthesis without capping the peptoid.  
           
 
The first aim was therefore to synthesis a MIDA boronate-containing builing block 
compatible with the submonomer method of peptoid synthesis that could be used to 
incorporate a boronic acid anywhere in a peptoid (Scheme 2.10). 
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Scheme 2.10 Aim one: Incorporation of a MIDA boronate into a peptoid via the sub-monomer 
Achieving this goal would open up access to a range of peptoids that could be used to 
target specific carbohydrates and thus enable selective delivery of therapeutics and 
imaging agents.   
The second aim in this chapter was to make and cyclise a boronic-acid containing 
peptoid and in the process, form a biaryl group (Scheme 2.11). Linear biaryl-containing 
peptoids have already been synthesised, however we wanted to explore the use of 
Suzuki-Miyaura cross-coupling as a route to cyclic peptoids, the utility of which have 
already been discussed in Chapter 1. It was envisaged that cyclic peptoids containing 
a biaryl motif could be useful as therapeutics to target protein-protein interactions in a 
similar manner to biaryl-containing peptides such as those in the biphenomycin family 
and, accordingly, the activity of these novel peptoid scaffolds against E. coli and S. 
aureus was then investigated. 
 
 
 
 
 
 
 
 
 
Scheme 2.11 Proposed Suzuki-Miyaura cross-coupling to form a cyclic peptoid and incorporate 
a biaryl group. 
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2.2 Making a boronic acid-containing building block with two potential 
coupling groups 
At present, primary amines containing a pinacol boronate esters (e.g. 67 and 69) are 
commercially available, as are MIDA boronates containing aldehyde and acid 
functionalities (e.g. 69 and 71).  
 
 
 
 
 
However, these cannot be incorporated directly into the middle of a peptoid via the 
submonomer method. The acid-functionalised MIDA boronate, 71 can be incorporated 
at the N-terminus of the peptoid, however, this will cap the peptoid meaning that the 
peptoid chain cannot be further extended. The ability to incorporate the boronic acid 
anywhere in a peptoid chain is desirable since this would give access to novel 
functionalities anywhere in the peptoid sequence via post-translational conversion of 
the boronic acids. Incorporation of a boronic acid without capping the peptoid also 
allows coupling of other groups, such as lanthanide probes for the investigation of cell-
penetrating ability, or chelators for MRI contrast agents so the peptoid can be used for 
imaging applications. 
Reductive amination is the reaction of an aldehyde with a primary amine to make a 
secondary amine (Scheme 2.12). A secondary amine used in the displacement step of 
the sub-monomer method of peptoid synthesis would cap the peptoid. However, if the 
amine used in the reductive amination reaction is a glycine, the resulting compound will 
have two reactive groups: a carboxylic acid and a secondary amine, effectively making 
a peptoid monomer (e.g. 72). This can be incorporated into a peptoid using standard 
solid phase peptide coupling conditions (e.g. PyBOP and DIPEA). Following this, 
peptoid synthesis can continue via the submonomer method. A suitable MIDA boronate 
which contains an aldehyde functional group, 4-formylphenylboronic acid MIDA ester is 
commercially available (69, 5g is £95.00 from Sigma Aldrich).  
 
Chapter 2: Boronic Acid-Containing Peptoids 
 
62 
 
 
 
 
 
 
 
 
Scheme 2.12 Proposed formation of a secondary amine by reductive amination, followed by 
removal of the acid protecting group to give a peptoid monomer with two reactive sites (72). The 
carboxylic acid is in red and the secondary amine is in blue. P is a generic protecting group. 
 
 
 
 
 
Glycine benzyl ester (73) was chosen as the amino acid as this most closely replicates 
the flexibility of the peptoid backbone and the benzyl ester is stable to acidic and basic 
conditions. Reaction of 4-formylphenyl boronic acid MIDA ester (69) with glycine benzyl 
ester (73) via reductive amination should give the monomer 74. 
The first attempted synthesis of the target molecule 74 was a one-pot reaction whereby 
MIDA boronate 69 and glycine benzyl ester (73) were added an hour before the 
reducing agent, sodium cyanoborohydride (Scheme 2.13). The first set of conditions 
used sodium cyanoborohydride as the reducing agent and acetonitrile as the solvent. 
Although ethanol tends to be the preferred solvent for reductive aminations, initial tests 
showed that MIDA boronate 69 was stable for several days in acetonitrile, whereas 
new spots were visible on the thin-layer chromatography (TLC) plates in less than an 
hour in ethanol. Glycine benzyl ester, 73, was added in a 1.1-fold excess in an attempt 
to reduce formation of the tertiary amine, 75.  
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Scheme 2.13 The first set of reductive amination conditions for the attempted synthesis of 
target compound 74.  
Whilst target molecule 74 was successfully synthesised, by the time it had been 
purified and isolated by column chromatography, the best yield obtained was 4%. 
Furthermore, the tertiary amine 75 was also isolated in an 8% yield after purification. 
We also suspected some deprotection of the MIDA ester because of the presence of 
multiple additional spots on the TLC and several peaks in the 11B NMR spectrum of the 
crude reaction mixture; however these additional compounds were not isolated. 
Indeed, it proved challenging to isolate all of these compounds as, in spite of 
apparently good separation on the TLC plates, these compounds appear to pull each 
other through the silica in the column, resulting in a significant overlap of fractions, 
leading to a reduction in yield. 
Alternatively, for reductive aminations, including those in the literature using 
compounds containing a boronic acid MIDA ester, sodium triacetoxyborohydride (30) is 
the reducing agent of choice.63 Whilst sodium cyanoborohydride is considered a mild 
reducing agent, sodium triacetoxyborohydride is even milder and has the added benefit 
of producing no toxic side products, unlike sodium cyanoborohydride which can 
generate hydrogen cyanide. The downside of using sodium triacetoxyborohydride is 
that it is water sensitive and as such, all reactions have to be carried out in dry 
conditions and under an inert atmosphere. Sodium triacetoxyborohydride should 
improve the efficiency of the reaction in two ways: first, as a milder reducing agent it 
would not remove the MIDA group, and second, it might also reduce the amount of 
tertiary amine, 75, produced. Both of these effects would not only directly improve the 
yield of target molecule 74, but by reducing the amount of, or not forming the side 
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products purification by column chromatography would be easier. This reaction was 
carried out slightly differently from the one described by Scheme 2.13; all reagents 
were added together and the best yield of 74 (34% after purification) was obtained 
using 1.5 molar equivalents of glycine benzyl ester (73) in relation to aldehyde 69 
(Scheme 2.14).  
 
 
 
 
 
Scheme 2.14: Reductive amination using sodium triacetoxyborohydride (30) as the reducing 
agent to give target peptoid monomer 74. 
It was found that this set of conditions was an improvement on the initial set of 
conditions in Scheme 2.13. TLC analysis showed only two spots: one corresponding to 
the starting aldehyde (69) and one new spot which was found after purification of the 
crude reaction mixture to be target compound 74. There was no evidence of any 
deprotection of the MIDA boronate group. The reaction was stopped after two days 
because LC mass spec. analysis indicated that tertiary amine 75 was starting to form, 
although this was evidently not present in a large amount as none was isolated from 
column chromatography of the crude reaction mixture. As a result of all of this, 
purification was much simpler and the isolated yield of monomer 74 was improved to a 
workable 34%. A further 14% can be attributed to unreacted aldehyde, 69. However, 
this still leaves around 50% of the yield unaccounted for. Monomer 74 was isolated as 
a colourless, sticky solid which, once out of solution proved very difficult to re-dissolve. 
Initial purification involved extracting monomer 74 into ethyl acetate and washing with 
aqueous sodium bicarbonate and water. However, after ethyl acetate had been 
removed, the crude reaction mixture would only re-dissolve in ethyl acetate when 
heated. It is therefore possible that some monomer 74 was left in the aqueous 
washings, contributing to the poor yield.  
The presence of starting aldehyde 69 clearly showed that the reductive amination 
reaction did not go to completion and this would be an obvious area to look at in order 
to improve the yield. The fact that it was the aldehyde, 69, that was present showed 
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that the problem was in imine formation rather than its subsequent reduction and 
therefore a possible route to improving the yield would be the addition of an acid 
catalyst. However, this could also lead to formation of the tertiary amine, 75. 
 
Scheme 2.15 Deprotection of the benzyl ester of monomer 74 and the compounds identified in 
the ESI LCMS of the crude reaction mixture (77 – 79, Figure 2.7).  
Deprotection of the benzyl ester was attempted next. Solubility of monomer 74 was 
problematic; it was completely insoluble in most solvents, including ethyl acetate, 
acetonitrile and isopropanol, and only sparingly soluble in methanol. This is unhelpful 
as MIDA boronates are known to decompose in solutions containing alcohols if left for 
more than an hour.66 This is consistent with the earlier TLC experiments which showed 
the appearance of new spots when 4-formylphenylboronic acid MIDA ester (69) was 
dissolved and left to stand in ethanol. Nevertheless, we proceeded with the 
hydrogenation using PdOH/C under argon (Scheme 2.15). The reaction was left for 
two hours at room temperature and ESI LCMS was used to determine that the reaction 
had finished. Unfortunately, the ESI LCMS (Figure 2.7) showed multiple compounds 
were present, including the target compound, 77, and its analogue with the free boronic 
acid, 78. The third major fraction in the ESI LCMS corresponded to the starting material 
with the boronic acid deprotected and benzyl ester intact, 79. Even though the benzyl 
ester had not been fully removed, the reaction was stopped since MIDA boronate 
decomposition was clearly already happening. 11B NMR of the crude product mixture 
(Figure 2.8) showed two peaks, including one at δ = 29.14 ppm which is characteristic 
of free boronic acids, providing further evidence of MIDA ester deprotection. Previous 
purifications of mixtures containing free and MIDA protected boronic acids were 
inefficient and extremely time-consuming, so no purification attempts were carried out.  
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Figure 2.7 Electrospray LCMS and chromatogram of the crude reaction mixture following 
attempted deprotection of the benzyl ester of monomer 74 (Scheme 2.15). A) Mass spectrum 
fraction containing peaks corresponding to target compound 77, [M + H]+ = 322, corresponding 
to 0.38 minutes in the chromatogram. B) Mass spectrum fraction containing peaks 
corresponding to the compound with a free carboxylic acid and free boronic acid, 78, [M + H]+ = 
211, corresponding to 0.24 minutes in the chromatogram. C) Mass spectrum fraction containing 
peaks corresponding to the starting material with free boronic acid, 79, [M + H]+ = 300, 
corresponding to 1.09 minutes in the chromatogram. D) The chromatogram of the reaction 
mixture (detection at 220 nm). 
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Figure 2.8 11B NMR of the crude reaction mixture following attempted deprotection of the 
benzyl ester of 74, using conditions shown in Scheme 2.15. 
 
2.3 Synthesis of Biaryl-Containing Cyclic Peptoids 
2.3.1 Synthetic Strategy 
Our chosen method of biaryl group formation was via Suzuki-Miyaura cross-coupling 
(Scheme 2.4). We wanted to carry out the cross-coupling reaction on resin. By keeping 
the linear parent peptoid on resin, the need for cleavage and purification prior to 
cyclisation is precluded. Solid phase reactions also simplify the final purification steps 
since unreacted materials and other side products can be washed off the resin prior to 
cleavage and subsequent HPLC purification. We also hoped that carrying out the 
cross-coupling reaction on resin would remove competition from intermolecular cross-
coupling, essentially generating pseudo-high dilution conditions.    
2.3.2 Incorporation of the reactive groups 
In order to carry out a cyclisation via Suzuki-Miyaura cross-coupling, the resin-bound 
linear parent peptoid must contain both an aromatic iodide and an aromatic boronic 
acid. 3-Iodobenzylamine (80) and 4-iodoaniline (81) are commercially available and 
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can be incorporated into the peptoid at any position via the submonomer method of 
synthesis (Scheme 2.16).  
Both the 3- and 4-carboxyphenyl boronic acid MIDA esters (82 and 71) were, at the 
time the reactions were carried out, commercially available from Sigma Aldrich (4-
carboxyphenyl boronic acid MIDA ester (71) has since been discontinued).  
 
 
 
 
 
 
Scheme 2.16: Incorporation of an aromatic iodide via the submonomer method of peptoid 
synthesis using 3-iodobenzylamine (80) or 4-iodoaniline (81). 
 
 
 
 
 
4-Carboxyphenyl boronic acid was used to test coupling conditions for suitability. A 
linear resin-bound peptoid containing iodoaniline (83) was first synthesised and 
confirmed by ESI LCMS on a portion of cleaved peptoid (84, Scheme 2.17).   
 
 
 
 
Scheme 2.17 Iodoaniline-containing peptoid (resin-bound peptoid 83 and free peptoid 84). 
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Couplings were then carried out on resin-bound peptoid 83 in the presence of DIC 
(Scheme 2.18) at room temperature for one hour and at 50°C for 30 minutes and 15 
minutes. Following coupling of the MIDA boronate, a portion of the peptoid (85) was 
cleaved from the resin (Scheme 2.19) and the free peptoid (86) was analysed by 
electrospray LCMS (Figures 2.9 – 2.11). 
 
 
 
 
 
 
 
 
 
 
Scheme 2.18 Incorporation of 4-carboxyphenyl boronic acid MIDA ester (71) into a peptoid to 
followed by cleavage from the resin for ESI LCMS analysis. 
 
 
 
 
 
 
In all three reactions, coupling of the MIDA boronate was incomplete. Peaks with m/z 
660 were seen in the LCMS of all three reactions. This corresponds to peptoid 84. The 
best level of conversion was seen in the reaction at room temperature for one hour. 
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However, the LCMS of each reaction mixture also showed evidence of deprotection of 
the MIDA group with peaks at m/z 809 and 405. The level of deprotection is unclear as 
the retention time is the same as that of the MIDA boronate. No further reactions at 
50°C were carried out as prolonged heating is likely to increase the rate of 
deprotection. All coupling reactions with MIDA boronates were subsequently carried 
out for one hour at room temperature. 
 
  
Figure 2.9 Electrospray LCMS and chromatogram following coupling of 4-carboxyphenylboronic 
acid MIDA ester (71) onto resin-bound peptoid 83 (Scheme 2.18). Coupling was carried out at 
room temperature for 1 hour. Test cleavage conditions are also shown in Scheme 2.18. A) 
Mass spectrum fraction containing peaks corresponding to linear peptoid 86, [M + H]+ = 919, 
corresponding to 1.79 minutes in the chromatogram. Also present are peaks corresponding to 
peptoid boronic acid 87, [M + H]+ = 809. B) Mass spectrum fraction containing peaks 
corresponding to unreacted linear peptoid 84, i.e. with no MIDA boronate, [M + H]+ = 660, 
corresponding to 0.19 minutes in the chromatogram. C) The chromatogram of the test-cleave 
mixture (detection at 220 nm).  
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Figure 2.10 Electrospray LCMS and chromatogram following coupling of 4-
carboxyphenylboronic acid MIDA ester (71) onto resin-bound peptoid 83 (Scheme 2.18). 
Coupling was carried out at 50°C for 15 minutes. Test cleavage conditions are also shown in 
Scheme 2.18. A) Mass spectrum fraction containing peaks corresponding to linear peptoid 86, 
[M + H]+ = 919, corresponding to 1.53 minutes in the chromatogram. Also present are peaks 
corresponding to peptoid boronic acid 87, [M + H]+ = 809.  B) Mass spectrum fraction containing 
peaks corresponding to unreacted linear peptoid 84, i.e. with no MIDA boronate, [M + H]+ = 660, 
corresponding to  0.35 minutes in the chromatogram. C) The chromatogram of the test-cleave 
mixture (detection at 220 nm).  
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Figure 2.11 Electrospray LCMS and following coupling of 4-carboxyphenylboronic acid MIDA 
ester (71) onto resin-bound peptoid 83 (Scheme 2.18). Coupling was carried out at 50°C for 30 
minutes. Test cleavage conditions are also shown in Scheme 2.18. A) Mass spectrum fraction 
containing peaks corresponding to linear peptoid 86, [M + H]+ = 919, corresponding to 1.68 
minutes in the chromatogram. Also present are peaks corresponding to peptoid boronic acid 87, 
[M + H]+ = 809.  B) Mass spectrum fraction containing peaks corresponding to unreacted linear 
peptoid 84, ie with no MIDA boronate, [M + H]+ = 660, corresponding to  0.22 minutes in the 
chromatogram. C) The chromatogram of the test-cleave mixture (detection at 220 nm). 
 
2.3.3 Synthesis of linear biaryl peptoids 
As previously mentioned, we wanted to carry out the cyclisation reaction whilst the 
peptoid was still on resin. The first set of conditions under which Suzuki cross-coupling 
was attempted used tetrakis palladium as the catalyst, with 2M Na2CO3 as a base in 
9:1 ethanol:toluene, heated at 95°C for 24 hours. These conditions were obtained from 
a 2005 paper by Fernàndez et al. in which they carried out Suzuki cross-coupling 
reactions onto Rink Amide resin-bound 5-bromonicotinic acid (88, Scheme 2.19).67 
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Scheme 2.19 Suzuki cross-coupling reaction carried out on resin-bound 5-nicotinic acid (88).67 
Before attempting to use these conditions to synthesise a cyclic peptoid, we first 
attempted Suzuki cross-coupling reactions on a series of linear peptoids (89 – 91, 
Figure 2.12).  
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Figure 2.12 The three resin-bound linear peptoids synthesised for test Suzuki-Miyaura cross-
coupling reactions. 
Two peptoids, 89 and 90, contained as the first residue, aromatic iodine functionalities 
from 4-iodoaniline, 81, and from 3-iodobenzylamine, 80 respectively. The aromatic 
iodide residues were incorporated as the first residue to investigate whether steric 
hindrance as a result of proximity to the resin would prevent the cross-coupling reaction 
from taking place. If the cross-coupling reaction failed to work for an intermolecular 
reaction, it would be unlikely to work for the intramolecular reaction. The peptoids were 
capped with an acyl group to prevent side-reactions with a free terminal amine. The 
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ESI LCMS of the test cleave mixture of the peptoid containing 4-iodoaniline (Figure 
2.13) showed two major components were present: the desired iodine-containing 
peptoid, 92, and a peptoid with deletion of the iodoaniline residue, 93, (Scheme 2.20) 
even after a nearly three hour reaction time.  
 
 
 
 
 
 
 
 
 
 
Scheme 2.20 Cleavage of a peptoid containing an iodoaniline functionality (89) from Rink 
Amide resin. 
The presence of the deletion side-product is not surprising. Aniline is known to be a 
difficult submonomer to incorporate into peptoids due to its low nucleophilicity. Using 
silver salts in the displacement step has been reported to accelerate the reaction up to 
76-fold.68 However, no further modifications to the reaction conditions were attempted. 
For the peptoid containing the 3-iodobenzylamine monomer, 90, the ESI LCMS of the 
test cleave mixture (Figure 2.14) showed only the desired peptoid, 94, (Scheme 2.21) 
with no detectable signals corresponding to a deletion.  
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Scheme 2.21 Cleavage of a peptoid containing a 3-iodobenzylamine functionality (90) from 
Rink Amide resin. 
 
Scheme 2.22 Test cleave reaction of a peptoid containing a terminal boronic acid MIDA ester 
(91) from Rink Amide resin   
The third linear peptoid made, 91, contained a terminal aromatic boronic acid MIDA 
ester. The ESI LCMS of the test cleave mixture (Figure 2.15) showed three major 
peaks in the chromatogram: one at 0.65 minutes, one at 0.82 minutes and one at 1.71 
minutes. The peak at 0.65 minutes corresponded to the free boronic acid-containing 
peptoid, 96 and the peak at 0.82 minutes corresponded to the MIDA boronate-
containing peptoid, 95. The peak at 1.71 minutes corresponded to a compound with a 
mass of 586 or 293. However, no reasonable reaction by-products or side products 
(e.g. deletions, partially deprotected species, starting material or reagents) correspond 
to either mass, so we proceeded on the assumption that this peak was not significant 
Chapter 2: Boronic Acid-Containing Peptoids 
 
76 
 
and ignored it. Two things were notable: first that there were no peaks corresponding to 
deletion of the boronate building block, indicating that coupling of 4-
carboxyphenylboronic acid had gone to completion, unlike in the previous test 
reactions. Second, that there was a separate peak in the LCMS chromatogram 
corresponding to the free boronic acid; in the test reactions (Scheme 2.18 and Figures 
2.9 – 2.11), masses corresponding to the free boronic acid were seen in the same peak 
in the chromatogram as the MIDA boronate. This indicates that MIDA deprotection 
occured in either the coupling reaction or in the test cleave reaction. However, since 
the next step is carrying out the Suzuki-Miyaura cross-coupling reaction, protection of 
the boronic acid is not critical. 
 
 
Figure 2.13 Electrospray LCMS and chromatogram of the crude reaction mixture following 
synthesis of iodoaniline-containing linear peptoid 89. Test cleave conditions are shown in 
Scheme 2.20. A) Mass spectrum fraction containing peaks corresponding to iodine-containing 
linear peptoid 92, [M + H]+ = 575, corresponding to 1.71 minutes in the chromatogram. B) Mass 
spectrum fraction containing peaks corresponding to peptoid with aromatic iodide deletion, 93, 
[M + H]+ = 316, [M + Na]+ = 338, corresponding to 0.24 minutes in the chromatogram. C) The 
chromatogram of the test cleave mixture (detection at 220 nm). 
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Figure 2.14 Electrospray LCMS and chromatogram of the crude reaction mixture following 
synthesis of 3-iodobenzylamine-containing linear peptoid 90. Test cleave conditions are shown 
in Scheme 2.21. A) Mass spectrum fraction containing peaks corresponding to iodine-
containing linear peptoid 94, [M + H]+ = 589, corresponding to 1.71 minutes in the 
chromatogram. B) The chromatogram of the test cleave mixture (detection at 220 nm). 
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Figure 2.15 Electrospray LCMS and chromatogram of the crude reaction mixture following 
synthesis of MIDA boronate-containing linear peptoid 91. Test cleave conditions are shown in 
Scheme 2.22. A) Mass spectrum fraction containing peaks corresponding to MIDA boronate-
containing linear peptoid 95, [M + H]+ = 589, corresponding to 0.82 minutes in the 
chromatogram. B) Mass spectrum fraction containing peaks corresponding to free boronic acid-
containing peptoid, 96, [M + H]+ = 479, corresponding to 0.65 minutes in the chromatogram. C) 
The chromatogram of the test cleave mixture (detection at 220 nm). 
Having successfully synthesised the linear peptoids 89 – 91, on resin Suzuki-Miyaura 
cross-coupling was attempted.  Resin-bound peptoids 89 and 90 were both reacted 
with phenylboronic acid (97) using the ethanolic toluene conditions (Schemes 2.23 and 
2.24). Following the reaction, the peptoid was cleaved from the resin and analysed by 
ESI LCMS. In both cases, biaryl-containing linear peptoids (98 and 99) were found in 
the ESI LCMS of the crude peptoids (Figures 2.16 and 2.17). These were, however, 
A)  
B) 
C) 
Peptoid 95 
Peptoid 96 
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not isolated. Whilst other peaks were visible in the respective ESI LCMS 
chromatograms, the masses of the compounds present could not be assigned to any 
peptoid-related byproduct. Notably, in the reaction with the iodoaniline-containing linear 
peptoid, 89, no mass peaks corresponding to unreacted peptoid were present, but in 
the reaction with the iodobenzylamine-containing linear peptoid, 94, unreacted peptoid 
appeared in the mass spec under the same peak in the chromatogram (1.63 minutes) 
as the biaryl-containing peptoid, 99. 
 
 
Scheme 2.23 Intermolecular Suzuki cross-coupling reaction carried out on aromatic iodide 
containing peptoid (89). 
 
Scheme 2.24 Intermolecular Suzuki cross-coupling reaction carried out on aromatic iodide 
containing peptoid (90).  
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Figure 2.16 Electrospray LCMS and chromatogram of the crude reaction mixture following the 
Suzuki cross-coupling reaction between iodoaniniline containing peptoid (89) and phenylboronic 
acid (97), Scheme 2.23. A) Mass spectrum fraction containing peaks corresponding to biaryl-
containing peptoid 98, [M + H]+ = 525, corresponding to 1.75 minutes in the chromatogram. B) 
The chromatogram of the test-cleave mixture (detection at 280 nm).  
 
Figure 2.17 Electrospray LCMS and chromatogram of the crude reaction mixture following the 
Suzuki cross-coupling reaction between iodobenzylamine-containing peptoid 90 with phenyl 
boronic acid (97), Scheme 2.24. A) Mass spectrum fraction containing peaks corresponding to 
biaryl-containing peptoid 99, [M + H]+ = 539, corresponding to 1.63 minutes in the 
chromatogram. B) The chromatogram of the test cleave mixture (detection at 280 nm).  
A)  
B) 
A)  
B) 
Linear biaryl peptoid 98 
Linear biaryl peptoid 99 
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The linear aromatic iodide-containing peptoids (89 and 90) were then reacted with 
phenylboronic acid MIDA ester (100, Schemes 2.27 and 2.28). The aim of these 
reactions was to see whether the cross-coupling reaction could be done without prior 
deprotection of the MIDA ester. Since MIDA boronates are deprotected in the presence 
of aqueous base we hoped that the sodium carbonate used for the cross-coupling 
reaction would also deprotect the MIDA ester. The reaction conditions remained the 
same and, again, following the reaction, the peptoid was cleaved from the resin and 
analysed by ESI LCMS. In both cases, linear biaryl-containing peptoids 98 and 99 were 
seen (Figures 2.18 and 2.19), though, again, neither was isolated. As with the 
reactions of the linear peptoids with phenylboronic acid, 97, unexplained peaks were 
present in the chromatogram, and unreacted linear iodobenzylamine-containing 
peptoid, 94, appeared in the ESI LCMS under the same chromatogram peak as the 
biaryl-containing peptoid, 99. 
 
Scheme 2.25 Intermolecular Suzuki cross-coupling reaction carried out on aromatic iodide 
containing peptoid (89).  
 
 
 
 
 
Scheme 2.26 Intermolecular Suzuki cross-coupling reaction carried out on aromatic iodide 
containing peptoid (90).  
Chapter 2: Boronic Acid-Containing Peptoids 
 
82 
 
 
Figure 2.18 Electrospray LCMS and chromatogram of the crude reaction mixture following the 
Suzuki cross-coupling reaction between iodoaniline-containing linear peptoid 89 with phenyl 
boronic acid MIDA ester (100), Scheme 2.25. A) Mass spectrum fraction containing peaks 
corresponding to biaryl-containing peptoid 98, [M + H]+ = 525 corresponding to 1.63 minutes in 
the chromatogram. B) The chromatogram of the test cleave mixture (detection at 280 nm).  
 
Figure 2.19 Electrospray LCMS and chromatogram of the crude reaction mixture following the 
Suzuki cross-coupling reaction between iodobenzylamine-containing linear peptoid 90 with 
phenyl boronic acid MIDA ester (100), Scheme 2.26. A) Mass spectrum fraction containing 
peaks corresponding to biaryl-containing peptoid 99, [M + H]+ = 539, and unreacted peptoid 94, 
[M+H]+ = 589.2 corresponding to 1.77 minutes in the chromatogram. B) The chromatogram of 
the test cleave mixture (detection at 280 nm).  
A)  
B) 
A)  
B) 
Linear biaryl peptoid 98 
Linear biaryl peptoid 99 and 
unreacted iodobenzylamine-
containing linear peptoid 94 
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Next, the Suzuki-Miyaura cross-coupling reaction was carried out on the MIDA 
boronate-containing linear peptoid, 91. Resin-bound peptoid 91 was then reacted with 
iodobenzene (101) under ethanolic toluene conditions (Scheme 2.27), cleaved from 
the resin and the crude peptoid (102) analysed by ESI LCMS (Figure 2.20).  Unlike the 
reactions on the iodine-containing linear peptoids (89 and 90), there was only one 
major peak in the chromatogram, corresponding to the biaryl-containing peptoid, 102. 
No peaks corresponding to the unreacted linear peptoid, 95, were seen.  
 
 
 
 
Scheme 2.27 Intermolecular Suzuki cross-coupling reaction carried out on a MIDA boronate-
containing short peptoid (91). 
 
Figure 2.20 Electrospray LCMS and chromatogram of the crude reaction mixture following the 
Suzuki cross-coupling reaction between MIDA boronate-containing linear peptoid 91 with 
iodobenzylamine (101), Scheme 2.27. A) Mass spectrum fraction containing peaks 
corresponding to biaryl-containing peptoid 102, [M + H]+ = 511, corresponding to 1.65 minutes 
in the chromatogram. B) The chromatogram of the test cleave mixture (detection at 280 nm).  
A)  
B) 
Linear biaryl peptoid 102 
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2.3.4 Cyclisation 
Having successfully carried out cross-coupling reactions on a series of linear peptoids, 
we then attempted cyclisation via an intramolecular Suzuki cross-coupling reaction. 
The previous ethanolic toluene conditions were applied to a resin-bound short linear 
peptoid containing both an aromatic iodide and an aromatic MIDA boronate (103, 
Scheme 2.28) which was synthesised using conditions previously described in Section 
2.3.2. The coupling time was extended to 48 hours to account for the increased 
difficulty in bringing the reactive groups together. The peptoid was then cleaved from 
the resin and purified by HPLC. However, in spite of seeing peaks in the ESI LCMS 
corresponding to the cyclic peptoid (104, Figure 2.21), we were unable to isolate it. 
Having failed to isolate the cyclic peptoid on several occasions, we therefore looked to 
adjust our reaction conditions. 
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Scheme 2.28 Intramolecular Suzuki cross-coupling to synthesise a biaryl-containing cyclic 
peptoid (104). 
In 2016 Nam and Seo screened different reaction conditions and reported Suzuki-
Miyaura cross-couplings on resin-bound peptoids.69 Unlike the ethanolic toluene 
conditions previously attempted, the reaction conditions screened in this study were 
carried out on a series on linear peptoids. Since their peptoids were more similar to our 
compounds than anything seen in previous work, we looked to adapt these optimised 
reaction conditions. To test these conditions we first looked to carry out intermolecular 
Suzuki-Miyaura cross couplings once more on linear peptoids. The intermolecular 
reactions were carried out on aromatic iodide-containing peptoids 89 and 90 (with 
phenylboronic acid MIDA ester, 100) as well as MIDA boronate-containing peptoid 105 
(with iodobenzene, 101, Scheme 2.29).  
Following purification by HPLC and subsequent ESI LCMS analysis of the fractions, we 
found that, surprisingly, the reaction had been unsuccessful with iodine-containing 
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peptoids (89 and 90), but had been successful on the peptoid containing the MIDA 
boronate (105) and the biaryl-containg linear peptoid, 106 was isolated as a white 
powder (8%).  
 
Figure 2.21 Electrospray LCMS and chromatogram of the crude reaction mixture following 
attempted cyclisation via Suzuki cross-coupling reaction of linear resin-bound linear peptoid 
103, under conditions described in Scheme 2.28. A) Mass spectrum fraction containing peaks 
corresponding to biaryl-containing cyclic peptoid 104, [M + H]+ = 651, corresponding to 1.65 
minutes in the chromatogram. B) The chromatogram of the test cleave mixture (detection at 280 
nm).   
 
 
 
 
 
 
Scheme 2.29 Intermolecular Suzuki-Miyarua cross coupling to synthesise linear biaryl-
containing peptoid (106). 
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In spite of the reaction failing for two of the linear peptoids and an 8% yield from the 
third, we decided to try carrying out a cyclisation reaction on the short linear peptoid 
103 (Scheme 2.30). Following HPLC purification, cyclic peptoid 104 was isolated as a 
white solid and confirmed by accurate mass analysis and analytical HPLC. Whilst 
biaryl-containing cyclic peptoid 104 was the only compound isolated, the elimination 
product (107) was seen in the ESI LCMS of some HPLC fractions. Another reaction 
byproduct seen in the ESI LCMS of the crude product (Figure 2.22) mixture and in 
some HPLC fractions arises from the elimination of iodine and deprotection of the 
MIDA boronate to give compound 108. 
 
Scheme 2.30 Solid phase cyclisation of parent linear peptoid (103) into resin bound cyclic 
peptoid (104) via Suzuki cross-coupling. 
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Figure 2.22 Electrospray LCMS and chromatogram of crude reaction mixture following 
attempted cyclisation via Suzuki-Miyaura cross-coupling of linear resin-bound peptoid 103 
under conditions described in Scheme 2.30. A) Mass spectrum fraction containing peaks 
corresponding to biaryl-linked cyclic peptoid 104, [M + H]+ = 651, corresponding to 0.92 minutes 
in the chromatogram. B) Mass spectrum fraction containing peaks corresponding to free boronic 
acid-containing peptoid byproduct, 108, [M + H]+ = 697, corresponding to 1.16 minutes in the 
chromatogram. C) The chromatogram of the test cleave mixture (detection at 280 nm). 
 
 
 
 
A)  
B) 
C) 
Cyclic biaryl peptoid 104 
Linear peptoid byproduct 108 
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Having shown that it is possible to carry out on resin cyclisation by Suzuki-Miyaura 
cross-coupling of linear peptoid, we wanted to investigate whether flexibility of the 
chain made a difference. To test this, we made peptoid 109, an analogue of peptoid 
103 where the third NLys residue was replaced by a glycine residue, essentially 
removing the side chain of the third residue, and carried out the cross-coupling reaction 
(Scheme 2.31). Again, the cyclic peptoid (110) was isolated as a white solid and 
confirmed by accurate mass analysis and analytical HPLC, and again, the elimination 
product, 111, whilst not isolated, was seen in the ESI LCMS of some HPLC fractions. 
As with the reaction on linear peptoid 103, the free boronic acid iodine elimination 
byproduct, 112, was also seen in the ESI LCMS of the crude reaction mixture (Figure 
2.23). 
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Scheme 2.31 Solid phase cyclisation of parent linear peptoid (109) into resin bound cyclic 
peptoid (110) via Suzuki cross-coupling. 
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Figure 2.23 Electrospray LCMS and chromatogram of crude reaction mixture following 
attempted cyclisation via Suzuki-Miyaura cross-coupling of linear peptoid 109 under conditions 
described in Scheme 2.31. A) Mass spectrum fraction containing peaks corresponding to biaryl-
linked cyclic peptoid 110, [M + H]+ = 581, corresponding to 1.43 minutes in the chromatogram. 
B) Mass spectrum fraction containing peaks corresponding to free boronic acid-containing 
peptoid byproduct, 112, [M + H]+ = 626, corresponding to 1.32 minutes in the chromatogram. C) 
The chromatogram of the test cleave mixture (detection at 280 nm). 
 
2.3.5 Synthesis of a peptoid library 
Next, we wanted to probe the effects of chain length and regio-isomerism of the MIDA 
boronate. Therefore, we synthesised a library of eight linear peptoids (103, 109 and 
113 – 118) on which cyclisation via intramolecular Suzuki-Miyaura cross-coupling was 
carried out to give eight cyclic biaryl-containing peptoids (104, 110 and 119 – 124, 
Table 2.1). 
 
 
 
A)  
B) 
C) 
Cyclic biaryl peptoid 110 
Linear peptoid byproduct 112 
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Table 2.1 The library of biaryl-linked cyclic peptoids and their linear parent peptoids 
Linear peptoid Cyclic peptoida Yield (%)b 
  
 
 
15 
  
 
 
9 
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23 
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Linear peptoid Cyclic peptoida Yield (%)b 
  
 
 
14 
N
H
O
N
O
N
3
B
O
NO
O
O
NHBoc
OH
N
O
I
116   
 
 
13 
  
 
 
3 
  
 
 
17 
a Cyclic peptoids synthesized from linear parent peptoids under conditions shown in Scheme 2.6 and 
Scheme 2.7 
b Isolated yields are calculated assuming that parent linear peptoids were synthesized with full conversion 
(e.g. 100% yield). 
 
 
 
Chapter 2: Boronic Acid-Containing Peptoids 
 
92 
 
Biaryl-containing cyclic peptoids were isolated from all of the linear sequences 
investigated but the isolated yields did vary. Perhaps predictably, the longer sequences 
(115 – 118) appeared to be more difficult to cyclise, presumably due to a larger 
entropic penalty associated with constraining more flexible chains. With the exception 
of cyclic peptoids 110 and 122, in each case, the yield of the cyclic peptoid recovered 
was lower as the sequence increased in length. For the shorter linear peptoids 
containing the 3-MIDA boronate building block (i.e. compare 103 and 109) 
incorporation of a less hindered glycine monomer into the sequence (109) reduced the 
yield of the cyclic peptoid obtained (i.e. compare 104 and 110). This may indicate that 
the Nlys monomer confers some level of secondary structure in the linear peptoid (103) 
that makes the cross-coupling cyclisation reaction more favorable, whereas the extra 
flexibility conferred by the glycine monomer in 109 results in a greater entropic penalty 
having to be paid.  Interestingly, the opposite is seen for the longer peptoids (i.e. 117 
and 118) with the glycine-containing linear peptoid (118) cyclising more readily than the 
Nlys-containing counterpart (117). For the shorter linear peptoids containing the 4-
MIDA boronate building block (113 and 114), the presence of the Nlys side chain 
versus the glycine monomer appeared to make little difference to the efficiency of 
cyclisation, however, both resulting cyclic peptoids (119 and 120) were isolated in 
higher yields than the cyclic peptoids (104 and 110) formed from the corresponding 
shorter 3-MIDA boronate containing linear peptoids (103 and 109). This perhaps 
suggests that the formation of 3,4-biaryl-linked cyclic peptoids (119 and 120) is favored 
over the formation of the corresponding 3,3-biaryl-linked cyclic peptoids (104 and 110). 
The same trend is also seen as peptoid sequence length is increased, i.e. 3,4-biaryl-
linked cyclic peptoid 124 was isolated in a higher yield than the corresponding 3,3-
biaryl-linked cyclic peptoid 122. However, given that the isolated yields in all of the 
aforementioned cases were not significantly different, it is difficult to draw any definitive 
conclusions from the data obtained. To gain more accurate information would require 
the linear peptoids to be cleaved and purified prior to Suzuki cross-coupling, but as 
discussed earlier the on-resin cyclisation confers many advantages in the overall 
synthetic strategy. 
 
 
2.3.5 Biological Testing against E. coli and S. aureus 
 
Five of the biaryl-containing peptoids were tested against Gram positive (S. aureus) 
and Gram negative (E. coli) bacteria: the linear biaryl peptoid, 106, and the four shorter 
biaryl-linked cyclic peptoids, 104, 110, 119 and 120. Peptoids were dissolved first in 
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water and then diluted further with Isosensitest broth. 50 μL of the resulting peptoid 
solution and 50 μL of bacteria were added to each test well to give the final peptoid 
concentrations listed in Table 2.2. Concentrations were deliberately high (i.e. in the mM 
ranges rather than μM ranges) in order to see if the peptoids showed any anti-bacterial 
activity, before any attempt to determine the minimum inhibitory concentration (MIC) 
ranges. Each compound was tested in triplicate, and positive (bacteria and medium 
with no peptoid) and negative (medium with no bacteria or peptoid) controls were also 
included. After incubation at 37°C for 16 hours with shaking the A650 readings were 
taken and the results are shown in Figure 2.24. Unfortunately, none of the peptoids 
tested showed activity against either S. aureus or E. coli and any differences in A650 
readings between peptoids and the control were within error. The concentrations tested 
were deliberately high (i.e. on a mmol scale) and so the lack of anti-bacterial activity is 
a potential indicator of difficulty in permeabilising the bacterial cell membranes.  
 
 
 
Figure 2.24 Results of bacterial testing of biaryl-containing peptoids against S. aureus and E. 
coli. Comparison of absorbance at 650 nm readings of peptoid-bacteria cultures and the 
positive control (i.e. bacteria only) following incubation at 37°C for 16 hours. 
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Table 2.2 Peptoids tested against S. aureus and E. coli and their concentrations 
Compound number Concentration/ mM 
 
 
 
1.4 
 
 
4.4 
 
 
4.0 
 
 
5.3 
 
 
 
4.3 
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 2.4 Conclusions 
2.4.1 Synthesis of the boronic acid-containing peptoid monomer 
A benzyl-protected MIDA boronate-containing peptoid monomer was successfully 
synthesised via a reductive amination reaction between 4-formylphenylboronic acid 
MIDA ester (69) and glycine benzyl ester (73). 
The first attempts at the reaction used sodium cyanoborohydride as the reducing 
agent. However, whilst the reaction afforded the benzyl-protected target monomer (74), 
the isolated yield was low as these conditions also produced the tertiary amine (75) 
and was suspected of causing partial loss of the MIDA group. This resulted in a crude 
reaction mixture that was difficult to purify. All of these factors contributed to a poor 
isolated yield of the target monomer (74) of only 4%. The use of sodium 
triacetoxyborohydride (76) as an alternative, milder reducing agent proved more 
effective; no tertiary amine was seen, nor any suspected deprotection of the MIDA 
boronate and after a much more straightforward purification, the target monomer was 
isolated in a 34% yield in the most effective reaction conditions used (Scheme 2.14).  
Unfortunately, the target monomer (74) turned out to be a sticky, resinous solid which 
was insoluble in non-alcoholic solvents, and only poorly soluble in ethanol and 
methanol. This meant that subsequent attempted deprotection of the benzyl ester 
resulted in partial deprotection of the MIDA boronate before complete removal of the 
benzyl ester.  
2.4.2 Synthesis of biaryl-linked cyclic peptoids 
Linear peptoids containing terminal MIDA-protected boronic acids were successfully 
synthesised using the peptoid submonomer method and standard solid phase peptoid 
coupling conditions (Scheme 2.18). 3- or 4-carboxyphenyl boronic acid (82 and 71 
respectively) were used as the MIDA boronate-containing monomer and treated as an 
amino acid. The MIDA ester remained intact following the coupling conditions used 
(DIC at room temperature for an hour) and following cleavage using 95% TFA.  
Aromatic iodine-containing linear peptoids were also made by using 3-iodobenzylamine 
(80) and 4-iodoanline (81) as amines in the displacement step of submonomer peptoid 
synthesis (Scheme 2.16), although use of 4-iodoaniline (81) resulted in the observation 
of a deletion product as a result of the low nucleophilicity of the aniline submonomer.  
On-resin intermolecular Suzuki-Miyaura cross-coupling using tetrakis palladium in 
ethanolic toluene conditions (Schemes 2.23 – 2.27) was attempted on the linear 
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peptoids and resulting LCMS analysis of the crude reaction mixtures showed that this 
had been successful, although none of the linear biaryl-containing peptoids were 
isolated at this stage.    
In spite of the apparent success of the intermolecular Suzuki-Miyaura cross-coupling 
reaction using ethanolic toluene conditions, when used to attempt the intramolecular 
cyclisation reaction on a peptoid containing both an aromatic iodide residue and a 
boronic acid-containing residue (103), the reaction was unsuccessful and we were 
unable to isolate the cyclic product (104). We therefore attempted the cross-coupling 
reactions using conditions described by Nam and Seo in a 2016 paper.69 Under these 
conditions we isolated linear biaryl peptoid 106 in an 8% yield (Scheme 2.29). When 
used in the intramolecular Suzuki-Miyaura cross-coupling reaction, we were able to 
isolate the cyclic biaryl-containing peptoid 104 in a 15% yield. (Scheme 2.30) However, 
we also observed in the LCMS of the HPLC fractions the presence of the linear 
elimination product (107) and the linear peptoid where the iodine has been removed 
and the MIDA boronate deprotected (108). 
We then synthesised a library of eight cyclic biaryl-containing peptoids (104, 110 and 
119 to 124) to test whether these conditions were applicable to peptoids of different 
chain lengths, chain flexibilities and in the case of regio-isomerism around the biaryl 
group. All peptoids were successfully synthesised in yields of 3 – 23% (Table 2.1).  
Finally, five of the biaryl-containing peptoids (one linear peptoid, 106, and four cyclic 
peptoids, 104, 110, 119 and 120) were screened against S. aureus and E. coli in high 
concentrations (1.4 – 5.3 mM, Table 2.2). Unfortunately, however, none showed any 
activity against either bacterial species at the concentrations tested. In spite of this, the 
methodology will develop to be more widely applicable to different peptoid structures to 
create a novel class of cyclic peptoids. Some of the future directions for this work are 
described in Chapter 5. 
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Chapter 3 
Nucleophosmin-Targeting Peptides and 
Analogues 
3.1 Nucleophosmin (NPM1) 
Nucleophosmin (NPM1) is part of the nucelophosmin/nucleoplasmin family of histone 
chaperones found in all animals.1 It is a phosphoprotein found in all tissues and 
primarily located in the nucleolus, but able to shuttle between nucleoli, the nucleoplasm 
and cytoplasm. It exists in three different isoforms (NPM1.1, NPM1.2 and NPM1.3). 
Both NPM1.2 and NPM1.3 are shorter than NPM1.1, with NPM1.2 missing an internal 
segment, whilst NPM1.3 is missing the final 35 amino acids at the 3’ end, with respect 
to NPM1.1 (Figure 3.1).2, 3 NPM1.1 is the most abundant isoform and is localised in the 
nucleolus.4 It is this isoform that is the primary target for anticancer drugs, and will be 
referred to as NPM1 from hereon in. NPM1 has multiple functions, including in 
ribosome biogenesis5 and transport,6-8 histone chaperoning,9-11 centrosome duplication 
during the cell cycle,12, 13 RNA expression14, 15 and DNA replication and repair.16, 17 
There is much interest in the numerous roles and mechanisms of action of NPM1, 
particularly since its implication in the pathogenesis of acute myeloid leukemia,18 and 
as such there are multiple reviews covering its various functions.1, 4, 19-22 For the 
purposes of our work, we are most interested in its oncogenic and tumour suppressing 
properties.  
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NPM1.1          MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV 
NPM1.2          MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV 
NPM1.3          MEDSMDMDMSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIV 
 
 
NPM1.1          EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE 
NPM1.2          EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE 
NPM1.3          EAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVE 
 
NPM1.1          EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD 
NPM1.2          EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD 
NPM1.3          EDAESEDEEEEDVKLLSISGKRSAPGGGSKVPQKKVKLAADEDDDDDDEEDDDEDDDDDD 
 
 
NPM1.1          FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG 
NPM1.2          FDDEEAEEKAPVKK-----------------------------GQESFKKQEKTPKTPKG 
NPM1.3          FDDEEAEEKAPVKKSIRDTPAKNAQKSNQNGKDSKPSSTPRSKGQESFKKQEKTPKTPKG 
 
 
      NPM1.1          PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL 
      NPM1.2          PSSVEDIKAKMQASIEKGGSLPKVEAKFINYVKNCFRMTDQEAIQDLWQWRKSL 
      NPM1.3          PSSVEDIKAKMQASIEKAH----------------------------------- 
                 
 
Figure 3.1 Comparison of the sequences of NPM1.1, 1.2 and 1.3. The N-terminal core domain 
is highlighted in cyan. Nuclear export signals (NES) in the N-terminal domain are in bolded red 
text. Acidic-rich regions in the central domain are highlighted in magenta, while the bipartite 
nuclear localization signal (NLS) is highlighted in green. The C-terminal nucleic acid binding 
domain is highlighted in yellow. Trp288 and Trp290, which form the nucleolar localization signal 
(NoLS) are in bolded blue text. The β-strand structures in the N-terminal core domain are 
indicated by the purple arrows above the sequence, whilst the three alpha helices of the C-
terminal domain are also indicated above the sequence. The aligned sequences were 
generated using the Clustal W software.23 
 
3.1.2 The structure of Nucleophosmin  
NPM1 is a modular protein consisting of three domains: the N-terminal, or core domain 
which is responsible for chaperone activity and oligomerisation, a central domain 
involved in ribonuclease activity, and the C-terminal domain associated with nucleic 
acid binding (Figure 3.2).2, 24, 25  The N-terminal is highly conserved throughout the 
nucleoplasmin family, and is considered the core domain. X-Ray crystallography shows 
the structure of the core domain to be a jelly roll barrel formed by the organisation of 
eight anti-parallel β strands. Five NPM1 monomers associate to form a crown-shaped 
pentamer. Two pentamers come together in a head-to-head fashion whereby each 
monomer from one ring only associates with one monomer from the second ring.26 
Charge distribution of the oligomer is asymmetric with negatively charged residues 
clustered on one face (Figure 3.3).  
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Figure 3.2 Crystal structure of the N-terminal core domain of NPM1. A) Five monomers 
associate to form a pentamer, two of which interact in a head-to-head fashion to form a 
decamer; B) The crown-shaped pentamer showing a channel through the middle forming the 
‘jelly roll barrel’ shape. Structures were obtained from the Protein Data Bank (4N8M, Mitrea et 
al.27) and generated using CCP4 software.28 
 
 
 
 
 
 
 
Figure 3.3 Electrostatic potential map of an NPM1 pentamer; negatively charged residues (red) 
are clustered on one face away from the neutral (white) and positive (blue) areas. Positively 
charged residues are clustered around the central pore. Structures were obtained from the 
Protein Data Bank (4N8M, Mitrea et al.27) and generated using CCP4 software.28 
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It is thought that the state of oligomerisation is related to a particular function of 
NPM1.29 For example, the oligomeric form of NPM1 is stabilised by hydrogen bonding 
and hydrophobic interactions indicating a level of chemical and thermal stability 
associated with chaperones.30 Further, the oligomeric form of NPM1 has been linked to 
nucleolar localisation and its role in cell proliferation.13,27,31,32 Conversely, the 
monomeric form of NPM1 is thought to be associated with induction of apoptosis and 
DNA repair.33 Destabilisation of the pentameric NPM1 appears to proceed via 
sequential phosphorylation of serine and threonine residues mediated by different 
kinases.27  
The central domain appears to be largely unstructured and contains two acidic 
stretches (residues 120-132 and 161-188) as a result of consecutive aspartate or 
glutamate residues. These residues result in areas of negative charge which are 
involved in binding to histones, possibly in conjunction with the N-terminal domain and 
perhaps by mimicking the charges of DNA and RNA.34,35 At either end of this acidic 
stretch is a bipartite nuclear localisation signal (NLS).  
The C-terminal domain is involved in binding to DNA and RNA, and is a three-helix 
bundle stabilised by two phenylalanine and two tryptophan residues which form a 
small, but well defined hydrophobic core (Figure 3.4). The aromatic region is part of an 
atypical nucleolar localisation signal (NoLS), possibly unique to NPM1. Mutations in 
this region, particularly of the Trp residues results in unfolding of the helices and loss of 
nucleolar localisation and is characteristic of patients with acute myeloid leukemia.36,37 
 
 
 
 
 
Figure 3.4 A solution-phase NMR structure of the three-helix bundle of the C-terminal domain. 
The two phenylalanine and tryptophan residues are also shown and form a hydrophobic core. 
Structures were obtained from the Protein Data Bank (2LLH, Gallo et al.38) and generated using 
CCP4 software.28 
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3.1.3 Nucleophosmin and cancer 
NPM1 shows both oncogenic and tumour supressing behaviour. It is overexpressed in 
many solid tumours, including pancreas,39 liver,40 prostate,41 thyroid,42 glioma43 and 
glioblastoma44 and colon.45 Overexpression of NPM1 correlates with metastatisation 
and a higher mitotic index, and as such is thought to be an indicator of a poor 
prognosis.46, 47 The exact mechanisms by which NPM1 influence tumorigenesis are not 
yet known, however several possible factors may contribute. First, NPM1 is involved in 
ribosome biogenesis and protein synthesis, both of which are increased in tumour 
cells.48 Second, NPM1 is involved in DNA repair and hence inhibits senescence and 
apoptotic responses.49,50  
NPM1 has a function in cell apoptosis via regulation of the ARF-p53 tumour suppressor 
pathway.51-54 The p53 protein prevents tumour formation and is sometimes called ‘the 
guardian of the genome.’55 Its anticancer role is carried out via several different 
pathways. p53 can activate DNA repair proteins where DNA has been damaged, thus 
preventing replication of damaged DNA. p53 can also stop cell growth by stopping the 
cell cycle at the G1/S phase whilst damaged DNA is repaired. In cases where DNA is 
damaged beyond repair, p53 will then trigger apoptosis. One of the proteins 
responsible for regulating p53 is MDM2. MDM2 binds to p53, transporting it from the 
nucleus to the cytoplasm, where it is ubiquinated and marked for degradation.56 One of 
the inhibitors of MDM2 is p14ARF. Free p14ARF complexes to the MDM2 protein, 
preventing the MDM2 protein from binding to p53 and marking it for degradation, thus 
allowing p53 to trigger DNA repair/cell apoptosis. In healthy, unstressed cells, NPM1 
binds to p14ARF in the nucleolus; in fact NPM1 is a major p14ARF reservoir.52 This 
means that MDM2 is able to down-regulate p53. However, when the cell is subject to 
stress, such as DNA damage, NPM1 releases p14 ARF which then binds to MDM2, 
preventing degradation of p53.53 In addition, NPM1 interacts directly with MDM2, 
protecting p53 from proteolysis. Therefore, depletion of NPM1 has been shown to 
increase cell apoptosis due to an increase in free p14ARF. Conversely, up-regulation 
of NPM1 increases nucleolar retention of p14ARF.51 
However, at low levels NPM1 acts as a tumour suppressor by interacting with 
unduplicated centrosomes. Phosphorylation of NPM1 triggers its release from the 
centrosomes, allowing duplication to occur.  During mitosis, NPM1 re-associates with 
the centrosomes and controls duplication. NPM1 inactivation allows unrestricted 
duplication of centrosomes, increasing the risk of cellular transformation, thereby 
promoting genomic instability.57 
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It is notable that, in some cancers, reduced levels of NPM1 have been observed and 
are associated with poor outcomes, for example in breast cancers in which there is 
evidence that it has a suppressive role.58,59   
 
3.1.3.1 Nuclophosmin and leukemia 
In blood cancers, mutations in NPM1 as well as chromosomal translocations are 
frequently seen. In acute myeloid leukemia (AML), the NPM1 gene is the most 
frequently mutated, seen 35% of all AML patients.60 Consequently, The World Health 
Organisation recognises AML with mutations in the NPM1 gene as a distinct category 
in its classifications.61 There are over 30 different identified mutations, but all occur at 
the C-terminus.59 One, but usually both tryptophan residues (Trp288 and Trp290) are 
replaced, destabilising the helical secondary structure of the C-terminal domain and 
disrupting the nucleolar localisation signal (NoLS). Furthermore, a new nuclear export 
signal (NES) is generated, reinforcing the two already present on the N-terminal 
domain, causing localisation of the mutant NPM1 in the cytosol.36 For this reason 
mutated NPM1 seen in AML is referred to NPM1c+, i.e. cytoplasm positive, and is a 
hallmark of AML. In addition, NPM1c+ oligomerises with wild-type NPM1, causing 
localisation of wild-type NPM1 into the cytoplasm, resulting in very little nucleolar 
localisation of NPM1.62 Moreover, NPM1 mutation in knock-in mice models resulted in 
AML initiation.63,64  
The exact mechanism by which NPM1c+ initiates AML is not fully understood, but it is 
thought that mutation of the NPM1 gene hinders several tumour suppression pathways. 
For example, the N-terminus is unaltered in NPM1c+, and so binding to p14ARF still 
occurs, and as a result p14ARF is transported into the cytoplasm and proteolytically 
degraded.65 NPM1c+ also binds to Fbw7γ- responsible for degrading several proto-
oncogenes- and transports it into the cytoplasm, resulting in degradation. Thus, in 
addition to weakening a tumour suppressing pathway, NPM1c+ also results in 
oncogene stabilisation.66 Finally, the mutated, unfolded C-terminal domain has also 
been shown to contain amyloidogenic sections, possibly resulting in the gain of 
cytosolic functions of NPM1c+.67   
As well as mutation of the C-terminus, NPM1 promotes oncogenesis by forming 
chimeric proteins in several other haematological malignancies. For example, in 
anaplastic large-cell lymphoma (ALCL) fusion of the 5’ end of the NPM1 gene with the 
3’ end of the anaplastic lymphoma receptor tyrosine kinase (ALK) gene is seen in 85% 
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of ALK+ patients, accounting for 30% of all ALCL cases.68 The resulting chimera is a 
protein where the N-terminal domain of NPM1 is fused to the kinase domain of ALK. 
The NPM-ALK protein dimer shows aberrant localisation in the cytoplasm, and further, 
the chimeric NPM-ALK may dimerise with wild-type NPM1, causing NPM1 dislocation 
into the nucleus. The chimeric NPM-ALK protein is a major driver of tumourigenesis in 
ALCL. It is thought that the role of NPM is to enable oligomerisation, which is a 
requirement for the autophosphorylation of tyrosine and, therefore, the activation of 
ALK. When active, ALK triggers a number of cell signalling pathways which result in 
increased cell proliferation and resistance to apoptosis.69  
In rare cases of acute promyelocytic leukemia (APL), a gene translocation causes the 
N-terminus of NPM1 to fuse with the DNA-binding domain of retinoic acid receptor α 
(RARα).70 As with the NPM-ALK chimera, the role of NPM is to facilitate dimerization. 
In doing so, this interferes with the transcriptional ability of RARα, stopping myeloid 
differentiation. Uniquely among leukemias, this arrest of differentiation in APL is 
reversible by treatment with all-trans retinoic acid.71 
 
3.1.4 Nucleophosmin as a target for anticancer compounds 
Due to its role in DNA repair and regulation of apoptopic pathways, as well as the 
association of mutations and translocations of the NPM1 gene, NPM1 has been widely 
investigated as a target for anticancer drugs.  Various approaches have been explored; 
targeting the N-terminal domain in order to disrupt oligomerisation or to inhibit its 
interaction with other proteins,72-74 targeting the C-terminal domain nucleic acid 
interactions to cause nucleolar stress75 or to promote refolding and relocalisation in the 
nucleolus,76 selective targeting of NPM1c+ mutants in AML,77,78 and targeting sites of 
NPM1 post-translational modification.79 These strategies have been detailed in the 
context of several promising NPM1-targeting compounds in a recent review4 and will 
not be discussed here. In our work, one particular compound is of interest: P15-Tat, or 
CIGB-300. 
 
3.1.4.1 P15-Tat or CIGB-300 and nucleophosmin 
CIGB-300, 125, Figure 3.5, is a cyclic peptide (P15) attached to a cell-penetrating 
peptide (Tat, derived from the HIV-Tat protein), sequence (GRKKRRQRRRPPQ-β-ala-
CWMSPRHLGTC).80 CIGB-300 (125) was identified by screening a random cyclic 
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peptide phage library against the human papillomavirus (HPV-16)E7 acidic domain. 
CIGB-300 was designed to target casein kinase 2 (CK2), a protein that phosphorylates 
threonine and serine. CK2 is implicated in tumourigenesis and elevated levels are 
associated with aggressive malignancies.81,82 CIGB-300 does not interact directly with 
CK2, but with its phosphorylation targets, specifically inhibiting phosphorylation of 
Ser125 on NPM1.79 Blocking phosphorylation of Ser125 appears to trigger nucleolar 
disassembly on tumour cells, which can be seen via confocal analysis on CIGB-300 
treated and untreated cell cultures (Figure 3.6). 
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Figure 3.5 Structure of anticancer peptide CIGB-300 (125). The active, cyclic peptide, p15, is 
highlighted in green. The active peptide is attached to cell-penetrating peptide derived from the 
HIV-Tat protein, highlighted in red, with a β-alanine linker, highlighted in blue. 
Following treatment with CIGB-300 (125), there appears to be initial concentration of 
NPM1/B23 and fibrillarin in the nucleolus (Figure 3.6, arrow two), followed by 
subsequent loss of nucleolar structure (Figure 3.6, arrows 3 and 4). Further, treatment 
of cells with CIGB-300 leads to apoptosis in several tumour cell lines, including breast, 
cervical, lung and laryngeal. It is unclear how nucleolar disassembly leads to apoptosis, 
though the nucleolus is considered a cellular stress sensor, it is possible that 
breakdown of the nucleolus triggers a proapoptotic response. Additionally, inhibition of 
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CK2 has been shown to trigger nucleolar breakdown and interfere with ribosome 
biogenesis. Mutation of Ser125 on NPM1, the target of CIGB-300, resulted in similar 
observations, suggesting CK2 regulation of ribogenesis operates through NPM1.4 
Finally, phosphorylation of NPM1 via CK2 regulates chaperone activity, interference 
with which may prevent proper folding of ribosomal proteins and also with histone 
assembly at nucleolar rDNA.83 Interestingly, work by Perera et al. in 2014 
demonstrated a synergistic effect in nude mice xenografted with human cervical 
tumours when treated with a combination of CIGB-300 (125) and a number of existing 
cancer treatments, most notably cisplatin and paclitaxel.84  
 
 
Figure 3.6 Confocal microscopy of CIGB-300 treated and untreated cell cultures showing 
nucleolar disassembly. Fibrillarin is a protein localised in the nucleolus, so changes in the 
distribution of both fibrillarin and NPM1 (labelled B23) indicated nucleolar dysfunction. F20-2 is 
a control peptide. Figure adapted from Perera et al., 2009.79  
CIGB-300 has attracted such interest as a novel anticancer drug that it has entered 
phase I clinical trials for locally advanced cervical cancer85,86 and phase II clinical trials 
for squamous cell carcinoma (ClinicalTrials.gov, identifier NCT01639625). Clinical trials 
in human patients with locally advanced cervical cancer found that administration of 
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CIGB-300 by injection into cervical malignancies was well tolerated and showed some 
benefits. In 75% of patients there was significant lesion reduction whilst 19% showed 
full histological regression, and no maximum-tolerated dose of dose-limiting toxicity 
was achieved.  
 
3.1.5 Aims  
CIGB-300 (125) is a novel anticancer peptide chimera which has been intensely 
investigated and has even entered clinical trials.86 However, cyclisation occurs via the 
formation of a disulphide bridge which is reversible.  
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Hence in vivo stability of the active peptide (p15, 126, the disulphide bridge is 
highlighted in red) may be compromised and may limit its versatility, for example by 
requiring local injection to solid tumour masses. We are interested in synthesising 
analogues of the active peptide, p15, with the aim of improving stability of the peptide 
whilst maintaining its binding affinity for NPM1. Our strategy for improving the stability 
of p15 is via alternative methods of cyclisation. The group has previously published 
work demonstrating the stapling of peptides via reaction of hexafluorobenzene with 
cysteine side chains.87 This is the first proposed analogue (F-p15, 127). Second, 
Grubbs ring-closing metathesis (RCM) is a well-established method of stapling 
peptides and thus stabilising secondary structures.88-90 A C=C stapled analogue of p15 
(C=C-p15) is the second analogue (128). A further analogue can then be accessed by 
hydrogenation of the double bond to obtain a C-C stapled analogue (129).  
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3.2 Synthesis of p15 peptide (126)  
Our strategy for the synthesis of the p15 peptide (126, Figure 3.7) was to use solid-
phase peptide synthesis (SPPS) with Fmoc-protected amino acids. 
 
Figure 3.7 Target compound p15 (126). 
Scheme 3.1 shows the generic method of SPPS in which the peptide is built onto a 
solid support, or resin, which can be washed after each amino acid coupling or 
deprotection step. Purification is then carried out by HPLC after cleavage of the peptide 
from the resin.  
 
Scheme 3.1 Generic method for solid phase peptide synthesis (SPPS). Other activating agents 
and additives may be used. 
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3.2.1 Problematic amino acids 
SPPS is the standard method of peptide synthesis and, since its introduction by 
Merrifield in 1963,91 has seen many advances in the resins and coupling reagents to 
improve reaction times and prevent side reactions including racemisation. Protection of 
reactive side chains, such as those containing amine, acid and thiol functionalities is 
vital, however, some amino acids remain problematic. In the p15 peptide (126) the 
amino acids that require attention are cysteine (130), histidine (131), methionine (132), 
and the combination of tryptophan (133), and arginine (134), Figure 3.8. 
Cysteine (130) is problematic for two reasons. When it is located at the C-terminus of a 
peptide, anchoring as an ester to the resin, elimination of the sulfhydryl group and 
subsequent addition of piperidine (135) may occur during any Fmoc deprotection step 
(Scheme 3.2).92 This happens regardless of the protecting group used, including two of 
the most widely used: trityl (Trt) and acetamidomethyl (Acm, both shown in Scheme 
3.2). Of the two, β-elimination happens more readily from the Acm group. Furthermore, 
the propensity for cysteine to undergo β-elimination is exacerbated if threonine (or 
serine) is adjacent to it. To reduce the occurrence of this side-reaction, trityl resins are 
used (e.g. 2-chlorotrityl chloride). The bulk around the C-terminal cysteine shields the 
α-proton from attack by base (Scheme 3.3), although β-elimination cannot be fully 
prevented.  
 
 
 
 
 
 
Figure 3.8 Amino acids in the p15 peptide that are prone to side-reactions (including 
racemisation) during synthesis or cleavage: cysteine (130), histidine (131), methionine (132), 
tryptophan (133) and arginine (134). 
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Scheme 3.2 Base-induced β-elimination followed by addition of piperidine (135) at C-terminal 
cysteine anchored at the resin by an ester. Cysteine and its subsequent modifications are 
highlighted in red. 
 
Scheme 3.3 Use of 2-chlorotrityl chloride resin to block base-induced β-elimination of the 
sulfhydryl group 
The second way in which cysteine (130) may be problematic is via racemisation, with 
trityl-protected cysteine (Cys(Trt)) particularly prone to this.93 Racemisation is base-
induced and may occur when cysteine is located at any position in the peptide and 
proceeds via the activated amino acid (Scheme 3.4). However, once a further coupling 
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to the cysteine at the N-terminus has been carried out, there seems to be little risk of 
racemisation. 
 
 
 
 
 
 
 
Scheme 3.4 Base-induced racemisation of cysteine proceeding via formation of an oxazolone 
ring followed by abstraction of the α-hydrogen. 
All amino acids have the potential for racemisation, but the activating agents used 
increase the rate of the coupling reaction enough that for most amino acids, 
racemisation is negligible. However, the sulfhydryl side chain increases the acidity of 
the α-hydrogen, making racemisation prior to coupling more likely. Cysteine 
racemisation happens with both Trt and Acm protection of the thiol. Common practice 
in SPPS is ‘preactivation’ of the amino acid to be coupled to the peptide; i.e. incubation 
of the amino acid, activating agent and base for five minutes prior to addition to the 
peptide. Removal of the preactivation step has been found to significantly reduce 
cysteine racemisation.93,94  
Histidine (131) is another amino acid that is particularly prone to racemisation. The 
mechanism is the same as for cysteine (Scheme 3.4), except that, unlike cysteine, the 
α-hydrogen is not abstracted by an added base, but by the side chain via the π-
nitrogen (Scheme 3.5).95 Protection of the π-nitrogen can shield the α-hydrogen,96, 97 
but these amino acids tend to be expensive. Fortunately, a study of amino acid 
racemisation in microwave assisted SPPS showed that racemisation of histidine only 
became significant (>5% D-histidine observed) at elevated temperatures; at 
conventional room temperature, the presence of D-histidine was only found at 0.65% 
(compared to 1.09% D-cysteine).95 
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Scheme 3.5. Abstraction of the α-hydrogen of histidine by the π-nitrogen of the side chain. 
Methonine (132) is prone to acid-catalysed oxidation to the sulfoxide (oxidation to the 
sulfone requires strong oxidants). This can happen during cleavage from resin when 
TFA is used (Scheme 3.6).98 Methionine sulfoxide can be reduced back to the thioester 
by treatment with Me4I/Me2S in neat TFA (Scheme 3.7).99 Oxidation can be 
suppressed by using scavengers such as dimethyl sulfide, 1,2-ethanedithiol (EDT) or 
thioanisole100 (although thioanisole has been shown to partially remove Acm protecting 
groups from cysteine).101  
 
 
 
 
 
 
Scheme 3.6 Oxidation of methionine to methionine sulfoxide. Further oxidation to methionine 
sulfone only occurs in the presence of strong oxidising agents. 
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Scheme 3.7 Reduction of methionine sulfoxide to methionine in the presence of Me4I/Me2S. 
Tryptophan (133) can sometimes be used in SPPS without protection of the indole 
group on the side chain. However, in peptides that also contain arginine (134) residues, 
modification of the indole can occur during cleavage via generation of sulfonyl moieties 
from arginine protecting groups such as Pmc and Pbf (Scheme 3.8).102 103 This can be 
almost completely prevented by Boc protection of the indole nitrogen.104 
 
 
 
 
 
 
 
 
Scheme 3.8 Side chain modification of tryptophan by transfer of the Pbf protecting group 
(highlighted in red) from arginine.  
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3.2.2 Synthesis of the linear p15 peptide (136) 
To minimise and prevent these side reactions described in Section 3.2.1, the following 
steps were taken: peptide synthesis was carried out on 2-chlorotrityl chloride resin to 
minimise base-induced β-elimination of the C-terminal cysteine, synthesis was carried 
out manually and at room temperature with no preactivation step to minimise cysteine 
and histidine racemisation and Fmoc-Trp(Boc)-OH was used to prevent Pbf transfer 
from the arginine. No extra precautions were initially taken to prevent methionine 
oxidation since the extent of this side reaction cannot be predicted and we hoped that it 
would not be significant enough to require specialist scavengers which are often stench 
hazards, toxic and difficult to handle. 
Cysteine was Acm-protected as removal of the Acm group can be achieved without 
removing the peptide from the resin and occurs with simultaneous disulphide formation. 
Accordingly, linear resin-bound p15 peptide (136, the Acm protecting groups are 
highlighted in red), was made (Scheme 3.9). 
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Scheme 3.9 Manual SPPS of linear, resin-bound p15 peptide with Acm-protected cysteine 
(136) on 2-chlorotrityl chloride resin. Fmoc manual SPPS conditions, amino acids used in order 
of addition: Fmoc-Cys(Acm)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-
His(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Met-OH, Fmoc-
Trp(Boc)-OH, Fmoc-Cys(Acm)-OH. Coupling conditions: Amino acid, PyBOP, DIPEA, DMF, r.t., 
1h. Fmoc-Ser(tBu)-OH and the second Fmoc-Cys(Acm)-OH underwent double coupling. Fmoc 
deprotection of amino acids: Piperidine (20% v/v in DMF), r.t. 2 x 20 minutes. 
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3.2.2.1 Optimisation of cleavage conditions 
After synthesis of linear resin-bound p15 (136) several test cleaves under different 
conditions were carried out. Three cleaves using trifluoroacetic acid (TFA) were carried 
out to investigate the extent of methionine oxidation (Scheme 3.10, compare 137 and 
138).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.10 TFA cleavage of linear resin-bound p15 peptide (136) to give target peptide 137. 
The methionine oxidised analogue is 138 with the oxidised methionine highlighted in red. 
Reagents and conditions: i) TFA:TIPS:water, 95:2.5:2.5 r.t. 4 h; ii) TFA:TIPS:water, 95:2.5:2.5, 
r.t. 2 h; iii) TFA: EDT: water:TIPS, 94:2.5:2.5:1, r.t. 4h.  
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A further cleave using 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) in dichloromethane,  
was carried out to yield the fully protected peptide (139, Scheme 3.11). Cleavage with 
TFA:TIPS:water resulted in complete removal of all acid-labile protecting groups after 
four hours. However, there appeared to be a significant amount of methionine oxidation 
and both the target peptide (137) and the methionine-oxidised analogue (138) were 
seen in the LCMS (Figure 3.9). Cleavage with the same cocktail but for 2 hours was 
carried out to see if this reduced methionine oxidation. The LCMS and chromatogram 
of the cleavage mixture are shown in Figure 3.10. The LCMS of the peptide obtained 
from the shortened cleavage not only showed only partial deprotection of the peptide 
with residual Pbf protection of arginine evident (see 140 and 141), but also that 
methionine oxidation was still significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.11 Cleavage of linear resin-bound p15, 13, using 20% HFIP in DCM to yield the fully 
protected peptide (139).  
Chapter 3: Nucleophosmin-Targeting Peptides and Analogues 
 
120 
 
 
 
Figure 3.9 LCMS following cleavage of p15 peptide from resin (TFA:TIPS:water, 95:2.5:2.5 for 
four hours). A) Mass spectrum of cleaved target peptide (137), ([M+H]+ = 1432) corresponding 
to the peak at 1.14 minutes in the chromatogram. B) Mass spectrum of the deprotected peptide 
with oxidised methionine (138), ([M+H]+ = 1448) corresponding to the peak at 1.00 minutes in 
the chromatogram. C) The chromatogram of the cleaved peptide mixture (detection at 280nm). 
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Figure 3.10 LCMS following cleavage of p15 peptide from resin (TFA:TIPS:water, 95:2.5:2.5 for 
two hours). A) Mass spectrum of the parent linear peptide (137), ([M+H]+ = 1432) corresponding 
to the peak at 1.73 minutes in the chromatogram. B) Mass spectrum of the linear parent peptide 
with oxidised methionine (138), ([M+H]+ = 1448) corresponding to the peak at 1.54 minutes in 
the chromatogram. C) Mass spectrum of peptide with residual Pbf protecting groups (140), 
([M+H]+ = 1685)  corresponding to the peak at 2.68 in the chromatogram. D) Mass spectrum of 
peptide with residual Pbf protecting groups and methionine oxidation (141), ([M+H]+ = 1702) 
corresponding to the peak at 2.61 in the chromatogram. E) The chromatogram of the cleaved 
peptide mixture (detection at 280nm). 
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Next, deprotection with the addition of EDT as a scavenger was attempted. The 
cleavage cocktail used was TFA:EDT:water:TIPS, 94:2.5:2.5:1, and the deprotection 
was for four hours. The LCMS and chromatogram are shown in Figure 3.11. Analysis 
of the LCMS and chromatogram showed only one major peak, corresponding to the 
deprotected peptide (137) with no evidence of methionine oxidation. However, EDT is 
toxic and very smelly; even on a test cleave scale all glassware had to be thoroughly 
cleaned with bleach. Work up of the peptide required use of the rotary evaporator 
which also had to be cleaned with bleach after use. As a result, it was decided to avoid 
the use of EDT for full cleaves, unless its use was necessary to obtain enough peptide 
for subsequent use.   
 
 
Figure 3.11 LCMS following cleavage of p15 peptide from resin (TFA:EDT:water:TIPS, 
94:2.5:2.5:1 for four hours). A) Mass spectrum of the target linear peptide (137), ([M+H]+ = 
1433) corresponding to the peak at 1.17 minutes in the chromatogram. B) The chromatogram of 
the cleaved peptide mixture (detection at 280nm). 
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Cleavage conditions to yield the fully protected peptide (139) were also investigated. 
Access to the fully protected peptide is desirable as this enables solution phase 
reactions to be carried out whilst minimising the risk of unwanted side-reactions. The 
cleavage conditions used were 20% HFIP in DCM and the LCMS and chromatogram 
are shown in Figure 3.12. The LCMS chromatogram shows two major peaks: one at 
3.38 minutes and one at 3.81 minutes. The peak at 3.81 minutes is the fully protected 
peptide ([M+2H]2+/2 = 1181), and the peak at 3.38 minutes is the fully protected peptide 
with a loss of the trityl protecting group on the histidine residue (142), ([M+2H]2+/2 = 
1061). Deprotection of the histidine is potentially problematic since the basic properties 
of the histidine nitrogen may interfere in subsequent reactions.  
 
  
 
Figure 3.12 LCMS following cleavage of p15 peptide from resin (20% HFIP in DCM for 30 
minutes). A) Mass spectrum of the protected peptide (139), ([M+2H]2+/2 = 1181) corresponding 
to the peak at 3.81 minutes in the chromatogram. B) Mass spectrum of the peptide with a free 
histidine (142), ([M+2H]2+/2 = 1061) corresponding to the peak at 3.38 minutes in the 
chromatogram. C) The chromatogram of the cleaved peptide mixture (detection at 280nm). 
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3.2.3 Formation of the disulphide bridge 
Disulphide bridges are found in naturally occurring peptides and proteins and provide a 
method of stabilising their biologically active forms.105-107 Disulphide formation is 
reversible and is generated by oxidative folding of cysteine-containing peptides. 
Synthetically, many methods of disulphide formation have been reported.108-112 
Disulphide formation may be carried out on the peptide in solution or whilst the peptide 
is still attached to the resin (solid-phase). The method of cysteine oxidation depends on 
the protecting group strategy employed. If trityl-protected cysteine is used, cleavage 
from the resin yields the linear peptide which is then cyclised by air oxidation in a buffer 
solution at pH 7.5 – 8 (Scheme 3.12).  
 
 
 
 
 
 
Scheme 3.12 Standard air oxidation approach for disulphide formation from trityl-protected 
cysteine. 
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Progress of the reaction is usually followed by HPLC and additives such as DMSO or 
H2O2 may be used to speed up the reaction. However, it should be noted that such 
additives, particularly H2O2, would also oxidise the methionine residue in the p15 
peptide and their use would therefore be inappropriate here. 
When Acm-protected cysteine is used, cyclisation is concomitant with removal of the 
Acm group (Scheme 3.13). Removal of the Acm group is carried out in the presence of 
iodine which also oxidises the cysteine to form the disulphide. This may be carried out 
in solution using iodine in 40% acetic acid followed by quenching of the solution by 1M 
ascorbic acid. Since cleavage of the peptide from the resin using TFA will leave the 
Acm groups intact, this method enables purification of the linear peptide prior to 
oxidation. Conversely, treatment of the resin-bound peptide with iodine will remove the 
Acm groups and form the disulphide, leaving the protecting groups on other residues 
intact. The iodine can then be washed off the resin, and the fully deprotected cyclic 
peptide obtained by cleavage with 95% TFA. Carrying out the cyclisation on the resin-
bound peptide has several advantages over solution-phase methods. In solution-
phase, oxidation has to be carried out in high dilution in order to favour intramolecular 
reaction over intermolecular reaction. Further, work up of the solution-phase reaction 
requires high volumes of ascorbic acid solution to destroy the iodine and prevent side 
reactions. This results in a high volume of peptide solution to purify, making this 
method very time consuming. Carrying out the reaction on resin results in pseudo-high 
dilution conditions, and the iodine can be simply washed off the resin after the reaction, 
making purification less tedious. This was, therefore, the method of choice.  
The disadvantage of the iodine oxidation method (Scheme 3.13) is that it is inherently 
inefficient; removal of the Acm groups can be slow, but extended reaction times are 
likely to result in side reactions, including over-oxidation of the cysteine to cysteic 
acid.113-115 The crude peptide will therefore contain a mixture of the cyclic peptide with 
residual mono- and bis- Acm-protected cysteine-containing peptide. However, the aim 
is to obtain enough cyclised peptide to carry out binding assays and attempt to get a 
crystal structure, so maximising the yield was not considered of primary importance. 
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Scheme 3.13 Standard approaches for disulphide formation from Acm-protected cysteine. 
 
Scheme 3.14 On-resin disulphide formation from Acm-protected cysteine following the Bachem 
procedure. 
The first set of conditions attempted was adapted from a procedure used by Bachem to 
form a single disulphide bridge from Acm-protected cysteine in a peptide on SASRIN 
resin (Scheme 3.14). This procedure involved swelling the resin in a mixture of 
DCM:MeOH:water (60:25:4 v/v/v) and then adding eight equivalents of iodine (relative 
to the resin-bound peptide) in DCM and 8 equivalents of DIPEA to neutralise the 
hydrogen iodide that is evolved as a by-product of the reaction. The peptide was put on 
a shaker for forty minutes initially, although reaction for 90 minutes was later 
attempted.  
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For the forty minute reaction, the results were as predicted; a mixture of bis- Acm 
protected (137), mono- Acm protected (143 and/or 144) and cyclised peptide (126) 
were obtained (Figure 3.13 shows the LCMS of a HPLC fraction containing all three 
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compounds). The bis-Acm protected peptide (137) appeared to be the primary product, 
appearing in the majority of HPLC fractions, whilst the cyclised p15 peptide (126) was 
not isolated. Increasing the reaction time to 90 minutes resulted in a greater level of 
deprotection with the mono-Acm protected peptide (143 and/or 144) appearing in more 
HPLC fractions and the bis-Acm protected peptide (137) appearing in fewer. Further, 
the cyclised p15 peptide (126) could be isolated, although yield was poor (0.8%).  
The poor yield was not only because of the inefficiency of the reaction. Cyclisation 
reactions were carried out on a 0.1 mmol scale, but the masses of crude peptide 
obtained following cleavage from the resin were smaller than expected; 6 mg – 16 mg 
of crude peptide was obtained from each reaction, whilst in a hypothetical scenario 
where the yield of cyclised p15 peptide (126) is 100%, this would require 128 mg of 
peptide. There are several possible reasons for such poor crude peptide yields. First, 
loading of the resin is poor; 2-chlorotrityl chloride resin is very moisture sensitive and 
contact with water either through prolonged exposure to atmospheric water, or poor 
handling during coupling of the first amino acid will result in a reduction of available 
loading sites. Second, peptide could be lost in the cleavage procedure, for example 
through inefficient filtration. Third, peptide could be cleaved in the course of the 
cyclisation reaction itself, for example through exposure to acid generated as a 
byproduct of the reaction (although DIPEA was used in order to neutralise any acidic 
byproducts). To find out which of the above possibilities was the reason for the poor 
yield, 0.1 mmol of bis-Acm protected linear peptide was cleaved from the resin using 
the same cleavage cocktail as the one used following the cyclisation reactions 
(TFA:TIPS:H2O, 95:2.5:2.5). The mass of crude peptide obtained from a 0.1 mmol 
reaction was 73 mg showing that, whilst there appear to be some problems with resin 
loading and/or cleavage of the peptide, large amounts of peptide are being cleaved in 
the cyclisation reaction itself. Since the presence of DIPEA should neutralise any acidic 
byproducts, we suspected the solvents used were responsible for the loss of peptide, 
and attempted the reaction in DCM only (Scheme 3.15).  
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Figure 3.13 LCMS of a HPLC fraction following attempted on-resin disulphide formation 
(Scheme 3.14, 40 minutes). A) Peaks corresponding to the bis-Acm protected peptide (137), 
[M+ H]+ =1433, the mono-Acm protected peptide (143 and/or 144), [M + H]+ = 1361 and cyclised 
p15 peptide (126), [M + H]+ = 1288, retention time 1.16 minutes; B) The chromatogram of the 
peptide mixture (detection at 280 nm).  
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Scheme 3.15 On-resin disulphide formation from Acm-protected cysteine using DCM as the 
only solvent. 
Cyclisation in DCM generated 67 mg of crude peptide, indicating that the presence of 
methanol and/or water, even in small volumes encourages cleavage of the peptide 
from the resin. Whilst, once again, a mixture of bis-Acm protected (137), mono-Acm 
protected (143 and/or 144) and cyclic p15 (126) could be seen in the mass spectra of 
the crude peptide and the HPLC fractions, the cyclised p15 peptide was isolated in a 
19% overall yield (Figure 3.14 shows the analytical HPLC trace of purified p15 peptide, 
126).  
 
Figure 3.14 Analytical HPLC trace of purified p15 peptide (126), λ = 280 nm. 
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3.3 Synthesis of the tetrafluoro-stapled p15 peptide (F-p15, 127) 
Previous work within the group has investigated the stapling of peptides using 
hexafluorobenzene (145), Scheme 3.16.87 We wanted to apply this methodology to 
create a tetrafluoro-stapled p15 analogue (F-p15, 3, Figure 3.15).  
 
Scheme 3.16 Tagging and stapling of peptides using hexafluorobenzene (145). 
NHN
O
O
NH
O
HN
O
HN
O
S S
HN
O
HN
O
NH
O
NH
O
H
N
O
H2N
NH
NH2
HN
HO
S
H
N
HO
O
OH
N
H
N
127
F F
F F
 
Figure 3.15 Target compound tetrafluoro-stapled p15 peptide (F-p15, 127). 
Two linear peptides were first synthesised using SPPS methods described in Section 
3.2, Scheme 3.9. The first was linear resin-bound p15 (136), i.e. with Acm-protected 
cysteine, and the second was the Trt-protected analogue (146), which was cleaved 
from the resin to give the fully deprotected p15 peptide (147, Scheme 3.17) which was 
used in the solution-phase reaction (Scheme 3.17). The LCMS of the crude linear 
peptide (Figure 3.16) was deemed clean enough to attempt the stapling reaction 
without prior purification of linear peptide 147. 
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Scheme 3.17 Cleavage of Cys(Trt) linear resin-bound p15 (146) to give the fully deprotected 
linear p15 peptide (147). 
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Figure 3.16 LCMS following cleavage of Cys(Trt) linear resin-bound p15 peptide (146, 
TFA:EDT:water:TIPS, 94:2.5:2.5:1 for four hours). A) Mass spectrum of the fully deprotected 
linear peptide (147), ([M+H]+ = 1290) corresponding to the peak at 1.29 minutes in the 
chromatogram. B) The chromatogram of the cleaved peptide mixture (detection at 280nm). 
Having synthesised the two linear peptides, 136 and 147, we proceeded to attempt the 
stapling reactions. Cyclisation was first attempted on the resin bound peptide (136, 
Scheme 3.18). Conditions were similar to those used for disulphide bond formation in 
Section 3.2.3 except with the addition of hexafluorobenzene which we hoped would 
intercept disulphide formation to give the target tetrafluorobenzene-stapled peptide (F-
p15, 3). However, the on-resin reaction of peptide 136 with hexafluorobenzene (145) 
suffered from the same problem as the disulphide formation reactions; only 3 mg crude 
peptide was generated from a 0.05 mmol scale reaction which corresponds to a 
maximum possible yield of 4%. Further, the reaction failed, producing a mixture of bis-
Acm protected peptide (137), mono-Acm protected peptide, (143 and/or 144) and 
cyclised (disulphide-containing) p15 (126). We therefore attempted the reactionon the 
linear peptide in solution. 
 
 
A)  
B)  
Linear peptide 147 
Chapter 3: Nucleophosmin-Targeting Peptides and Analogues 
 
134 
 
 
Scheme 3.18. Attempted on-resin stapling of p15 with hexafluorobenzene (145). 
For the solution-phase reaction of peptide 147 with hexafluorobenzene (145), five 
equivalents of hexafluorobenzene (145) were added to a solution of linear peptide 147 
in 50 mM DIPEA in DMF and shaken at room temperature for four hours (Scheme 
3.19). The LCMS of the crude reaction mixture (Figure 3.17) showed the tetrafluoro-
stapled peptide to be the main component, but some of the mono-adduct (148 and/or 
149- the specific regio-isomer cannot be distinguished here) was also seen, as well as 
some uncyclised linear parent peptide, 147. 
 
 
Scheme 3.19 Attempted solution-phase stapling of p15 with hexafluorobenzene (145). 
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Figure 3.17 LCMS of the crude reaction mixture after reaction with hexafluorobenzene (145) 
following conditions described in Scheme 3.18. A) Mass spectrum of F-p15 (127) 
corresponding to the peak at 1.31 minutes in the chromatogram, [M + H]+ = 1437. B) Mass 
spectrum of the mono-adduct (148 and/or 149) corresponding to the peak at 1.49 minutes in the 
chromatogram, [M + H]+ = 1457 C) The chromatogram of the peptide mixture (detection at 280 
nm).  
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Subsequent purification of the crude reaction mixture gave F-p15 (127) in 32% yield 
(Figure 3.18 shows the analytical HPLC trace of the purified F-p15 peptide, 127). This 
was sufficient for use in binding assays and crystallisation studies so no further 
reactions were deemed necessary. 19F NMR was also carried out (δF(376 MHz, D2O)) 
and the spectra showed two peaks: one corresponding to TFA (m, -76.5), leaving one 
peak corresponding to aromatic fluorines (m, -133.36 – -134.27). This is consistent with 
all four fluorine atoms being in very similar environments. 
 
 
 
Figure 3.18 Analytical HPLC trace of purified F-p15 peptide (127), λ = 280 nm. 
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3.4 Synthesis of C=C stapled p15 (128) 
Grubbs’ ring-closing metathesis (RCM) is a well-established method of stapling 
peptides, both as a replacement for disulphide bridges and as a way of stabilising 
existing secondary structures such as alpha helices.88, 89 Grubbs’ RCM on peptides is 
usually carried out whilst the peptide is still attached to the resin; the resin-bound 
peptide will be fully protected, precluding side-reactions with reactive side chains, and 
attachment of the peptide to a solid support generates pseudo-high dilution conditions, 
thus reducing cross-methathesis reactions. We therefore used Grubbs’ RCM to 
synthesise a C=C stapled p15 peptide analogue (128, Figure 3.19). 
 
 
Figure 3.19 Target compound C=C stapled p15 peptide (128). 
We first synthesised a linear p15 peptide on the cysteine residues were replaced with 
allyl glycine residues (150, Scheme 3.20). The peptide was synthesised on Rink Amide 
resin as this is easier to handle than 2-chlorotrityl resin. LCMS analysis following a test 
cleave of the linear allyl glycine peptide (150) showed that synthesis had been 
successful by the appearance of linear peptide 151 in the spectrum (Figure 3.20). 
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Scheme 3.20 Manual SPPS of linear, resin-bound fully protected linear allylglycine p15 peptide 
analogue (150) on Rink amide resin. Fmoc manual SPPS conditions, amino acids used in order 
of addition: Fmoc-allylglycine-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-
His(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Met-OH, Fmoc-
Trp(Boc)-OH, Fmoc-allylglycine-OH. Coupling conditions: Amino acid, PyBOP, DIPEA, DMF, 
r.t., 1h. Fmoc-Ser(tBu)-OH and the Fmoc-allylglycine-OH underwent double coupling. Fmoc 
deprotection of amino acids: Piperidine (20% v/v in DMF), r.t. 2 x 20 minutes. 
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Figure 3.20 LCMS of test cleave mixture of linear allyl glycine peptide (27). A) Mass spectrum 
of linear peptide 151, corresponding to the peak at 2.00 minutes in the chromatogram, [M+ H]+ = 
1501. B) The chromatogram of the crude reaction mixture (detection at 280 nm).  
Having successfully synthesised the linear resin-bound parent peptide (150) we 
attempted cyclisation by Grubbs’ RCM (Scheme 3.21).116 The reaction conditions and 
their results are summarised in Table 3.1.  
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Scheme 3.21 Formation of C=C-p15 (128) by Grubbs’ RCM, stapling a resin-bound allyl 
glycine-containing parent peptide (150). 
      
Figure 3.21 Grubbs’ RCM catalysts used in RCM reactions attempted: 2nd Generation 
Hoveyda-Grubbs catalyst (152)117 and 1st Generation Grubbs catalyst (153).118 
Table 3.1 Summary of RCM reaction conditions attempted on linear parent peptide 150. 
Reaction 
number 
Catalyst Solvent 
LiCl (0.4 M 
in DMF) 
Temperature 
Reaction 
time 
Cyclic peptide 
128 
1 152 DCM No r.t 2 h 
Not seen in crude 
LCMS 
2 152 DCE No r.t 2 h x 2 
Not seen in crude 
LCMS 
3 152 DCM Yes reflux 18 h 
Crude LCMS 
inconclusive  
4 153 DCE No r.t 2 h x 2 
Not seen in crude 
LCMS 
5 153 DCE Yes r.t 2 h x 2 
Not seen in crude 
LCMS 
6 152 DCE Yes 80°C 18 h 
5% isolated yield 
(0.1 mmol scale) 
7* 152 DCE Yes 80°C 24 h x 2 
11% isolated 
yield (0.1 mmol 
scale) 
*EDT used in cleavage step 
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The first set of reaction conditions attempted used the 2nd Generation Hoveyda Grubbs’ 
catalyst (152, Figure 3.21) in DCM which was added to the resin-bound peptide (150). 
The reaction mixture was then refluxed for two hours under nitrogen (Reaction number 
1, Table 3.1). Following work-up, the LCMS of the crude peptide showed only one 
peak corresponding to the uncyclised peptide, 151, (Figure 3.22).  
 
 
Figure 3.22 LCMS of the crude reaction mixture after Grubbs’ RCM using 2nd generation 
Hoveyda Grubbs’ catalyst in DCM, refluxed for 2 hours A) Mass spectrum of linear peptide 151 
corresponding to the peak at 2.09 minutes in the chromatogram, [M+ H]+ = 1278. B) The 
chromatogram of the crude reaction mixture (detection at 280 nm).  
Following this, the reaction was repeated replacing DCM with 1,2-dichloroethane 
(DCE) as the solvent. This time the reaction was carried out at room temperature, and 
after the first two hours, a second portion of catalyst (20 mol% in DCE) was added and 
the reaction left for a further two hours (Reaction number 2, Table 3.1). However, the 
result was the same with only uncyclised peptide 151 obtained. 
 
 
A)  
B)  
Linear peptide 151 
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The third set of conditions attempted used DCM as a solvent once again, and 20 mol% 
of 2nd generation Hoveyda-Grubbs catalyst (152, Figure 3.21). However, 1 mL of a 
stock solution of DCM containing 10% lithium chloride (0.4M) in DMF was added to the 
reaction mixture to prevent any aggregation of the resin-bound peptide.119 The reaction 
mixture was refluxed for 18 hours (Reaction number 3, Table 3.1). The LCMS of the 
crude reaction mixture showed mostly the uncyclised peptide (27), but following HPLC 
purification, a peak possibly corresponding to cyclised C=C stapled peptide (128) was 
seen in one of the fractions, as a mixture with the uncyclised peptide (151, Figure 
3.23).  
 
 
 
Figure 3.23 LCMS of the a HPLC fraction from reaction of allyl glycine-containing linear peptide 
(150) with Grubbs’ RCM using 2nd generation Hoveyda Grubbs’ catalyst, 152, in DCM with 
lithium chloride as an additive, refluxed for 18 hours A) Mass spectrum of the HPLC fraction 
containing a peak corresponding to the uncyclised peptide (151), [M + H]+ = 1278, and possible 
C=C stapled peptide (128), [M + H]+ = 1250, corresponding to the peak at 1.38 minutes in the 
chromatogram. B) The chromatogram of the crude reaction mixture (detection at 280 nm).  
 
 
A)  
B)  
Linear peptide 151 and 
suspected C=C stapled 
p15 peptide 128 
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The 2nd generation Hoveyda-Grubbs catalyst (152) is often preferred over 1st and 2nd 
Generation Grubbs catalysts because, although it is more expensive, it is also much 
less air and moisture sensitive.120 However, the trade-off for this is a lower reactivity.121 
To find out if this was the reason for the failure of the reaction, several reactions were 
carried out: two using the 1st generation Grubbs catalyst (153, Reaction numbers 4 and 
5, Table 3.1) and one using the 2nd generation Hoveyda-Grubbs catalyst (152) heated 
in DCE for 18 hours (Reaction number 6, Table 3.1). The conditions used for the 
reactions with the 1st generation catalysts were based on those described by Kim et al. 
in Nature Protocols.89 The first reaction used 20 mol% 1st generation Grubbs catalyst in 
DCE and the reaction mixture was stirred at room temperature under nitrogen for two 
hours before a second addition of catalyst (20 mol% in DCE) and the reaction mixture 
stirred for a further two hours under nitrogen (Reaction number 4, Table 3.1). The 
second reaction followed the same steps except with an addition of 1 mL DCE 
containing 10% lithium chloride (0.4M) in DMF (Reaction number 5, Table 3.1). The 
LCMS of the resulting crude reaction mixtures showed, once again, only the linear 
peptide (151). The final reaction of this set used the 2nd generation Hoveyda-Grubbs 
catalyst (152) 20 mol% in DCE, the lithium chloride additive and was heated at 80 °C 
for 18 hours (Reaction number 6, Table 3.1). This set of conditions was chosen 
because DCE has a higher boiling point than DCM and so the reaction can be heated 
at a higher temperature, and this might be enough to force a reaction. The LCMS of the 
crude reaction mixture showed both the C=C stapled peptide, (128), and the uncyclised 
peptide (151, Figure 3.24).  
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Figure 3.24 LCMS of the crude reaction mixture after reaction of allyl glycine-containing linear 
peptide (150) with Grubbs’ RCM using 2nd generation Hoveyda Grubbs’ catalyst (152) in DCE 
with lithium chloride as an additive, refluxed for 18 hours A) Mass spectrum fraction containing a 
peak corresponding to C=C stapled peptide (128), [M + H]+ = 1250, corresponding to the peak 
at 1.09 minutes in the chromatogram. B) Mass spectrum fraction containing a peak 
corresponding to the uncyclised peptide (151), [M + H]+ = 1278, corresponding to the peak at 
1.18 minutes in the chromatogram. C) The chromatogram of the crude reaction mixture 
(detection at 280 nm).  
Subsequent purification of the crude reaction mixture gave the C=C stapled peptide 
(128) in 12% yield. However, the reaction was only carried out on a 0.02 mmol scale, 
so further material was needed in order for binding assays and crystallisation studies to 
be carried out, and for further reaction to obtain the C-C stapled p15 peptide (129). The 
reaction was therefore repeated on a 0.1 mmol scale. However, this time yield of the 
C=C stapled peptide was only 5%. LCMS of the crude reaction mixture (Figure 3.25) 
and of HPLC fractions from the subsequent purification showed peaks in the mass 
spec of mass 1265 and 1293. These correspond to the C=C stapled and linear 
peptides with oxidised methionine (154 and 155). The methionine is likely to be 
oxidised in the cleavage by TFA. This can be reduced by the use of EDT as an additive 
during the cleave, as described in Section 3.2.2. The reaction was therefore carried 
out again using the same conditions, except with a second addition of catalyst solution 
after 24 hours of heating, followed by a further 24 hours of stirring at 80 °C.  
A)  
B)  
C)  
Linear peptide 151 
C=C stapled p15 peptide 128 
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The peptide was cleaved from the resin using TFA:EDT:water:TIPS 94:2.5:2.5:1 and 
purified by HPLC. This time, no masses relating to methionine-oxidised side-products 
(154 and 155) were seen in the LCMS of any HPLC fractions. Furthermore, the yield 
was an improved 11%. The analytical HPLC trace of the purified C=C stapled p15 
peptide is shown in Figure 3.26. 
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Figure 3.25 LCMS of the crude reaction mixture (0.1 mmol) after Grubbs’ RCM using 2nd 
generation Hoveyda Grubbs’ catalyst (152) in DCE with lithium chloride as an additive, refluxed 
for 18 hours. A) Mass spectrum fraction containing a peak corresponding to C=C stapled 
peptide 128, [M + H]+ = 1250, corresponding to the peak at 1.06 minutes in the chromatogram. 
B) Mass spectrum fraction containing a peak corresponding to the C=C stapled peptide with 
oxidised methionine 154, [M + H]+ = 1265, corresponding to the peak at 0.94 minutes in the 
chromatogram. C) Mass spectrum fraction containing a peak corresponding to uncyclised 
peptide 151, [M + H]+ = 1278, corresponding to the peak at 1.12 minutes in the chromatogram. 
D) Mass spectrum fraction containing a peak corresponding to the uncyclised peptide with 
oxidised methionine 155, [M + H]+ = 1293, corresponding to the peak at 1.03 minutes in the 
chromatogram. D) The chromatogram of the crude reaction mixture (detection at 280 nm).  
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Figure 3.26 Analytical HPLC trace of purified C=C stapled p15 peptide (128), λ =280 nm. 
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3.6 Synthesis of the C-C stapled p15 peptide (129) 
Having isolated the C=C stapled p15 peptide (128), the C-C stapled p15 peptide (129, 
Figure 3.27) was made. 
 
Figure 3.27 Target compound C-C stapled p15 peptide (129). 
To a solution of 2 mg of the C=C stapled p15 peptide (128) in ethanol, palladium on 
carbon was added (Scheme 3.22). The mixture was stirred under a hydrogen 
atmosphere for two hours, after which LCMS analysis (Figure 3.28) showed complete 
hydrogenation of the double bond to give peptide 129 in a 50% yield without further 
purification.   
 
 
 
 
 
 
 
 
Scheme 3.22 Formation of C-C-p15 (129) by palladium-catalysed hydrogenation of C=C-p15, 
(128, 2mg). 
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Figure 3.28 LCMS following hydrogenation of C=C-p15 (128) to form C-C-p15 (5) using 
conditions described in Scheme 3.21. Mass spectrum of C-C-p15 (129), [M+H]+ = 1252. 
An analytical HPLC trace of C-C stapled peptide (Figure 3.29) was obtained, and 
based on this, no further purification was carried out.  
 
Figure 3.29 Analytical HPLC trace of C-C stapled p15 peptide (129), λ = 280 nm. 
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3.6 Binding assays 
Having synthesised p15 (126) and three analogues, F-p15 (127), C=C-p15 (128) and 
C-C-p15 (129), we wanted to see whether the structural alterations affected the ability 
of the peptides to bind to the target protein, NPM1. Binding assays are being carried 
out by the Law group at The Hong Kong Polytechnic University and this work is still in 
progress. However, preliminary results from bio-layer interferometry (BLI) binding 
assays are shown in Figure 3.30. These results indicate that p15 (126) and C-C p15 
(129) bind more strongly with NPM1 than F-p15 (127) and C=C p15 (128). This is as 
expected; C-C p15 (129) is the most structurally similar to p15 (126) of all the 
analogues we made, and so we would expect to see similar binding affinities. Work is 
ongoing in the Law lab to gain further information, such as dissociation constants for 
p15 (126) and each of the analogues made (127 – 129).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30 Results from BLI assays showing binding interactions between p15 and analogues 
and NPM1. A) Association (0 -100 seconds) followed by dissociation (from 100 seconds) 
observed between p15 (126) and NPM1 and C-C p15 (129) and NPM1. B) Association (0 -100 
seconds) followed by dissociation (from 100 seconds) observed between F-p15 (127) and 
NPM1 and C-C p15 (128) and NPM1.  
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3.7 Crystallisation studies 
Crystallisation of the four p15 analogues, p15 (126), F-p15 (127), C=C-p15 (128) and 
C-C-p15 (129) was attempted via screening of peptide solutions in water at 
concentrations shown in Table 3.2. Crystallisation was carried out on each peptide in 
isolation. Vapour diffusion conditions in the hanging drop format were set up manually 
using 2 μL of peptide solution per well in addition to 2μL of pre-prepared solutions for 
each set of conditions for the JCSG+ screen.122 At the time of writing, no crystal 
structures had been obtained. 
 
Table 3.2 Concentrations of peptides used in crystallisation studies 
Peptide Concentration/ mg/mL 
p15 (126) 12 
F-p15 (127) 10 
C=C-p15 (128) 5 
C-C-p15 (129) 0.4 
 
 
3.8 Conclusions  
The synthetic p15 peptide (126) and three analogues: F-p15 (127), C=C-p15 (128) and 
C-C-p15 (129) were successfully made and BLI binding assays were carried out by the 
Law lab at The Hong Kong Polytechnic University.  
Where the first residue was cysteine (p15 and F-p15), linear peptides were synthesised 
on 2-chlorotrityl chloride to suppress base-induced elimination of the first cysteine 
residue (Scheme 3.9). For C=C p15 and C-C p15, the linear parent peptide had 
allylglycine as its first residue and Rink Amide resin was used since this is easier to 
handle than 2-chlorotrityl resin and base-induced elimination was not a problem for this 
peptide (Scheme 3.20).  
Investigations into peptide cleavage conditions found that methionine was readily 
oxidised under standard 95% TFA conditions. However, methionine oxidation could be 
suppressed by the addition of EDT to the cleavage cocktail. 
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We used solid-phase cyclisation conditions to obtain p15 (126) and C=C-p15 (128), 
and solution-phase cyclisation conditions to obtain F-p15 (3). C-C-p15 (129) was 
obtained by hydrogenation of C=C-p15 (128). Solid-phase iodine oxidation conditions 
on Acm-protected cysteine were used to obtain cyclic p15 (126, Scheme 3.15) 
because reaction times are necessarily short (30 minutes – 2 hours, compared to 72 
hours for air oxidation, Scheme 3.13, according to literature procedures).80 However, 
iodine oxidation is inherently inefficient with a limited maximum achievable yield due to 
the propensity of side-reactions as a result of over oxidation. Accordingly the best 
isolated yield obtained was 19%.  
Cyclisation of F-p15 (127) was carried out in solution on the fully deprotected peptide 
using a procedure based on methodology developed by previous work within the group 
(Scheme 3.19).87 The best isolated yield achieved was 32%, however mono-
substituted, uncyclised peptide (148 and/or 149), as well as the uncyclised parent 
peptide (147) could be seen in the LCMS suggesting that the low yield was a result of 
the reaction not going to completion.   
Grubb’s RCM was used to make C=C p15 (128) from the resin-bound allylglycine-
containing linear parent peptide (150). Various reaction conditions were attempted 
including the use of Grubb’s 1st Generation Catalyst (153) and Hoveyda-Grubb’s 2nd 
Generation Catalyst (152), use of DCM and DCE as solvents, different reaction times 
and temperatures and the use of LiCl as an additive to prevent aggregation (Table 
3.1). The most effective conditions were found to use the Hoveyda-Grubb’s 2nd 
Generation Catalyst (152) in DCE with10% LiCl (0.4 M in DMF) for 48 hours at 80°C 
with a second addition of catalyst solution after 24 hours (Scheme 3.21, Table 3.1, 
Reaction number 7). This gave the purified C=C p15 peptide in 11% yield when EDT 
was used in the cleavage cocktail to suppress methionine oxidation.  
Hydrogenation of C=C p15 (128) using Pd/C under a hydrogen atmosphere (Scheme 
3.22) gave C-C p15 (129) in a 50% yield with no further purification after work up. Since 
only a small quantity of C=C p15 (128) was taken forward for the hydrogenation 
reaction, small losses of peptide in the work up translated into a large loss of yield. 
Overall yields for each peptide were low with the best being 32% for F-p15 (127). 
However, little time was spent optimising the synthesis of any peptide since the main 
objective was to get sufficient amounts to use in binding assays and initial 
crystallisation screens. In this respect, we were successful for p15 (126), F-p15 (127) 
and C=C-p15 (128), having prepared enough to send to our collaborators to carry out 
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binding assays and also to run full crystallisation screens for each in the hanging drop 
format at recommended concentrations (between 5 and 40 mg/mL). However, the 
maximum concentration solution of C-C-p15 (129) we were able to make and use to 
carry out a full screen was very low and so failure to crystallise may be a result of this.  
Preliminary results from BLI binding assays carried out by the Law lab at The Hong 
Kong Polytechnic University (Figure 3.30) showed that p15 (126) and C-C p15 (129) 
bound more strongly to NPM1 than F-p15 (127) and C=C p15 (128). Work is ongoing 
to obtain more information, such as dissociation constants, however, these results 
indicate that C-C p15 (129) has binding activity with NPM1 that is comparable to the 
anticancer peptide p15 (126) and therefore has the potential to be a more stable 
alternative. 
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Chapter 4 
Peptide-Peptoid hybrids 
4.1 Cell-penetrating peptoids 
In Chapter 1, Section 1.2.1 we briefly described the features of cell-penetrating 
peptoids: similar to cell-penetrating peptides, they are short (~12 residues) and 
amphiphilic. Whilst many cell-penetrating peptides have been reported and used as 
transporters for therapeutics, such as in CIGB-300 (125, see Chapter 3), research into 
cell-penetrating peptoids is still in its infancy and there are no reports on their use in the 
transport of biologically active cargo.   
Several peptoids have already been synthesised that show promising cell permeability 
and, in some cases, the ability to localise in different organelle. Kӧlmel et al 
synthesised a library of short peptoids (4 residues, 156 – 161) containing cationic 
lysine side chains. Each peptoid was tagged with Rhodamine B, which fluoresces red, 
in order to visualise the location of the peptoids within the cell.1   
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The peptoids were then incubated with HeLa cells at 37°C for 24 hours. The nucleus 
and mitochondria were co-stained with dyes that fluoresce at different wavelengths (the 
nucleus was stained with Hoechst 33342 which fluoresced blue and the mitochondria 
stained with 100 nM Mitochondria GreenTM which fluoresced green). When all three 
dyes were excited together, it was possible to see whether the peptoids had entered 
the nucleus or the mitochondria. All peptoids, to some degree, showed up in the 
nucleus, but of particular interest were the peptoids that also entered the mitochondria, 
two examples of which (159 and 161) are shown in Figure 4.1. Mitochondria are 
involved in many metabolic and pathological processes and thus are attractive 
therapeutic targets.2-4  
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Figure 4.1 Peptoids 159 and 161 were able to enter mitochondria of HeLa cells. The nuclei are 
stained blue with Hoechst 33342 (A and E), mitochondria are stained green with 100 nm 
Mitochondria Green (B and F), peptoids are red as are result of the Rhodamine B tag (C and 
G). D and H are merges of the respective emission channels to highlight co-localisation of the 
peptoids in the mitochondria or nuclei. Microscopy images adapted from Kӧlmel et al., 
Pharmaceuticals, 2012.1 
This was followed up with the synthesis of further cell penetrating peptoids. The 
peptoids were, again, short (6 residues). However, in this paper, they incorporated side 
chain functionality by copper-catalysed alkyne azide cycloaddition (CuAAC, Scheme 
4.1).5  
 
 
 
 
 
Scheme 4.1 Copper catalysed alkyne azide cycloaddition as a way of incorporating different 
functionalities into peptoids. 
N
H
O
N
N
O
R1
NN
N
N
N
N
R2
R2
N
H
O
N
N
O
R1 N3 R2
CuI, DIPEA, THF
 A B 
  
C D 
E F 
G H 
Chapter 4: Peptide-Peptoid hybrids 
 
162 
 
In this method, the peptoid backbone chain is synthesised using the sub-monomer 
method, but the amine used contains an alkyne. Once the peptoid chain has been 
made to the desired length, the alkyne group or groups can be reacted, still on resin, 
with an azide via click chemistry.  
Two different R groups may be incorporated if one of the alkyne building blocks is 
protected by TIPS. The group made four peptoids; two of which had hydrophilic side 
chains, 162 and 163 and two of which were amphiphilic, 164 and 165 (Figure 4.2). 
Uptake was investigated once again by confocal microscopy. The hydrophilic peptoids 
showed internalisation in HeLa cell nuclei, followed by accumulation in the endosomal 
compartments and release into the cytosol over 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Structures of cell-penetrating peptoids made using CuAAC by S. B. L. Vollrath et al. 
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The amphiphilic peptoids, 164 and 165 showed an increase in cellular uptake and 
intracellular distribution when cellular fluorescence from the confocal images was 
quantified using Leica LASAF software. These results showed that, first, the triazole 
group did not hinder the cell penetrating ability of the peptoids, second that whether the 
terminal group was an amide or an acid made little difference, and third, that an overall 
lower net positive charge allowed for effective internalisation. The reason for this has 
not yet been established, though it could be due to an amphiphilic structural motif. 
Studies seem to indicate that a helical conformation with an overall positive charge is 
necessary for internalisation of some cell-penetrating peptoids,6 so it is possible that 
amphiphilic peptoids more readily adopt the favoured helical conformation. 
CuAAC was also used in a study in 2014 to incorporate novel cationic side chains into 
hexameric peptoids (166 – 170) and these peptoids were found to localise either in 
endosomal compartments or, in one case, the cytosol itself.7  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Structure of cell penetrating peptoids containing novel cationic side chains. 
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The cationic side chains incorporated were chosen for their high charge density, 
containing multiple amino functionalities, a quaternary ammonium salt or a 
triphenylphosphonium salt (Figure 4.3). As in the 2012 study, the peptoids were 
incubated with HeLa cells at 37°C for 24 hours and subsequently subjected to confocal 
microscopy. It was found that peptoid 167 accumulated in the cytosol of the HeLa cells 
whilst peptoids 166 and 168 – 170 accumulated exclusively in vesicles, thought to be 
endosomal in nature. It is suspected that the reason for peptoid 167 localising in the 
cytosol is due to the presence of the multiple amine groups in the side chains, resulting 
in greater positive charge density, enabling peptoid 167 to overcome endosomal 
entrapment. This is supported by the observation that monomeric to tetrameric 
analogues of peptoid 167 also accumulated in vesicles.  
Huang et al. also synthesised a library of cell penetrating peptoids to investigate their 
cell permeability. The peptoids synthesised were amphipathic and contained either an 
N-lysine or N-guanidine side chain as the source of positive charge with 5(6)-
carboxyfluorescein (CF) tagged on the end. CF-(Arg)8-NH2 and a polyguanide peptoid 
CF-(Nbtg)8-NH2 (see Figure 4.4 for key to abbreviations) were included as 
comparators. Four peptoids consisted of repeating units of three residues to form one 
9-mer and eight 12-mers and two more peptoids were 12-mers consisting of four 
hydrophobic residues and eight NLys residues (Table 4.1).8 
 
 
 
 
 
 
 
 
 
Figure 4.4 Peptoid monomer side-chain structures and abbreviations 
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Table 4.1 Library of polyguanidine cell penetrating peptoids.8 
Group Compound number Sequence 
Polyguanidine 
comparators 
171 CF-(Arg)8-NH2 
172 CF-(Nbtg)8-NH2 
NLys(1/3) variants 
173 CF-(NLys-Nspe-Nspe)3-NH2 
174 CF-(NLys-Nspe-Nspe)4-NH2 
175 CF-(NLys-Nphe-Nphe)4-NH2 
176 CF-(NLys-Nssb-Nssb)4-NH2 
NLys(2/3) variants 
177 CF-(NLys-NLys-Nspe)4-NH2 
178 CF-(NLys)8-(Nspe)4-NH2 
179 CF-(NLys)8-(NLeu)4-NH2 
Guanidylated variants 
180 CF-(Nbtg-Nspe-Nspe)4-NH2 
181 CF-(Nbtg-Nbtg-Nspe)4-NH2 
 
 
Cell uptake was measured by mean fluorescence arising from the 5(6)-
carboxyfluorescein. Important results from this study were that cellular uptake and 
cytotoxicity of peptoid chains containing the non-aromatic residues Nssb and NLeu 
(176 and 179) was much lower compared to peptoid chains containing aromatic 
residues Npm and Nspe (173, 174, 178, 179, 180 and 181). Additionally, the cellular 
uptake and cytotoxicity of the 9-mer was considerably decreased compared to the 
analogous 12-mer. The chiral Nspe group also displayed better cellular uptake and 
higher cytotoxicity compared to the non-chiral Npm group. 
It is also important to control the ratio of hydrophobic residues to cationic residues with 
the best results coming from peptoids with two hydrophobic residues to every one 
cationic residue. Finally, guanidylation had no effect on cell penetration where there 
was only one cationic side chain to two hydrophobic side chains (compare 19 and 25) 
but where there were two cationic side chains to one hydrophobic side chain (compare 
177 and 181) guanidylation dramatically increased cell uptake and cytotoxicity, i.e 181 
showed increased cell penetration compared to 177. The two peptoids that showed the 
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most efficient cell penetration were 174 and 181 with 181 being slightly less cytotoxic 
(Figure 4.5).  
 
 
 
 
 
 
Figure 4.5 Structures of the two peptoids which showed the best cell-penetration (174 and 181) 
according to the 2012 Huang et al. study.  
These findings can be rationalised; the Nbtg group gives more penetrating peptoids 
due to stronger membrane interactions by the guanidinium heads9 whilst the chiral 
aromatic hydrophobic groups induce formation of an alpha helix, further favouring 
membrane interactions and promoting internalisation. In terms of the intracellular 
distribution of the peptoids, the comparators CF-(Arg)8-NH2 and CF-(Nbtg)8-NH2 (171 
and 172) showed distinctly different behaviour in comparison to two of the peptoids 
with the best cellular uptake (174 and 181). For all three peptoids looked at, cellular 
uptake gradually increased with incubation time whilst for CF-(Arg)8-NH2 (171) the 
maximum uptake was reached at around four hours after which there was a marked 
decrease in uptake. This is consistent with degradation of the peptide contributing 
further evidence of the comparatively superior stability of peptoids. However, both 
comparators (171 and 172) had a much more diffuse distribution compared to the other 
two peptoids; the comparators showed a much more uniform distribution and were 
found throughout the cells whereas the other two peptoids were found mainly or solely 
in the cytosol. 
The mechanism of peptoid internalisation is not currently known, however it is widely 
believed that both energy-dependent endocytosis and energy-independent direct 
translocation are involved.10 As a final part of the above study, the incubation 
temperature was lowered to 4oC and the effect on peptoid internalisation was 
investigated. The uptake of 174 was greatly reduced as was the uptake of 181, 
although the latter still showed considerable uptake, indicating that the mechanism of 
internalisation was either energy-dependent or very sensitive to membrane fluidity. To 
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compare, CF-(Arg)8-NH2 (171) and CF-(Nbtg)8-NH2 (172) showed markedly different 
behaviour; uptake was not reduced at 4oC, in fact the uptake of CF-(Arg)8-NH2 (171) 
was even higher at 4oC, indicating a different mechanism of uptake compared to the 
other two peptoids.8 Finally, it should be noted that with all of these studies, the 
fluorescent labels are small. The results described in these papers therefore give no 
indication of the level of uptake or the distribution of cell-penetrating peptoids 
conjugated to larger cargo.  
In 2017, Marouseau et al. designed a guanidine rich peptoid motif (182) and the cell-
penetrating ability of these peptoids investigated by flow cytometry. The cell-
penetrating ability of these novel peptoid scaffolds was compared to polyaminated 
peptoids (183), benzyl peptoids (184) and polyguanidine comparators (185, Figure 
4.6).11    
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Structures of the guanidine-rich peptoids (182), polyaminated peptoids (183), benzyl 
peptoids (184) and polyguanidine comparators (185) whose cell-penetrating ability was 
investigated by flow cytometry. Each set of compounds has a modular structure consisting of a 
fluorophore (red), β-alanine spacer (blue) and peptoid or peptide chain (purple). 
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It was found that the polyaminated peptoids (183) up to n = 4 and benzyl peptoids 
(184) up to n = 6 showed no significant cell penetration when compared to a blank 
control. However, the guanidine-rich peptoids (182) reached a maximal uptake when n 
= 4 of 80% of the polyguanidine comparator (185). This showed that the backbone and 
fluorophore were not responsible for cell uptake, but that the presence of the guanidine 
groups was key to cell-penetration for these peptoid motifs.  
4.1.2 Aims 
In this chapter, we describe the synthesis of a series of peptide-peptoid chimeras using 
a selection of the short cell-penetrating peptoids described by Kӧlmel et al.1 as 
transporters for biologically active peptides. The first peptide we will use is the 
anticancer KLA peptide (186, Figure 4.7) which induces apoptosis by targeting 
mitochondrial membranes.12, 13 As previously discussed, Kӧlmel et al. synthesised a 
series of short, cell-penetrating peptoids which were shown to localise in mitochondria. 
It is envisaged that conjugation of the KLA peptide onto these cell-penetrating peptoids 
will result in an effective anticancer agent.  
 
Figure 4.7 Structure of the anticancer KLA peptide (186). 
The second peptide we will use is the p15 peptide (126, Figure 4.8), which we 
discussed in Chapter 3. 
As previously discussed in Chapter 3, the p15 peptide (126) is the active domain of the 
anticancer peptide CIGB-300 (Figure 4.8). It targets NPM1 which is localised in the 
nucleolus.14 However, the active p15 peptide is not cell-penetrating and therefore, on 
its own, will show no anticancer activity. For this reason, the p15 peptide is conjugated 
to a TAT sequence (hence p15-TAT).15 TAT is a cell-penetrating peptide derived from 
HIV with a sequence GRKKRRQRRRPPQ and the sequence of p15-TAT, or CIGB-300 
is GRKKRRQRRRPPQ-β-ala-CWMSPRHLGTC.16 The TAT sequence can be taken up 
by cells and localised in the nucleus. The mechanism of cell-uptake is disputed and 
appears at least partly dependent on the properties of the attached cargo, for example, 
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its size, the linkage between peptide and cargo and orientation of the peptide relative to 
the cargo.17  
 
 
Figure 4.8 Structure of anticancer peptide CIGB-300 (125). The active, cyclic peptide, p15, is 
highlighted in green. The active peptide is attached to cell-penetrating peptide derived from the 
HIV-Tat protein, highlighted in red, with a β-alanine linker, highlighted in blue. 
Whilst the TAT sequence is clearly successful at delivering the active p15 peptide to 
cancerous cells, as demonstrated by success in clinical trials in human patients with 
cervical cancer, it will encounter the same problems in vivo as any other peptide as a 
result of susceptibility to proteolytic degradation. Administration of CIGB-300 in all 
clinical trials has been by injection directly into cervical malignancies.18, 19 Chapter 3 
detailed our attempts to improve the stability of the active p15 peptide via replacement 
of the disulphide bridge with different linkages. In this chapter, we will investigate more 
proteolytically stable alternatives to TAT. Improving the stability of both the active 
peptide and its cell-penetrating domain could allow it to be used to treat forms of 
cancer where the tumours are less accessible and local injection unfeasible. Peptoids 
may offer a proteolyitically stable alternative to the TAT sequence. The short, cell-
penetrating peptoids synthesised by Kӧlmel et al. were shown to localise in the nucleus 
to various extents, although nucleolar localisation was not investigated. We will, 
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therefore synthesise a series of p15-peptoid hybrids to investigate their anticancer 
properties. 
 
4.2 Synthesis of the peptide-peptoid hybrids 
The peptide-peptoid hybrids we will make will have a modular design consisting of the 
cell-penetrating peptoid, active peptide (KLA, 186 or p15, 126) and luminescent probe, 
with spacers between the peptoid, peptide and, for the p15 hybrids, the probe as well 
(Figure 4.9). The spacer between the peptoid and peptide is two glycine residues and 
the spacer between the peptide and probe is derived from 5-hexynoic acid. Our 
compounds are configured in this way because we wanted to have the luminescent 
probe at an end of the sequence but attached to the active peptide. If the conjugate 
was configured as follows: peptide-peptoid-probe, presence of the probe would only 
show localisation of the cell penetrating peptoid whilst the active peptide could have 
degraded or detached from the peptoid. The colours of the different components in 
Figure 4.9 will also be used to represent the different components of our structures, i.e. 
the cell-penetrating peptoid will be purple, spacers will be blue, the active peptide will 
be green and the imaging component will be red. 
 
 
 
 
Figure 4.9 Structure of our peptide-peptoid conjugates. 
 
4.3 KLA peptide-peptoids  
4.3.1 The KLA sequence as an anti-cancer peptide 
The KLA peptide (186) has been widely studied for its anticancer properties. It was 
initially designed as an antimicrobial peptide and subsequently found to induce 
apoptosis by targeting mitochondrial membranes.20, 21 The KLA peptide has a 
sequence of D(KLAKKLAK)2, 186.  
Cell penetrating 
peptoid 
Spacer Active peptide (KLA or p15) Probe Spacer 
Chapter 4: Peptide-Peptoid hybrids 
 
171 
 
The KLA peptide (186) has a cationic α-helical amphipathic structure, and it is this that 
enables interaction with the mitochondrial membranes22 and induces subsequent 
permeation and mitochondrial swelling. This triggers the release of cytochrome c and 
cell apoptosis.23, 24  
As with the p15 peptide (126), KLA suffers from poor cell-penetrating ability and thus 
has been conjugated to various targeting moieties in an attempt to deliver the peptide 
into cells more efficiently.22 Examples of such delivery vehicles include cell-penetrating 
peptides,12, 13, 23, 25, 26 nanoparticles27-29 and cyclic peptides.30 Whilst conjugation of KLA 
with these compounds improves drug delivery, there are downsides such as the ease 
of conjugation and stability of the targeting moiety. Cell-penetrating peptoids provide a 
more proteolytically stable alternative. Kӧlmel et al. synthesised a library of short cell-
penetrating peptoids, some of which localised in the mitochondria.1 These peptoids are 
therefore suitable candidates for the delivery of the KLA peptide. Furthermore, since 
KLA consists of D-amino acids, it is far more stable to proteolytic degradation than 
peptides made of naturally occurring L-amino acids. Therefore, a KLA-peptoid 
conjugate is expected to be proteolytically stable than a KLA-peptide conjugate. 
 
4.3.2 The KLA peptide-peptoids   
(Note: Peptide synthesis and purification was carried out by Jingyi Zong at Durham University) 
Initially, six cell-penetrating peptoids with two terminal glycine residues as spacers (187 
– 192) were made. This glycine ‘spacer’ was included to minimise steric interactions 
between the peptoid and the peptide and to prevent interference of the peptoid in the 
KLA peptide’s anticancer activity.  
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On to these peptoids, the KLA sequence was built to give six KLA-peptoid hybrids (193 
– 198). The D-KLA-amide (199) was also made for use as a reference to which the 
activity of the KLA-peptoid hybrids could be compared.  
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The KLA-peptoid hybrids were made by first synthesising the cell penetrating peptoids 
onto Rink Amide resin via the sub-monomer method (Scheme 4.2. Then a spacer 
consisting of two glycine units was attached to the end via solid-phase peptide 
synthesis (SPPS) conditions (see Table 4.2 for a summary of the peptoids made). At 
this point a test cleave was carried out in order to confirm successful peptoid synthesis 
by LCMS analysis (Figure 4.10 shows the LCMS and chromatogram of peptoid-GG 
33). Finally, the KLA sequence was built onto the resin-bound peptoid-spacer using 
SPPS conditions (Scheme 4.2). The peptide-peptoid hybrids were then cleaved from 
the resin using 95% TFA (Scheme 4.2) and analysed by ESI LCMS, MALDI, accurate 
mass and analytical HPLC. Table 4.3 shows the peptoid-peptide hybrids made and 
their MALDI data. Following purification by HPLC, the cytotoxicity of the peptide-
peptoid hybrids (193 – 198), as well as the free D-KLA amide (199), was tested against 
HeLa cells.  
  
 
 
 
Scheme 4.2 Approach to building linear KLA-peptide hybrids 
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Table 4.2 List of cell-penetrating peptoids with glycine spacers synthesised 
Name Sequence Molecular weight Observed mass 
CPPo1 (187) Fmoc-GG-NlysNlysNpcbNlys-NH2  919.52 920.8 = [M+H]+ 
CPPo2 (188) Fmoc-GG-NlysNlysNlysNphe-NH2 885.08 886.0 = [M + H]+ 
CPPo3 (189) Fmoc-GG-NpmbNlysNlysNphe-NH2 934.11 935.0 = [M + H]+ 
CPPo4 (190) Fmoc- GG-NpmbNlysNpcbNlys-NH2 968.55 969.5 = [M + H]+ 
CPPo5 (191) Fmoc- GG-NlysNlysNpcbNphe-NH2 938.52 939.9 = [M + H]+ 
CPPo6 (192) Fmoc- GG-NpmbNlysNpcbNphe-NH2 987.55 988.3 = [M + H]+ 
 
 
 
Figure 4.10 LCMS of the test cleave mixture of peptoid-GG 189. A) Mass spectrum of the 
fraction containing peptoid-GG 189, [M+H]+  = 935, retention time 1.78 minutes; B) The 
chromatogram of the test cleave mixture (detection at 220 nm). 
 
 
 
A) 
B) 
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Table 4.3 List of peptoid-peptide hybrids made and their MALDI-ToF data 
Name Sequence 
Molecular 
weight 
Observed mass 
KLA-CPPo1 
(193) 
H-(KLAKKLAK)2-GG-NlysNlysNpcbNlys-NH2  2200.5 2203.5 = [M+H]+ 
KLA-CPPo2 
(194) 
H-(KLAKKLAK)2 -GG-NlysNlysNlysNphe-NH2 2167.4 2191.5 = [M +Na]+ 
KLA-CPPo3 
(195) 
H-(KLAKKLAK)2-GG-NpmbNlysNlysNphe-NH2 2216.4 2240.5 = [M + Na]+ 
KLA-CPPo4 
(196) 
H-(KLAKKLAK)2- GG-NpmbNlysNpcbNlys-NH2 2250.4 2252.9 = [M + H]+ 
KLA-CPPo5 
(197) 
H-(KLAKKLAK)2- GG-NlysNlysNpcbNphe-NH2 2220.4 2244.4 = [M + H]+ 
KLA-CPPo6 
(198) 
H-(KLAKKLAK)2- GG-NpmbNlysNpcbNphe-NH2 2269.3 2293.2 = [M + Na]+ 
 
4.3.3 Cytoxicity of KLA and KLA-CPPos  
(Note: MTT experiments were carried out by Lijun Jiang at Hong Kong Baptist University). 
The cytotoxicity assays showed that the D-KLA peptide amide (199) was not very toxic 
against HeLa cells; there was very little activity at concentrations below 200 μM, and 
even at 500 μM, 60% of the HeLa cells survived (Figure 4.11). Conversely, at the 
highest concentration measured (100 μM), all bar one (194) of the six peptoid-KLA 
hybrids were more toxic to the HeLa cells than D-KLA. Hybrids 193 – 195 whilst either 
as effective as or better at killing the HeLA cells than the D-KLA, were still not very 
toxic against the HeLa cells. This suggests that the three peptoids were able to carry 
the KLA peptide into the cells, but perhaps do not localise in the mitochondria. This is 
supported by the much stronger toxicity seen for KLA-peptoids 196 – 198.  Peptoid-
KLA hybrid 198 was the most effective- it was as effective at 10 μM as D-KLA was at 
200 μM (Figure 4.12). This was as expected since in the original study, the 
corresponding cell-penetrating peptoid (161) was most effective at localising in the 
mitochondria. 
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Figure 4.11 MTT assay determined cell viability of HeLa cell line after incubation with D-KLA 
(199) for 24 hours at 37°C.  
 
Figure 4.12 Cell viability inhibitory activities of the KLA-peptoid hybrids (193-198) on HeLa 
cells.  
Because there was such a large increase in cell viability between 20 μM (~20%) and 
10 μM (~70%) of KLA-CPPo6 (198), further MTT assays were carried out between 5 
μM and 20 μM to define an IC50 value (Figure 4.13). It was found that at 8 μM, viability 
of the HeLA cells was 37.97 % ± 0.5%, but at 5 μM, HeLa cell viability jumps to over 
100%. 
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Figure 4.13 MTT assay determined cell viability of HeLA cell line after incubation with KLA-
CPPo6 (198) for 24 hours at 37°C.  
 
4.3.4 Cellular uptake and in vitro imaging 
(Note: Rhodamine B conjugation was carried out by Jingyi Zong at Durham University. Flow 
cytometry and confocal microscopy was carried out by the Wong group at Hong Kong Baptist 
University). 
To confirm that peptoid-KLA hybrid 198 was localising in the mitochondria the peptoid-
KLA hybrid was synthesised once more, except this time, before cleavage, Rhodamine 
B (200) was conjugated to the end using DIC and HOBt as coupling agents to give 
Rhod-KLA-CPPo6 (201, Scheme 4.3). The crude peptoid was purified by HPLC and 
analysed by LCMS, MALDI-ToF and analytical HPLC (see experimental section, 
Chapter 6). The analytical HPLC trace showed two peaks in the pure product (Figure 
4.14). Rhodamine is known to form an equilibrium between a ‘non-fluorescent’ closed 
spirolactam form and a ‘fluorescent’ form with an open structure. This is proton-
mediated (Scheme 4.4). Previous work by Birtalan et al.,31 showed that the ‘non-
fluorescent’ form has a shorter retention time than the ‘fluorescent form. Therefore the 
first peak should represent the ‘non-fluorescent’ form (202) and the second peak 
should represent the ‘fluorescent’ form (203). Addition of a few drops of 1% TFA in 
water results in an increase in absorbance of the second peak relative to the first, 
providing evidence that the second peak is indeed the ‘fluorescent’ form (203). 
  
 
 
Scheme 4.3 Conjugation of rhodamine B (200) onto the resin-bound KLA-CPPo6 to make Rhod-KLA-CPPo6 (201). 
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Scheme 4.4 Interconversion of the rhodamine B moiety of Rhod-KLA-CPPo6 (201). 
 
Figure 4.14 Analytical HPLC trace of pure Rhod-KLA-CPPo6 (201) showing two peaks: one 
corresponding to the closed, ‘non-fluorescent’ form (202) and the second corresponding to the 
open, ‘fluorescent’ form (203).  
The uptake of Rhod-KLA-CPPo6 (201) was analysed by flow cytometry. Rhod-KLA-
CPPo6 (201) was incubated with HeLa cells for 12 hours and its uptake was compared 
to a blank sample (Figure 4.15). The uptake of Rhod-KLA-CPPo6 (201) could be seen 
clearly. 
Having shown the ability of Rhod-KLA-CPPo6 (201) to enter the HeLa cells, confocal 
microscopy experiments were carried out to investigate localisation within the cells. 
Rhod-KLA-CPPo6 (201) was incubated with HeLa cells for 24 hours and examined by 
laser confocal microscopy. Mito-tracker was used to locate the mitochondria within the 
cells and the merge of the images of Rhod-KLA-CPPo6 (201) and Mito-tracker showed 
clear co-localisation (Figure 4.16). This confirmed that CPPo6 delivers the KLA into the 
mitochondria of HeLa cells, thus resulting in a significant improvement in anticancer 
activity. 
203 
202  
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Figure 4.15 Cellular uptake of Rhod-KLA-CPPo6 (201) by flow cytometry in HeLa cells.  
 
Figure 4.16 Confocal microscopy images of Rhod-KLA-CPPo6 (201) in HeLa cells. 
Concentration = 10 μM, incubation time= 24 hours.  
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4.4 Delivery of the p15 peptide 
Having demonstrated the ability of the short cell-penetrating peptoids synthesised by 
Kӧlmel et al. (156 – 161) to deliver biologically active cargo into cells and induce 
anticancer activity, we aim to make a series of p15-peptoid conjugates (204 – 209). A 
luminescent probe will be attached to the N-terminus of the peptide-peptoid to give a 
modular probe, as described in Figure 4.9. Each conjugate will then be used to monitor 
inhibition of cell proliferation in several different cell lines in work that will be carried out 
by the Law lab at The Hong Kong Polytechnic University.  
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4.4.1 Synthesis of the peptoid-peptide hybrids 
Synthesis of the peptoid-peptide hybrids is summarised in Scheme 4.5. The cell-
penetrating peptoids (210 – 215) were manually synthesised on 2-chlorotrityl chloride 
resin using the sub-monomer method. The resin was swollen in DCM for 40 minutes 
before addition of bromoacetic acid. After our initial attempts to synthesise peptoids 
201 – 215, we struggled to obtain enough peptoid for even LCMS analysis. This is 
because when 2-chlorotrityl chloride resin is used, in the loading step, acidic by-
products are released that can cause premature cleavage of the peptoid from the resin. 
This can be prevented by the addition of neat DIPEA in the loading step to neutralise 
any acidic by-products. The loading step of our second attempt at peptoid synthesis 
therefore used bromoacetic acid and DIPEA, and the resin was left on the shaker at 
room temperature for 40 minutes. Following the loading step, sub-monomer synthesis 
proceeded as usual with amine displacements for 1 hour at room temperature and 
subsequent bromoacetic couplings in the presence of DIC for 20 minutes at room 
temperature. Bromoacetylation and amine displacement steps were repeated until the 
final submonomer was added. At this point test cleaves (using 20% 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) in DCM for half an hour at room temperature) were 
carried out to confirm successful peptoid synthesis (Figure 4.17 shows the LCMS and 
chromatogram of peptoid 59). The Boc-NLys protected peptoids, 210 – 215 were 
obtained from this cleavage cocktail (see Table 4.3 for a summary of the peptoids 
synthesised and their LCMS data). 
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Scheme 4.5 Approach to building linear peptoid-p15 hybrids 
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Table 4.4 List of Boc-protected cell-penetrating peptoid acids made and their LCMS data 
Name Sequence Molecular weight Observed mass 
CPPo7 (210) BocNlysBocNlysNpcbBocNlys-OH  884.51 885.5 = [M+H]+ 
CPPo8 (211) BocNlysBocNlysBocNlysNphe-OH 850.07 851.5 = [M + H]+ 
CPPo9 (212) NpmbBocNlysBocNlysNphe-OH 798.98 800.5 = [M + H]+ 
CPPo10 (213) NpmbBocNlysNpcbBocNlys-OH 833.42 834.4 = [M + H]+ 
CPPo11 (214) BocNlysBocNlysNpcbNphe-OH 803.40 804.4 = [M + H]+ 
CPPo12 (215) NpmbBocNlysNpcbNphe-OH 752.31 753.4 = [M + H]+ 
 
 
Figure 4.17 LCMS of the test cleave mixture of Boc-protected peptoid acid 214. A) Mass 
spectrum of the fraction containing peptoid 214, [M+H]+  = 804, retention time 2.95 minutes; B) 
The chromatogram of the test cleave mixture (detection at 220 nm). 
To the peptoid was then added two glycine residues by standard solid-phase Fmoc 
synthesis using PyBOP and DIPEA for the coupling steps and 20% piperidine v/v in 
DMF for the Fmoc deprotections. From here, the p15 peptide was built onto the peptoid 
via the glycine spacers using standard solid-phase Fmoc synthesis, and as described 
in Chapter 3, Scheme 3.8. Synthesis was carried out manually and at room 
temperature with no preactivation step to minimise cysteine and histidine racemisation 
and Fmoc-Trp(Boc)-OH was used to prevent Pbf transfer from the arginine. To confirm 
successful synthesis of the peptide-peptoid hybrid, a test cleave using TFA:TIPS:water 
A) 
B) 
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was carried out and the resulting crude peptide-peptoid analysed by ESI LCMS and 
MALD-ToF. Table 4.5 summarises the MALDI-ToF data for the peptide-peptoid hybrids 
made at this stage (216 – 221). Finally, 5-hexynoic acid (Hyx) was added to the N-
terminus of the peptide whilst still on resin using PyBOP and DIPEA and left for 1 hour 
on the shaker at room temperature (Scheme 4.5). At this point a final test cleave was 
carried out (using TFA:TIPS:water) and the resulting crude peptoid-peptide hybrids 
were analysed by LCMS and MALDI-ToF to confirm successful synthesis of the 
hexynoic acid-peptoid-peptide hybrid. Table 4.6 summarises the peptoid-peptide 
hybrids made (222 – 227) and their MALDI-ToF data. The six resin-bound Hyx-p15-
CPPos (228 – 233) were sent to the Law lab at The Hong Kong Polytechnic University. 
Table 4.5 List of p15-peptoid hybrids made and their MALDI-ToF data 
Name Sequence 
Molecular 
weight 
Observed mass 
p15-CPPo7 (216) Fmoc-p15-GG-NlysNlysNpcbNlys-OH  2335.2 2336.6 = [M+H]+ 
p15-CPPo8 (217) Fmoc-p15 -GG-NlysNlysNlysNphe-OH 2300.8 2301.5 = [M +H]+ 
p15-CPPo9 (218) Fmoc-p15-GG-NpmbNlysNlysNphe-OH 2349.8 2350.3 = [M + H]+ 
p15-CPPo9 (219) Fmoc-p15- GG-NpmbNlysNpcbNlys-OH 2384.2 2384.9 = [M + H]+ 
p15-CPPo10 (220) Fmoc-p15- GG-NlysNlysNpcbNphe-OH 2354.2 2355.0 = [M + H]+ 
p15-CPPo11(221) Fmoc-p15- GG-NpmbNlysNpcbNphe-OH 2403.2 2404.0 = [M + H]+ 
 
Table 4.6 List of Hyx-p15-peptoid hybrids made and their MALDI-ToF data 
Name Sequence 
Molecular 
weight 
Observed mass 
Hyx-p15-CPPo7 
(222) 
Hyx-p15-GG-NlysNlysNpcbNlys-OH  2207.1 2208.5 = [M+H]+ 
Hyx-p15-CPPo8 
(223) 
Hyx-p15 -GG-NlysNlysNlysNphe-OH 2172.6 2173.4 = [M +H]+ 
Hyx-p15-CPPo9 
(224) 
Hyx-p15-GG-NpmbNlysNlysNphe-OH 2221.7 2222.7 = [M + H]+ 
Hyx-p15-CPPo9 
(225) 
Hyx-p15- GG-NpmbNlysNpcbNlys-OH 2256.1 2257.3 = [M + H]+ 
Hyx-p15-CPPo10 
(226) 
Hyx-p15- GG-NlysNlysNpcbNphe-OH 2226.1 2227.1 = [M + H]+ 
Hyx-p15-
CPPo11(227) 
Hyx-p15- GG-NpmbNlysNpcbNphe-OH 2275.1 2276.1 = [M + H]+ 
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The peptide can then be cyclised whilst still on resin using iodine and DIPEA in DMF or 
DCM, as discussed in Chapter 3. The peptoid-peptide hybrid can be simultaneously 
deprotected and cleaved from the resin using TFA:EDT:water:TIPS 94:2.5:2.5:1 for 
four hours (Scheme 4.6). Finally, the 5-hexynoic acid provides a handle through which 
the probe can be connected to the peptoid-peptide hybrid via a copper-catalysed azide-
alkyne cycloaddition (CuAAC) (Scheme 4.7).  
  
 
Scheme 4.6 Proposed cyclisation of the linear p15-peptoid hybrids.
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Scheme 4.7 Proposed conjugation of the imaging agent to the peptoid-peptide hybrids 
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4.5 Conclusions 
Cell-penetrating peptides have been well researched as a means of internalising 
biologically active cargo within cells. Cell-penetrating peptoids can be considered a 
proteolytically stable alternative to cell-penetrating peptides. In this Chapter we 
synthesised a series of six cell-penetrating peptoids (187 – 192) whose sequences 
were first reported by Kӧlmel et al. in 2012. Onto these peptoids were built the known 
anticancer peptide sequence D-(KLAKKLAK)2 (186) to make six KLA-CPPos (193 - 
198, Scheme 4.2). The KLA peptide targets mitochondrial membranes, but is unable to 
enter the cell on its own. Conjugation of the KLA peptide to a transporter which can 
localise the peptide in the mitochondria should therefore enhance anticancer activity. 
The six KLA-peptoid hybrids (193 – 198) were used in cell-proliferation assays against 
HeLa cells and their activity compared to the D-KLA peptide amide (199, Figures 4.11 
and 4.12). Of the six KLA-peptide hybrids, KLA-CPPo6 (198) was the most effective 
with an IC50 of ~8μM (Figure 4.13) and over 60 times lower than the D-KLA amide. 
This was as predicted since the cell-penetrating peptoid CPPo6 (198) was derived from 
the cell-penetrating peptoid (161) which showed the best mitochondrial localisation in 
the work by Kӧlmel et al.  
To prove that KLA-CPPo6 localises in the mitochondria, Rhodamine B was conjugated 
to the end of KLA-CPPo6 to form Rhod-KLA-CPPo6 (201, Scheme 4.3). The uptake of 
the chimera could then be studied by flow cytometry and localisation within the cell 
seen with confocal microscopy. Uptake of Rhod-KLA-CPPo6 could clearly be seen 
from flow cytometry (Figure 4.15) and the confocal microscopy showed that Rhod-
KLA-CPPo6 was able to localise in the mitochondria (Figure 4.16).  
Having shown the ability of cell-penetrating peptoids to transport the KLA peptide and 
enhance its anticancer activity, we investigated whether the peptoids could also be 
effective transporters for the p15 peptide. We have previously discussed the p15 
peptide in Chapter 3; it is the active domain of the known anticancer peptide CIGB-300 
(125). In CIGB-300, the p15 peptide is conjugated to the cell-penetrating TAT peptide. 
We wanted to find out whether replacing the TAT sequence with a cell-penetrating 
peptoid would make a more proteolytically stable compound whilst retaining or 
improving the overall anticancer activity. To this end, we synthesised the six cell-
penetrating peptoids we used in the KLA studies on 2-chlorotrityl chloride resin, and 
onto these built the linear p15 sequence (Scheme 4.5). Finally, onto the end of the 
p15-CPPos we conjugated 5-hexynoic acid (Scheme 4.5) to give resin-bound Hyx-p15-
CPPos (228 – 233). The 5-hexynoic acid moiety acts as a spacer and a handle onto 
which the imaging probe can be attached via CuAAC. The resin-bound Hyx-p15-
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CPPos (228 – 233) were sent to collaborators in Hong Kong, where their activity will be 
investigated by the Law lab at The Hong Kong Polytechnic University. We are currently 
awaiting the results of these studies. 
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Chapter 5  
Conclusions and Future Work 
The aims of this project were two-fold: first we aimed to widen the diversity of peptoid 
architecture by the synthesis of peptoids containing synthetically useful building blocks 
and novel motifs. This work was described in Chapter 2. The second aim was to 
stabilise a known cyclic anticancer peptide by synthesising stapled analogues of the 
active peptide and by using cell-penetrating peptoids as transporters. This work is 
described in Chapter 3 and Chapter 4.  
 
5.1 Novel peptoid architecture 
In Chapter 2 we successfully synthesised a peptoid monomer which contained a 
MIDA-protected boronic acid as the side chain (74). This was achieved via a reductive 
amination reaction between glycine benzyl ester (73) and 4-formylphenyl boronic acid 
MIDA ester (69). 
The benzyl ester protected peptoid monomer was successfully synthesised in a 34% 
yield by using sodium triacetoxyborohydride as a reducing agent and acetonitrile as the 
reaction solvent. However, subsequent deprotection had to be carried out in methanol 
and as a result, removal of the MIDA ester from the boronic acid was seen within two 
hours. Attempts to optimise the reductive amination step were not carried out, but 
these could include use of acid catalysts to improve the efficiency of imine formation. 
However, there is little point carrying out optimisation if the end product is going to 
decompose on deprotection of the benzyl ester. Therefore, any future work would look 
at using a different acid protecting group, e.g. a tert-butyl (tBu) protected acid (234). 
Chapter 5: Conclusions and Future Work 
 
200 
Deprotection of a tBu-ester is achieved by addition of TFA- something we have already 
seen the MIDA boronate is largely stable to. The tBu-ester analogue may also change 
properties of the peptoid monomer, such as solubility, making it easier to handle and 
purification more efficient. If this is the case, the yield from the reductive amination step 
may be inherently higher and optimisation of the reaction may be unnecessary. 
 
Chapter 2 also detailed our work on the synthesis of biaryl-linked cyclic peptoids. A 
library of biaryl-linked cyclic peptoids (104, 110, 119 – 124) was made via on-resin 
Suzuki-Miyaura cross-coupling in yields of 3 – 23%. The primary aim of this work was 
to synthesise novel peptoid scaffolds as proof of concept which can now be applied to 
other peptoid-based structures. 
Optimisation of the reaction conditions is the obvious next stage in this work as this 
would enable the isolation of greater quantities of cyclic peptoid. Some of the 
byproducts of the Suzuki-Miyaura cross-coupling reaction arose from 
hydrodehalogenation of the iodine. This is a commonly observed side-reaction in cross-
coupling reactions.1-3 This competing reaction can be influenced by identity of the 
catalyst, strength and number of equivalents of base, solvent used and reaction 
temperature.1,3 Thus, optimisation would involve screening for metal source, ligand, 
base, solvent and reaction temperature. This would allow better NMR spectra to be 
obtained, including NOE experiments. Data from NMR experiments can provide 
insights into the structure of these novel scaffolds. 
Work in the group is currently underway to obtain crystal structures of these 
compounds in order to gain insight into how the biaryl group influences secondary 
structure. Crystal structures may also provide information that would be useful for 
optimisation of reaction conditions.  
The peptoid library could be expanded to include chiral side-chains (example structure, 
235). The inclusion of a chiral side-chain would enable the use of circular dichroism 
experiments in order to gain insight into the structure of this class of cyclic peptoid. 
Furthermore, Suzuki-Miyaura cross-coupling is orthogonal to other methods of peptoid 
cyclisation (as discussed in Chapter 1), and therefore could provide a route to bicyclic 
peptoid scaffolds, for example by using carrying out Suzuki-Miyaura cross-coupling 
followed by CuAAC to generate a scaffold similar to bicyclic peptoid 236. 
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Further work would also investigate the biological activity of these compounds. 
Unfortunately, none of the peptoids tested (linear biaryl-containing peptoid 106 and 
cyclic biaryl-containing peptoids 104, 110, 119 and 120) showed antibacterial activity 
against either E. coli or S. aureus at the concentrations tested. However, alteration of 
the peptoid side chains, for example by changing the length of NLys side-chains, or 
replacement of a positively charged side-chain with a hydrophobic group may result in 
some antibacterial activity. In addition to antibacterial screening, the group has a 
particular interest in anti-leishmanials, so biaryl-linked cyclic peptoids could also be 
screened for activity against L. mexicana. Any screening for antimicrobial and 
antiparasitic activity should also be carried out alongside cell toxicity and haemolysis 
studies.  
 
5.2 Nucleophosmin-targeting peptide (p15) and analogues 
In Chapter 3 we successfully synthesised the active domain of the nucleophosmin 
(NPM1)-targeting anticancer peptide, p15 (126, best isolated yield 19%) along with 
three stapled analogues: F-p15, (127, best isolated yield 32%), C=C p15 (128, best 
isolated yield 11%) and C-C p15 (129, best isolated yield from C=C-p15 50%).  BLI 
binding assays were carried out by the Law lab at The Hong Kong Polytechnic 
University and preliminary results showed that p15 (126) and C-C p15 (129) bound to 
NPM1 more strongly than F-p15 (127) and C=C p15 (128) 
The isolated yields of all the peptides synthesised were low, and little time was spent 
optimising conditions. This is an obvious area for further work. Loading of the 2-
chlorotrityl chloride resin was not very efficient, as demonstrated by the lower than 
expected masses obtained from cleavage of the crude linear peptides. This could be a 
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result of the high water and acid sensitivity of 2-chlorotrityl chloride resin. As the resin 
ages and is exposed to atmospheric water, the loading sites will start to become 
‘capped’ meaning fewer available loading sites and a lower resin loading. Alternatively, 
the resin-bound peptide could be partially cleaved during the course of the synthesis, 
as happened in the course of our initial attempts to form the disulphide bridge of p15 
(126). A solution to this would be to use Rink Amide resin which is less water and acid 
sensitive. However, using Rink Amide results in an amide at the C-terminus rather than 
an acid, and this could affect the peptide’s affinity for the target protein. That said, it 
should be noted that p15 needs to be attached to a cell-penetrating moiety to show 
activity in a cellular environment. Therefore, the functional group at the C-terminus may 
be irrelevant, particularly if attached to a cell-penetrating peptide or peptoid from this 
end.  
Formation of the disulphide bond in p15 (127) was carried out via simultaneous 
deprotection of the Acm group on the cysteine and oxidation using iodine. This is an 
inherently inefficient method since prolonged reaction times result in undesired side-
reactions, but limiting reaction times leads to only partial removal of the Acm groups 
from the cysteine residues and thus limits cyclisation.4-6 An alternative method is 
solution-phase air oxidation of the deprotected peptide in a buffer solution at pH 7.5 – 
8. For the p15 peptide, this is time consuming as the use of additives such as H2O2 to 
speed up the reaction is precluded by the presence of methionine which can also be 
oxidised. However, the final achievable yield of the desired peptide is higher than for 
the iodine oxidation method, and this is the method usually seen in the literature 
syntheses of p15.7 
F-p15 (128) was synthesised via a solution-phase stapling reaction between the fully 
deprotected linear p15 peptide (147) and hexafluorobenzene (145). Following the 
reaction, the mono-substitued, uncyclised peptide (148 and/or 149), as well as the 
uncyclised parent peptide (147) could be seen in the LCMS. Increasing the 
concentration of the reaction mixture may speed up the reaction and push it to 
completion, but care must be taken not to increase concentration too much or the di-
substituted, linear peptide may be seen. If increasing the concentration results in the 
appearance of the di-substituted linear peptide, increasing the reaction time, or heating 
the reaction mixture may be a better alternative route to improving the yield. 
We also synthesised C=C p15 (128) via Grubbs’ RCM on the resin-bound linear 
peptide where the cysteine residues had been replaced with allylglycine residues (150). 
Initial attempts at Grubbs’ RCM resulted in only the uncyclised peptide (151) so 
different conditions were screened (Table 3.1). After each Grubbs’ RCM, uncyclised 
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peptide could be seen in the LCMS, and this is likely to account for the poor yield. 
Longer reaction times and further additions of catalyst solution could improve this. 
Alternatively, the more reactive Grubbs’ first and second generation catalysts could be 
used; whilst some of the conditions screened used the first generation catalyst, the 
reactions were only carried out at room temperature. Using the first and second 
generation catalysts at reaction temperatures similar to those used with the Hoveyda-
Grubbs’ second generation catalyst may result in faster reaction times. 
The major problem with hydrogenation of C=C-p15 (128) to C-C-p15 (129) is that only 
a small quantity of C=C-p15 (128) was taken forward into the reaction. This means that 
small losses of peptide, for example in the course of removal from the palladium 
catalyst, translate into a large impact on the yield. Improvement of the RCM reaction to 
obtain more C=C-p15 (128) will enable the reaction to be carried out on a larger scale. 
Optimising reaction conditions for the synthesis of all peptides enables the isolation of 
more pure peptide. This means that a wider range of crystallisation conditions can be 
screened. Obtaining crystal structures of the peptides, both individually and co-
crystallised with NPM1, may offer insight into the binding of p15 and its analogues to 
NPM1 and enable further structural modifications to improve binding affinity and hence 
effectiveness in the treatment of cancers.  
Should further results from binding assays confirm that C-C p15 (129) has comparative 
affinity to NPM1 when compared the original p15 (126), the next step will be to build 
p15 (126) and C-C p15 (129) onto cell-penetrating peptoids (CPPos), with a view to 
using the CPPos as more stable alternatives to the cell-penetrating TAT sequence 
used in CIGB-300 (125). Working to optimise the cyclisations is therefore worthwhile as 
this will allow more efficient synthesis of the chimeric peptides, allowing us to 
investigate their therapeutic effectiveness. Preliminary efforts in these investigations 
are described in Chapter 4. 
 
5.3 Peptoid-p15 hybrids  
In Chapter 4 we described the synthesis of a series of six cell-penetrating peptoids 
(CPPos, 187 – 192) that were first reported in 2012 by Kӧlmel et al.8 Onto each of 
these CPPos was built the KLA peptide (186); a known anticancer peptide of sequence 
D-(KLAKKLAK)2 to give six KLA-CPPos (193 – 198). The KLA peptide interacts with 
mitochondrial membranes, triggering permeation and mitochondrial swelling which 
induces apoptosis.9, 10 Some of the CPPos synthesised by Kӧlmel et al. were shown to 
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localise in the mitochondria, and so cell viability assays were carried out on each of the 
KLA-CPPos (Figures 4.12 and 4.13) to investigate whether the CPPos improved the 
activity of KLA. Cell viability assays were also carried out on D-KLA amide (199, Figure 
4.11) as a comparison to the KLA-CPPos (193 – 198). The KLA-CPPo conjugate with 
the best activity was KLA-CPPo6 (198) had an IC50 of ~8μM: more than 60 times lower 
than that of D-KLA amide. This was as expected: in the original work by Kӧlmel et al., 
the corresponding CPPo showed the best mitochondrial localisation. Mitochondrial 
localisation of KLA-CPPo6 was confirmed by flow cytometry and confocal microscopy 
experiments on the Rhodamine B tagged conjugate Rhod-KLA-CPPo6 (201, Figures 
4.15 and 4.16). Further work could include the incorporation of a targeting moiety that 
improves selectivity for cancerous cells over healthy cells, and the corresponding in 
vivo experiments. 
Having shown the ability of CPPos to transport a biologically active peptide into cells 
and improve activity over the free peptide, we then conjugated the p15 peptide (126) 
onto each CPPo. The p15 peptide (126) is the active domain of the anticancer peptide 
CIGB-300 (125) which was first discussed in Chapter 3. The p15 peptide triggers 
apoptosis by interacting with NPM1 which is localised in the nucleolus.11 The CPPos 
reported by Kӧlmel et al. showed nuclear localisation to varying extents, although 
specific nucleolar localisation was not investigated. We therefore wanted to investigate 
whether the CPPos could act as a proteolytically stable alternative to the TAT peptide 
which is the cell-penetrating peptide used to transport p15 as CIGB-300. Six p15-
CPPos were synthesised and on the end of each was attached 5-hexynoic acid to 
provide an alkyne as a reactive handle for the conjugation of an imaging probe via 
copper-catalysed azide-alkyne cycloaddition (CuAAC). The resin-bound Hyx-p15-
CPPos (228 – 233) were sent to the Law lab at The Hong Kong Baptist University 
where the imaging component will be attached and anticancer activity evaluated. 
Should any of our p15-CPPo conjugates show anticancer activity, we can then 
progress this work by synthesising the stapled C-C p15 analogue (129) onto the 
CPPos. These C-Cp15-CPPo hybrids would be expected to be more proteolytically 
stable than CIGB-300, and their respective anticancer properties could be compared.   
 
5.4 Final Comments 
In summary, we have successfully synthesised a library of biaryl-linked cyclic peptoids. 
Whilst these did not show any activity against E. coli or S. aureus, these compounds 
represent novel peptoid scaffolds which contain a ‘privileged structure.’ 
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We have also successfully synthesised the active domain of the anticancer peptide 
CIGB-300 (p15) and three stapled analogues. BLI binding assays were carried out by 
the Law lab at The Hong Kong Polytechnic University and preliminary results showed 
that p15 (126) and C-C p15 (129) bound to NPM1 more strongly than F-p15 (127) and 
C=C p15 (128). However, work is ongoing to confirm these results and to obtain 
quantitative information on the binding affinity of these peptides to NPM1. 
Continuing our work on making stabilised bioactive peptides, we synthesised a series 
of peptide-CPPo hybrids. The first set of peptide-peptoid hybrids were KLA-CPPos. We 
demonstrated that the conjugation of D-KLA to a CPPo which localised in the 
mitochondria significantly improved KLA activity compared to the free D-KLA amide. 
We then used the same CPPos and conjugated the p15 peptide to them, thus replacing 
the cell-penetrating TAT sequence of CIGB-300 with a more proteolytically stable 
alternative. We are awaiting the results of investigations into the anticancer activities of 
the p15-CPPos.  
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Chapter 6 
Experimental 
6.1 Materials and equipment 
All the chemical reagents and solvents from commercial sources were used without 
further purification. N-(tert-Butoxycarbonyl)-1,4-diaminobutane was purchased from 
TCI (Tokyo, Japan). 3-Iodobenzylamine was purchased from Acros Organics (Geel, 
Belgium). PyBOP was purchased from Apollo Scientific (Stockport, UK). All resins and 
amino acids were purchased from Novabiochem by Merck (Darmstadt, Germany). All 
other reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
NMR solvents were purchased from Goss Scientific (Crewe, UK). Solid phase peptoid 
and peptide synthesis was performed in Bond Elut solid phase extraction (SPE) 
cartridges with two polypropylene frits (20 mL) from Crawford Scientific (Lanarkshire, 
Scotland). Peptoid and peptide syntheses were performed manually in the Bond Elut 
cartridges. A Radleys Discovery Technology shaker was also used to mix solutions 
where indicated and aqueous solutions were lyophilised using a Christ Alpha 1-2 LD 
Plus freeze-drier. Solvents were removed under reduced pressure using a Büchi 
Rotavapor R11. 
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6.2 Characterisation 
6.2.1 Liquid chromatography electrospray ionisation mass spectrometry 
Analytical LC-MS data were obtained using a triple quadrupole mass spectrometer 
equipped with an Acquity UPLC (Waters Ltd, UK) and a photodiode array detector. 
Samples were injected onto the Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm × 50 
mm) with a flow rate of 0.6 mL min-1 and a linear gradient of 5–95 % of solvent B over 
3.8 min (A = 0.1 % formic acid in H2O, B = 0.1 % formic acid in acetonitrile). The flow 
was introduced into the electrospray ion source of the Aquity TQD mass spectrometer. 
 
6.2.2 Quadrupole time-of-flight mass spectrometry 
Measurements were performed using a QToF Premier mass spectrometer with an 
Acquity ultra-performance liquid chromatography system (Waters Ltd, UK). Samples 
were injected to the Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm x 100 mm) with a 
flow rate of 0.6 mL min-1 and a linear gradient of 0–99 % of solvent B over 6 min (A = 
0.1 % formic acid in H2O, B = 0.1 % formic acid in acetonitrile). The solvent flow from 
the UPLC was injected into a 0.2 mL/min flow of acetonitrile which was introduced into 
the electrospray ion source. 
6.2.3 Matrix-assisted laser desorption/ionisation mass spectrometry 
MALDI-ToF analysis was obtained using an Autoflex II ToF/ToF mass spectrometer 
(Bruker Daltonik GmBH) equipped with a 337 nm nitrogen laser. The sample solution 
(ideally at 1 mg mL-1) was mixed with matrix solution, typically α-cyano-4- 
hydroxycinnamic acid (~ 50 mg mL-1) in the ratio 9:1 matrix to sample. 1 μL of the 
matrix/sample solution was spotted to the MALDI target and allowed to evaporate prior 
to analysis, where the metal target is placed into the MALDI ion source. The samples 
were analysed in positive detection mode with reflectron enhanced mass resolution for 
m/z between 500 and 5000. Internal mass calibration with known standards was used 
to established the mass accuracy. Variable laser intensities were used to ensure the 
most representative mass spectra for samples were produced. MALDI MS/MS was 
performed using LIFT technology (MALDI LIFT-ToF-ToF) which enables detection of 
product ions that result from elevated laser power. 
 
Chapter 6: Experimental 
 
209 
6.2.4 Nuclear magnetic resonance spectroscopy 
1H, 13C, 19F NMR and 11B spectra were obtained on the following machines; Varian 
Mercury-400 MHz, Varian VNMRS-600 MHz and Bruker Avance-400 MHz 
spectrometers. Chemical shifts are reported in parts per million (δ ppm) and relative to 
residual solvent peaks. J couplings are reported in megahertz (MHz). Multiplicities: s = 
singlet, d = doublet, t = triplet. 
 
6.3 Chemical Synthesis  
6.3.1 Mono-MIDA boronate (74) 
Sodium triacetoxyborohydride (365 
mg, 1.72 mmol) was added to a 
stirred suspension of 4-
formylphenylboronic acid MIDA ester 
(69, 300 mg, 1.15 mmol) and glycine 
benzyl ester (73, 348 mg, 1.72 mmol) 
in dry acetonitrile (10 mL) under 
nitrogen and the reaction mixture left to stir at room temperature for 48 hours. The 
mixture was quenched with saturated aqueous sodium bicarbonate and the acetonitrile 
removed in vacuo. The mixture was resuspended in water (20 mL) and washed with 
ethyl acetate (3 x 50 mL), then the organic layers were collected, dried over 
magnesium sulphate and the solvent removed in vacuo to yield the crude product as a 
sticky yellow solid (358 mg) which was further purified by column chromatography 
(ether:acetonitrile 9:1 ~ 1:1 gradient) to give MIDA boronate (74) as a colourless solid 
(160 mg, 34%). δB (128 MHz CD3CN) 11.80;  δH (700 MHz CD3CN) 2.48 (3 H, s, H-15 ), 
3.40 (2 H, s, H-7), 3.86 (2 H, s, H-8), 3.85 – 4.07 (4 H, m, H-14), 5.14 (2H, s, H-5), 7.31 
– 7.45 (9 H, m, H1-3 and H10-11); δC (176 MHz CD3CN)* 48.4, 50.7, 53.4, 62.7, 66.9, 
128.7, 129.1, 129.1, 129.5, 133.5, 137.4, 142.2, 169.5, 173.1; HRMS (ESI+) 
C21H2410BN2O6+ ([M+H]+) requires 410.1764; found 410.1759.  
*Missing peak corresponding to 1 x quaternary carbon 
Spectra can be found in Appendix A. 
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6.3.2 Di-MIDA boronate (75) 
4-formylphenylboronic acid MIDA ester 
(69, 100 mg, 0.38 mmol) was added to a 
stirred suspension of glycine benzyl ester 
(73, 83 mg, 0.41 mmol) in acetonitrile (2 
mL) and stirred at room temperature for 
1 hour. Sodium cyanoborohydride (52 
mg, 0.82 mmol) was added to the 
reaction mixture and left to stir at room 
temperature overnight. The solvent was removed in vacuo and the crude mixture 
redissolved in ethyl acetate (20 mL) and washed twice with saturated aqueous sodium 
bicarbonate (2 x 10 mL), then once with water (10 mL). The organic layers were 
combined, dried over magnesium sulphate and the solvent removed in vacuo to yield 
the crude product as a yellow oil which was further purified by column chromatography 
to give MIDA boronate (75) as a colourless solid (20 mg, 8%). δB (128 MHz CD3CN) 
11.70; δH (700 MHz CD3CN) 2.46 (6 H, s, H-15 ), 3.30 (2 H, s, H-7), 3.78 (4 H, s, H-8), 
3.97 (8 H, m, H-14), 5.11 (2H, s, H-5), 7.38 (13 H, m, H1-3 and H10-11); δC (176 MHz 
CD3CN)* 48.4, 54.5, 58.5, 62.7, 66.7, 129.1, 129.1, 129.4, 129.5, 133.4, 137.4, 141.3, 
169.5, 171.9; HRMS (ESI+) C33H3610B2N3O10+ ([M+H]+) requires 654.2659; found 
654.2662. 
*Missing peak corresponding to 1 x quaternary carbon 
Spectra can be found in Appendix A. 
 
6.4 Peptoid Synthesis 
Solid phase sub-monomer synthesis of peptoids is detailed here.1 Amines used for 
peptoid synthesis were N-(tert-Butoxycarbonyl)-1,4-diaminobutane for Nlys side-
chains, benzylamine for Nphe side-chains, 4-chlorobenzylamine for Npcb side-chains, 
4-methoxybenzylamine for Npmb side-chains, 3-iodobenzylamine and 4-iodoaniline.  
6.4.1 Rink Amide resin: 
Fmoc-protected Rink Amide resin (normally 100–300 mg, 0.1–0.2 mmol, typical loading 
between 0.6 – 0.8 mmol g-1) was swollen in DMF (at least 1 hour, overnight preferred, 
at room temperature) in a 20 mL polypropylene syringe fitted with two polyethylene 
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frits. The resin was deprotected with piperidine (20 % in DMF v/v, 2 x 20 min) and 
washed with DMF (5 x 2 mL). The resin was treated with bromoacetic acid (2 mL, 0.6 
M in DMF) and DIC (0.20 mL, 50 % v/v in DMF) for 20 minutes at room temperature at 
400 rpm. The resin was washed with DMF (5 x 2 mL), before the desired amine sub-
monomer was added (2 mL, 0.8–2.0 M in DMF) and allowed to react for 60 minutes at 
room temperature on the shaker. The resin was again washed with DMF (5 x 2 mL) 
and the bromoacetylation and amine displacement steps were repeated until the final 
submonomer had been added and the desired peptoid sequence had been obtained. 
The resin was shrunk in diethyl ether to remove DMF in preparation for cleavage, as 
described in Section 6.7.1 and purified using RP-HPLC as described in Section 6.7.1. 
If further modification of the peptoid was required, the resin was covered with DMF until 
required. If the peptoid was to be left for more than a day, the resin was washed with 
diethyl ether (5 x 2 mL) and stored in the fridge. 
6.4.2 2-Chlorotrityl chloride resin: 
2-Chlorotrityl chloride resin (normally 100–250 mg, 0.1–0.2 mmol, typical loading 1.22 
mmol g-1) was swollen in dry DCM (45 minutes at room temperature) in a 20 mL 
polypropylene syringe fitted with two polyethylene frits. The resin was washed with dry 
DCM (3 x 2 mL) and loaded with bromoacetic acid (2 mL, 0.6 M in DMF) and neat 
DIPEA (16 eq. with respect to the resin) for 30 minutes at RT on a shaker at 400 rpm. 
The resin was washed with DMF (5 x 2 mL), before the desired amine sub-monomer 
was added (2 mL, 1.5 M in DMF) and allowed to react for 60 minutes at RT on the 
shaker. The resin was again washed with DMF (5 x 2 mL) and the resin was treated 
with bromoacetic acid (2 mL, 0.6 M in DMF) and DIC (0.2 mL, 50 % v/v in DMF) for 20 
minutes at RT on the shaker. The resin was washed again with DMF (3 x 2 mL) and 
amine displacement and bromoacetylation steps repeated until the final sub-monomer 
had been added and the desired linear peptoid had been obtained. The resin was 
shrunk in diethyl ether to remove DMF in preparation for cleavage, as described in 
Section 6.7.  If further modification of the peptoid was required, the resin was covered 
with DCM until required. If the peptoid was to be left for more than a day, the resin was 
washed with diethyl ether (5 x 2 mL) and stored in the fridge. 
6.4.3 Addition of 3- or 4- carboxyphenylboronic acid MIDA ester 
The resin-bound peptoid was treated with a solution of 3- or 4- carboxyphenyl boronic 
acid MIDA ester (8 eq. with respect to the resin, in DMF) and DIC (0.4 mL, 50 % v/v in 
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DMF) and left for 1 hour at RT on the shaker. Following this, the resin was washed with 
DMF (5 x 2 mL) and then left suspended in DMF until ready for attempted cyclisation. 
6.4.4 Addition of glycine residue or glycine-glycine spacer to N terminus 
of peptoids 
The linear peptoid was synthesised via manual SPPS, as in Sections 6.4.1 or Section 
6.4.2 and the glycine spacer added as follows. Peptoids on resin were swollen in DMF 
in a polypropylene syringe fitted with a polyethylene frit (at least 1 hour, overnight 
preferred, at RT). DIPEA (5 equivalents with respect to the resin) was added to a 
solution Fmoc-protected glycine (5 equivalents with respect to the resin, dissolved in 
the miniumum amount of DMF) and PyBOP (5 equivalents with respect to the resin in 
DMF). The DIPEA/PyBOP/glycine solution (2.0 mL) was then added to the resin bound 
peptoid and left for 1 hour at 25 ˚C on a shaker at 400 rpm. The resin was washed with 
DMF (5 x 2 mL) and treated with piperidine (20 % in DMF v/v, 2 x 20 minutes) and then 
washed with DMF (5 x 2 mL). Where the aim was addition of a glycine-glycine spacer, 
the procedure was repeated. Otherwise the peptoid was suspended in DMF in 
preparation for the addition of 3- or 4- carboxyphenyl boronic acid MIDA ester. 
6.4.5 On-resin Suzuki-Miyaura cross-coupling 
6.4.5.1 Intermolecular cross-coupling: synthesis of linear peptoid 106 
Following removal of DMF, the resin-bound peptoid 105 (0.1 mmol) was treated with a 
mixture of tetrakis palladium (6 mg, 5.0 mol %), potassium carbonate (138 mg, 1.0 
mmol), SPhos (4 mg, 0.01 mmol) in DMF (2 mL) and iodobenzene (0.11 mL, 1.0 mmol) 
and heated at 80 ˚C on the shaker at 400 rpm for 8 hours. The solution phase was 
removed by filtration and the resin washed with DMF (5 x 2 mL), DCM (5 x 2 mL), 
methanol (5 x 2 mL), water (5 x 2 mL), methanol 5 x 2 mL), DCM (5 x 2 mL) and diethyl 
ether (5 x 2 mL). Following cleavage from the resin and lyophilisation as described in 
Section 6.7.1, the crude peptoid was purified by RP-HPLC as described in Section 
6.8.1 to give the linear peptoid (106) as a white solid. Characterisation data can be 
found in Section 6.10, Table 6.1 and Appendix B. 
6.4.5.2 Intramolecular cross-coupling: synthesis of cyclic peptoids  
Following removal of DMF, the resin-bound peptoid (0.1 mmol) was treated with a 
mixture of tetrakis palladium (6 mg, 5.0 mol %), potassium carbonate (138 mg, 1.0 
mmol) and SPhos (4 mg, 0.01 mmol) in DMF (2 mL) and heated at 80 ˚C on the shaker 
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at 400 rpm for 8 hours. The solution phase was removed by filtration and the resin 
washed with DMF (5 x 2 mL), DCM (5 x 2 mL), methanol (5 x 2 mL), water (5 x 2 mL), 
methanol (5 x 2 mL), DCM (5 x 2 mL) and diethyl ether (5 x 2 mL). Following cleavage 
from the resin and lyophilisation as described in Section 6.7.1), the crude peptoid was 
purified by RP-HPLC as described in Section 6.8.1 to give the cyclic peptoid as a white 
solid. Characterisation data can be found in Section 6.10, Table 6.1 and Appendix B. 
 
6.5 Solid Phase Peptide Synthesis 
Fmoc SPPS procedures are detailed in the following sections. Amino acid side chain 
functionality was protected as follows: Fmoc-D-Ala-OH, Fmoc-allylglycine-OH Fmoc-
Arg(Pbf)-OH, Fmoc-Cys(Acm)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-
OH, Fmoc-Leu-OH, Fmoc-D-Leu-OH, Fmoc-D-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Pro-
OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Trp(Boc)-OH,. Fmoc deprotections 
were carried out using a 20 % (v/v) solution of piperidine in DMF. 
6.5.1 Loading procedures 
Rink Amide Resin 
Fmoc-protected Rink Amide resin (normally 100–300 mg, 0.1–0.2 mmol, typical loading 
between 0.6 – 0.8 mmol g-1) was swollen in DMF (at least 1 hour, overnight preferred, 
at room temperature) in a 20 mL polypropylene syringe fitted with two polyethylene 
frits. The resin was deprotected with piperidine (20 % in DMF v/v, 2 x 20 min) and 
washed with DMF (5 x 2 mL). DIPEA (5 equivalents with respect to the resin) was 
added to a solution. Fmoc-protected allylglycine (5 equivalents with respect to the 
resin, dissolved in the miniumum amount of DMF) and PyBOP (5 equivalents with 
respect to the resin in DMF). The DIPEA/PyBOP/glycine solution (2.0 mL) was then 
added to the resin bound peptoid and left for 1 hour at RT on a shaker at 400 rpm. The 
resin was washed with DMF (5 x 2 mL) and treated with piperidine (20 % in DMF v/v, 2 
x 20 minutes) and then washed with DMF (5 x 2 mL). Peptide synthesis then 
proceeded as detailed in Section 6.5.2. 
2-Chlorotrityl Chloride Resin 
2-Chlorotrityl chloride resin (normally 100–250 mg, 0.1–0.2 mmol, typical loading 1.22 
mmol g-1) was swollen in dry DCM (45 minutes at room temperature) in a 20 mL 
polypropylene syringe fitted with two polyethylene frits. The resin was washed with dry 
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DCM (3 x 2 mL) and loaded with Fmoc-Cys(Acm)-OH or Fmoc-Cys(Trt)-OH (2.5 
equivalents with respect to the resin, dissolved in the minimum amount of DCM) and 
neat DIPEA (2.5 eq. with respect to the resin) for 30 minutes at RT on a shaker at 400 
rpm. The resin was then washed with DMF (5 x 2 mL) and treated with a 2:1 solution of 
DCM:MeOH with DIPEA (2.5 equivalents with respect to the resin) for 10 minutes on 
the shaker. Peptide synthesis then proceeded as detailed in Section 6.5.2. 
6.5.2 Peptide Synthesis 
Peptide synthesis was either carried out directly onto the resin (see Section 6.5.1 for 
loading procedures) or onto a linear peptoid sequence with a terminal glycine-glycine 
spacer (see Sections 6.4.2 and 6.4.4). If not already swollen, the sequence on resin 
was swollen in DMF if on Rink Amide resin, DCM if on 2-chlorotrityl chloride resin, in a 
polypropylene syringe fitted with a polyethylene frit (at least 1 hour, overnight preferred, 
at RT). The resin was washed with DMF x 5. DIPEA (5 equivalents with respect to the 
resin) was added to a solution of Fmoc-protected amino acid (5 equivalents with 
respect to the resin) and PyBOP (5 equivalents with respect to the resin) in the 
minimum amount of DMF. The DIPEA/PyBOP/amino acid solution (2.0 mL) was 
immediately added to the resin bound peptoid and left for 1 hour at RT on a shaker at 
400 rpm. The resin was washed with DMF (5 x 2 mL) and treated with piperidine (20 % 
in DMF v/v, 2 x 20 minutes) and then washed with DMF (5 x 2 mL). Further amino acid 
couplings and Fmoc-deprotection steps were made as necessary. The resin was 
washed with DMF (5 x 2 mL) and diethyl ether (5 x 2 mL) prior to cleavage from the 
resin as described in Section 6.7 and purification by RP-HPLC as described in 
Section 6.8.1. If further modification of the peptoid was required, the resin was covered 
with DMF (for Rink Amide resin) or DCM (for 2-chlorotrityl chloride resin) until required. 
If the peptoid was to be left for more than a day, the resin was washed with diethyl 
ether (5 x 2 mL) and stored in the fridge. 
6.5.3 Addition of 5-Hexynoic Acid Monomers 
The linear peptide was synthesised via manual SPPS, as in Section 6.5.2 and 5-
hexynoic acid added as follows. Peptides on resin were swollen in DCM in a 
polypropylene syringe fitted with a polyethylene frit (at least 1 hour, overnight preferred, 
at RT). The resin was washed with DMF x 5 and DIPEA (5 equivalents with respect to 
the resin) was added to a solution 5-hexynoic acid (5 equivalents with respect to the 
resin) and PyBOP (5 equivalents with respect to the resin) in the minimum amount of 
DMF. The DIPEA/PyBOP/5-hexynoic acid solution (2.0 mL) was immediately added to 
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the resin bound peptide and left for 1 hour at 25 ˚C on a shaker at 400 rpm. The resin 
was washed with DMF (5 x 2 mL) and another addition of DIPEA/PyBOP/5-hexynoic 
acid solution (2.0 mL) was carried out. After washing with DMF (5 x 2 mL), the resin 
was washed with diethyl ether (5 x 2 mL) and a portion cleaved from the resin  as 
described in Section 6.7.1. 
6.5.4 Synthesis of linear p15 peptide with Acm-protected cysteine (136) 
The peptide was synthesised on 2-chlorotrityl chloride resin and loaded with Fmoc-
Cys(Acm)-OH as described in Section 6.5.1 on an 0.2 mmol scale with respect to the 
resin. The Fmoc group was deprotected by addition of piperidine (20 % in DMF v/v, 2 x 
20 minutes) and the resin washed with DMF x 5. DIPEA (5 equivalents with respect to 
the resin) was added to a solution of Fmoc-Thr(tBu)-OH (5 equivalents with respect to 
the resin) and PyBOP (5 equivalents with respect to the resin) in the minimum amount 
of DMF. The DIPEA/PyBOP/amino acid solution (2.0 mL) was immediately added to 
the resin bound peptoid and left for 1 hour at RT on a shaker at 400 rpm. The resin was 
washed with DMF (5 x 2 mL) and treated with piperidine (20 % in DMF v/v, 2 x 20 
minutes) and then washed with DMF (5 x 2 mL). Further amino acid couplings and 
Fmoc-deprotection steps were made as necessary. Fmoc-Ser(tBu) and Fmoc-
Cys(Acm)-OH underwent double coupling. The resin was washed with DMF (5 x 2 mL). 
The peptide was then cyclised according to Section 6.6.1. A portion of the resin was 
washed with diethyl ether (5 x 2 mL) prior to test cleavage from the resin as described 
in Section 6.7).  
6.5.5 Synthesis of linear p15 peptide with Trt-protected cysteine (147) 
The peptide was synthesised on 2-chlorotrityl chloride resin and loaded with Fmoc-
Cys(Trt)-OH as described in Section 6.5.1 on an 0.2 mmol scale with respect to the 
resin. The Fmoc group was deprotected by addition of piperidine (20 % in DMF v/v, 2 x 
20 minutes) and the resin washed with DMF x 5. DIPEA (5 equivalents with respect to 
the resin) was added to a solution of Fmoc-Thr(tBu)-OH (5 equivalents with respect to 
the resin) and PyBOP (5 equivalents with respect to the resin) in the minimum amount 
of DMF. The DIPEA/PyBOP/amino acid solution (2.0 mL) was immediately added to 
the resin bound peptoid and left for 1 hour at RT on a shaker at 400 rpm. The resin was 
washed with DMF (5 x 2 mL) and treated with piperidine (20 % in DMF v/v, 2 x 20 
minutes) and then washed with DMF (5 x 2 mL). Further amino acid couplings and 
Fmoc-deprotection steps were made as necessary. Fmoc-Ser(tBu) and Fmoc-Cys(Trt)-
OH underwent double coupling. The resin was washed with DMF (5 x 2 mL). The resin 
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was washed with diethyl ether (5 x 2 mL) prior to cleavage from the resin as described 
in Section 6.7.1 and hexafluorobenzene stapling as described in Section 6.6.2. 
6.5.6 Synthesis of linear allylglycine p15 peptide analogue (150) 
The peptide was synthesised on Rink Amide resin and loaded with Fmoc-allylglycine-
OH as described in Section 6.5.1 on an 0.2 mmol scale with respect to the resin. The 
initial allylglycine coupling step was repeated and the resin washed with DMF x 5. The 
Fmoc group was deprotected by addition of piperidine (20 % in DMF v/v, 2 x 20 
minutes) and the resin washed with DMF x 5. DIPEA (5 equivalents with respect to the 
resin) was added to a solution of Fmoc-Thr(tBu)-OH (5 equivalents with respect to the 
resin) and PyBOP (5 equivalents with respect to the resin) in the minimum amount of 
DMF. The DIPEA/PyBOP/amino acid solution (2.0 mL) was immediately added to the 
resin bound peptoid and left for 1 hour at RT on a shaker at 400 rpm. The resin was 
washed with DMF (5 x 2 mL) and treated with piperidine (20 % in DMF v/v, 2 x 20 
minutes) and then washed with DMF (5 x 2 mL). Further amino acid couplings and 
Fmoc-deprotection steps were made as necessary. Fmoc-Ser(tBu) and Fmoc-
allylglycine-OH underwent double coupling. The resin was washed with DMF (5 x 2 
mL). The peptide was then cyclised according to Section 6.6.3. A portion of the resin 
was washed with diethyl ether (5 x 2 mL) prior to test cleavage from the resin as 
described in Section 6.7.1.  
6.5.7 Synthesis of KLA-peptoid hybrids  
(Note: Peptide synthesis and purification was carried out by Jingyi Zong at Durham University). 
Peptoids were synthesised on Rink Amide resin as described in Section 6.4.1 on an 
0.1 mmol scale. Following addition of two glycine residues as described in Section 
6.4.4, the peptide sequence was synthesised as described in Section 6.5.2. Peptide-
peptoids were cleaved from the resin as described in Section 6.7.1 and purified by RP-
HPLC as described in Section 6.8.1. LCMS and MALDI data can be found in Section 
6.10, Table 6.3 and Appendix D. 
 
6.5.8 Synthesis of Rhod-KLA-CPPo6  
(Note: Procedure carried out by Jingyi Zong at Durham University). 
CPPo6 was synthesised on Rink Amide resin as described in Section 6.4.1 on a 0.03 
mmol scale. Following addition of two glycine residues as described in Section 6.4.4, 
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the peptide sequence was synthesised as described in Section 6.5.2.  The Rhodamine 
(59.6 mg, 0.125 mmol, 5.0 equiv) was coupled by addition of DIC (31.9μL, 0.125 mmol, 
5.0 equiv) and HOBt (16.9 mg, 0.125 mmol, 5.0 equiv) in DMF and incubated for 1 hour 
at RT. Rhodamine coupling was repeated to ensure the completion of the reaction. The 
final product was cleaved by addition of trifluoroacetic acid (95% in CH2Cl2) and 
incubated for 2.5 hours. The cleavage solution was filtered and the resin was 
thoroughly washed with MeOH. This procedure of adding cleavage solution and rinsing 
with methanol was repeated until the cleavage solution was colourless. The cleavage 
solution was diluted with water and lyophilised to give the crude product. HRMS and 
MALDI data can be found in Section 6.10, Table 6.3, and in Appendix D. 
6.5.9 Synthesis of p15-peptoid hybrids 
Peptoids were synthesised on 2-chlorotrityl resin as described in Section 6.4.2. A 
portion of the resin was washed with diethyl ether x 5 prior to cleavage as described in 
Section 6.7.3. Following addition of two glycine residues as described in Section 
6.4.4, the peptide sequence was synthesised as described in Section 6.5.2. Addition of 
5-hexynoic acid was carried out as described in Section 6.5.3. The resin was washed 
with diethyl ether x 5, a portion set aside for test cleavage as described in Section 6.6 
and the remainder sent to Hong Kong Polytechnic University. MALDI data can be found 
in Section 6.10, Table 6.4 and in Appendix E. 
6.6 Peptide post-translational modifications 
6.6.1 Disulphide bridge formation 
The linear peptide was synthesised on 2-chlorotrityl chloride and loaded with Fmoc-
Cys(Acm)-OH as described in Section 6.5.4. A solution of iodine (127 mg, 1.0 mmol) in 
DCM (1 mL) and DIPEA (0.18 mL, 1.0 mmol) was added to the resin-bound peptide 
(0.1 mmol) and left on the shaker at 400 rpm for 90 minutes. The peptide was washed 
with DCM x 5, DMF x 5 and diethyl ether x5 prior to cleavage from the resin as 
described in Section 6.7.1 and purification as described in Section 6.8.1. Cyclised p15 
(126) was obtained as a white powder in 19% yield. Characterisation data can be found 
in Section 6.10, Table 6.2 and in Appendix C. 
6.6.2 Hexafluorobenzene stapling 
The linear peptide was synthesised on 2-chlorotrityl chloride and loaded with Fmoc-
Cys(Trt)-OH as described in Section 6.5.5. The cleaved, fully deprotected, crude 
peptide (12 mg, 0.01 mmol) was dissolved in 1 mL of DIPEA (50 mM) in DMF and 
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hexafluorobenzene (0.006 mL, 0.05 mmol) was added and the reaction mixture left on 
the shaker at 400rpm for 4 hours at room temperature. The DMF was removed in 
vacuo and the crude peptide was purified by HPLC, as described in Section 6.8.1 to 
give F-p15 (127) as a white powder in 32% yield. Characterisation data can be found in 
Section 6.10, Table 6.2 and in Appendix C. 
6.6.3 Grubbs Ring-Closing Metathesis of peptides 
The linear peptide was synthesised on Rink Amide resin as described in Section 6.5.6. 
The linear peptide was washed with DCM (3 x 2 mL) and DCE (3 x 2 mL). The 
Hoveyda-Grubbs 2nd generation catalyst (20 mol%) was dissolved in 2 mL of a solution 
of DCE containing 10% LiCl (0.4M) in DMF. This catalyst solution was added to the 
resin-bound linear peptide and the mixture stirred at 80 °C for 48 hours. The peptide 
was washed with DCE (5 x 2 mL), DCM (5 x 2mL), MeOH (5 x 2mL), water (5 x 2 mL), 
MeOH (5 x 2 mL), DCM (5 x 2 mL), DMF (5 x 2 mL) and diethyl ether (5 x 2 mL) before 
being cleaved from the resin as described in Section 6.7.2 and purified by HPLC as 
described in Section 6.8.1 to give C=C p15 (128) as a white powder in 11% yield. 
Characterisation data can be found in Section 6.10, Table 6.2 and in Appendix C. 
 
6.6.4 Hydrogenation of C=C stapled peptides 
C=C p15 (129) was synthesised as described in Sections 6.5.6 and 6.6.2. Hydrogen 
was passed over a stirred mixture of the cleaved, purified peptide and palladium on 
carbon in ethanol for 2 hours at room temperature and the progress of the reaction 
monitored by LCMS. On completion of the reaction, the reaction mixture was 
centrifuged at 13400 rpm for 5 minutes, the supernatant transferred to a round-
bottomed flask and ethanol removed in vacuo to afford the pure C-C stapled peptide 
(129) as a white powder in 50% yield with respect to the starting C=C p15 peptide 
(128). Characterisation data can be found in Section 6.10, Table 6.2 and in Appendix 
C. 
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6.7 Cleavage from acid-labile resins 
6.7.1 Rink Amide Resin or 2-Chlorotrityl chloride resin when simultaneous 
deprotection of side-chains is desired 
Final cleavage from resin was achieved using TFA (95 %), H2O (5 %) and TIPS (5 %). 
For test cleaves approximately 1 mL of the cleavage cocktail was used and for 
cleavage from 100 mg resin, approximately 4 mL of the cleavage cocktail was added. 
The resin was then placed on the shaker at 400 rpm for 2 hours for peptoids and 4 
hours for peptides and the resin removed by filtration. The cleavage cocktail was 
removed in vacuo, the crude product precipitated in diethyl ether (45 mL) and the 
precipitate retrieved by trituration. The crude product was dissolved in a mixture of 
acidified H2O and MeCN and lyophilised. 
6.7.2 Rink Amide resin or 2-Chlorotrityl chloride resin when simultaneous 
deprotection of side-chains is desired and avoidance of methionine 
oxidation is necessary 
Final cleavage from resin was achieved using TFA (94 %), EDT (2.5 %), H2O (2.5 %) 
and TIPS (1 %). For test cleaves approximately 1 mL of the cleavage cocktail was used 
and for cleavage from 100 mg resin, approximately 4 mL of the cleavage cocktail was 
added. The resin was then placed on the shaker at 400 rpm for 4 hours and the resin 
removed by filtration. The cleavage cocktail was removed in vacuo, the crude product 
precipitated in diethyl ether (45 mL) and the precipitate retrieved by trituration. The 
crude product was dissolved in a mixture of acidified H2O and MeCN and lyophilised. 
6.7.3 2-Chlorotrityl Chloride Resin leaving acid labile side-chain protecting 
groups intact 
Final cleavage from resin was achieved using hexafluoroisopropanol in DCM (20 % 
v/v). For test cleaves approximately 1 mL of the cleavage cocktail was used and for 
cleavage from 100 mg resin, approximately 4 mL of the cleavage cocktail was added. 
The resin was then placed on the shaker at 400 rpm for 30 minutes and the resin 
removed by filtration. The cleavage cocktail was removed in vacuo, the crude product 
dissolved in a mixture of H2O and MeCN and lyophilised. 
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6.8 Purification Procedures 
6.8.1 Preparative high performance liquid chromatography 
Preparative RP-HPLC was performed with a semi-preparative Perkin Elmer Series 200 
LC pump fitted with a 785A UV/Vis detector using a SB-Analytical ODH-S optimal 
column (250 × 10 mm, 5 Cm); flow rate 2 ml min−1; linear gradient elution 0-50% of 
solvent B over 60 min, then 50-100% of solvent B over 30 min (A = 0.1% TFA in 95% 
H2O and 5% MeCN, B = 0.1% TFA in 5% H2O and 95% MeCN) with detection at 280 
nm. Relevant fractions were collected, lyophilised and analysed by LC-MS. 
6.8.2 Analytical high performance liquid chromatography 
Samples were dissolved in 100 μL acidified water and the purity of products was 
estimated by an injection of 50 μL to analytical RP-HPLC using a Perkin Elmer 200 
Series LC pump with a Perkin-Elmer 785A UV-vis detector on an SB Analytical column 
(ODS-H Optimal), 4.6 x 100mm , 3.5 μm; flow rate = 1 mL min-1; loop size = 20 μL; λ = 
280 nm; gradient: 0–100 % solvent B over 30 min (solvent A: 95 % H2O, 5 % MeCN, 
0.05 % TFA; solvent B: 95 % MeCN, 5 % H2O, 0.03 % TFA). 
6.9 Biological Experiments 
6.9.1 Antibacterial Testing against S. aureus and E. coli 
6.9.1.1 Bacterial culture preparation 
Escherichia coli K-12 wild-type strain (W3110 / ATCC27325, F-, λ-, rpoS(Am), rph-
1,Inv(rrnD-rrnE)), Staphylococcus aureus (3R7089 strain Oxford / ATCC9144) were 
selected for bacteriological studies as representative Gram-negative (E. coli) and 
Gram-positive (S. aureus)species. Bacterial cultures were prepared by streaking 
bacterial strains onto LB agar plates with an inoculation loop and incubated overnight 
at 37°C. A single colony was selected and placed in 5 mL of Iso-sensitest broth (Oxoid, 
ThermoScientific) and incubated with shaking for 16–18 h at 37 °C to provide liquid 
cultures for testing. 
6.9.1.2 Antibacterial plate preparation 
Plates were prepared according to the previously described protocol for MIC 
determination.2 Testing was conducted in 96-well plates (Sarsted, Fisher Scientific). 
Bacteria were grown from overnight cultures in Iso-sensitest broth to an A650nm of 
0.07 equivalent to a 0.5 MacFarland standard (240 μM BaCl2 in 0.18 M H2SO4). This 
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culture was diluted ten-fold with Iso-sensitest broth before use. Peptoids were initially 
dissolved in water (300 μL) and diluted further in Iso-sensitest broth (150 μL) to 
achieve maximum concentrations to test the available peptoids in triplicate at a single 
concentration each (Table 2.2).  50 μL of inoculum and 50 μL of peptoid solution were 
added to each test well. Experiments were performed in triplicate. A positive control for 
bacterial growth contained only the inoculum and Isosensitest broth. A sterile control 
contained only isosensitest broth (100 μL). The plates were incubated at 37 °C for 16 h 
with shaking. Quantitative data was attained from absorbance values using a Biotek 
Synergy H4 plate reader. 
6.9.2 Bio-layer interferometry (BLI) binding assays 
(Note: BLI assays were carried out by the Law group at The Hong Kong Polytechnic University). 
The binding kinetics of B23-peptides to recombinant human B23 protein was 
determined using BLI on Octet RED (FortéBio, Shanghai, China) following 
manufacturer protocol. All the interaction analyses were performed at 30°C in PBS 
0.2% DMSO buffer. Loading of Nickel-charged Tris-NTA (Ni-NTA) biosensors 
(FortéBio) was conducted by exposing His-tagged B23 containing 0.1mg/mL to 
biosensor tips for two hours. The 96-well microplates used in the Octet were filled with 
200μl of sample or buffer per well and agitated at 1000 rpm. The loaded biosensors 
were washed in buffer for 600 seconds and transferred to the wells containing 30µg 
B23 peptides in buffer, respectively. The association and dissociation was observed for 
100 seconds for each sample. 
6.9.3 Cell culture  
Human cervical carcinoma HeLa cells were purchased from the American type Culture 
Collection (ATCC) (#CCL-185, ATCC, Manassas, VA, USA). The HeLa cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin and streptomycin at 37°C and 5% CO2.  
6.9.4 MTT assay  
(Note: MTT experiments were carried out by Lijun Jiang at Hong Kong Baptist University). 
Cells (105per sample) were incubated in a 96 well-plate overnight. Afterwards, HeLa or 
MRC-5 cells treated with the peptide or peptoidfor 24 hours were further incubated in 
dark for 24h. Cell viability was determined by the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2-H-tetrazolium bromide (MTT) reduction assay. The cell monolayers were 
rinsed with PBS and then incubated with 0.5 mg/ml MTT solution for 3h (5% CO2, 
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37°C). The formazan crystal formed was dissolved in DMSO and the absorbance of 
dissolved formazan crystal at 540 and 690 nm was measured using a 96 -well plate 
reader (ELx800 Absorbance Microplate Reader). 
6.9.5 Flow cytometry analysis on cellular uptake  
(Note: Flow cytometry was carried out by the Wong group at Hong Kong Baptist University). 
Cells (105 per sample) were seeded to 35 mm Petri dish for overnight and then the 
cells were incubated with Rhod-KLA-CPPo6. Afterwards cells were trypsinized and 
washed twice with phosphate -buffered saline (PBS). The Rhod-KLA-CPP06’s uptake 
by cells was analysed by flow cytometry. The cells were excited with 488 nm argon 
laser and emission was collected with FL - 3 (equipped with 650 nm long pass filter) 
and 10000 events were analysed.  
6.9.6 Confocal microscopic imaging  
(Note: Confocal microscopy was carried out by the Wong group at Hong Kong Baptist 
University). 
Cells were seeded onto coverslip in 35 mm culture dishes overnight. The cells were 
initially incubated with Rhod-KLA-CPPo6 for 30 min in the dark. The emitted 
fluorescent signals were examined using a Leica SP5 (upright configuration) confocal 
microscope equipped with argon laser, HeCd laser and a femtosecond - pulsed Ti: 
Sapphire laser (Libra II, Coherent) inside the tissue culture chamber (5% CO2, 37 °C). 
A 40*oil immersion objective and a pinhole size of 110 μm was used for image 
capturing. 
 
 
 
 
 
 
 
 
Chapter 6: Experimental 
 
223 
6.10 Characterisation of Peptides and Peptoids: Tables 
Table 6.1 Biaryl-containing peptoids 
Compound number 
Accurate Mass 
Calculated [M+H]+ Observed [M+H]+ 
106 454.2818 454.2819 
104 651.3982 651.4004 
110 580.2347 580.3238 
119 651.3982 651.3933 
120 580.2347 580.3260 
121 779.4932 779.4903 
122 708.4197 708.4199 
123 779.4932 779.4959 
124 708.4197 708.4185 
  
Table 6.2 p15 peptides and analogues 
Compound number 
Accurate Mass 
Calculated [M+H]+ Observed [M+H]+ 
126 1288.5389 1288.5404 
127 1436.5326 1436.5377 
128 1249.6265 1249.6272 
129 1251.6421 1251.6460 
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Table 6.3 KLA-CPPo hybrids 
Name 
Accurate Mass 
MALDI-ToF 
Calculated Observed 
D-KLA (199) 1523.0889 = [M+H]+ 1523.0907 1545.9 = [M+Na]+ 
KLA-CPPo1 
(193) 735.1549 = [M+3H]
3+ 735.1545 2203.5 = [M+H]+ 
KLA-CPPo2 
(194) 1085.2479 = [M+2H]
2+ 1085.2368 2191.5 = [M +Na]+ 
KLA-CPPo3 
(195) 1109.7399 = [M+2H]
2+ 1109.7328 2240.5 = [M + Na]+ 
KLA-CPPo4 
(196) 1126.7205 = [M+2H]
2+ 1126.7159 2252.9 = [M + H]+ 
KLA-CPPo5 
(197) 1111.7152 = [M+2H]
2+ 1111.7184 2244.4 = [M + H]+ 
KLA-CPPo6 
(198) 1136.2072 = [M+2H]
2+ 1136.2086 2293.2 = [M + Na]+ 
Rhod-KLA-
CPPo6 (201) 540.3324 = [M+5H]
5+ 540.3219 2696.5 = [M+H]+ 
 
 
Table 6.4 p15-CPPo hybrids (crude) 
Name MALDI-ToF 
Hyx-p15-CPPo7 (222) 2208.5 = [M+H]+ 
Hyx-p15-CPPo8 (223) 2173.4 = [M +H]+ 
Hyx-p15-CPPo9 (224) 2222.7 = [M + H]+ 
Hyx-p15-CPPo9 (225) 2257.3 = [M + H]+ 
Hyx-p15-CPPo10 (226) 2227.1 = [M + H]+ 
Hyx-p15-CPPo11 (227) 2276.1 = [M + H]+ 
 
6.11 References 
1. R. N. Zuckermann, J. M. Kerr, S. B. H. Kent and W. H. Moos, J. Am. Chem. Soc., 1992, 
114, 10646-10647. 
2. J. M. Andrews, J. Antimicrob. Chemother., 2001, 48 Suppl 1, 5-16. 
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1. Spectra of Mono-MIDA boronate (74) 
 
Figure A1 11B NMR of mono-MIDA ester 74.
δB(128 MHz CD3CN) 
  
 
 
Figure A2 1H NMR of mono-MIDA ester 74.
δH(700 MHz CD3CN) 
  
 
 
Figure A3 13C NMR of mono-MIDA ester 74.
δc(176 MHz CD3CN) 
  
 
 
 
  
Figure A4 HRMS of mono-MIDA ester (74), C21H2410BN2O6, calculated [M+H]+ = 410.1764, observed [M+H]+ = 410.1759.
  
 
2. Spectra of Di-MIDA boronate (75) 
 
Figure A5 11B NMR of di-MIDA ester 75.
δB(128 MHz CD3CN) 
  
 
 
Figure A6 1H NMR of di-MIDA ester 75.  
δH(700 MHz CD3CN) 
  
 
 
Figure A7 13C NMR of di-MIDA ester 75.
δc(176 MHz CD3CN) 
  
 
 
 
Figure A8 HRMS of di-MIDA ester (75), C33H3510B2N3O10, calculated [M+H]+ = 654.2659, observed [M+H]+ = 654.2662. 
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1. Linear Biaryl-Containing Peptoid 106 
 
 
 
 
 
 
 
Figure B1 Synthesis of linear biaryl-containing peptoid 106. Synthesis was carried out on Rink 
Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1 and 6.4.3. Suzuki-Miyaura cross-coupling was carried out on a 0.1 mmol scale 
according to procedure and 6.4.5.1. Cleavage and purification was carried out according to 
procedures 6.7.1 and 6.8.1.  
 
 
 
Figure B2 LCMS of crude linear peptoid 105. 
 
 
[M+H]+ = 533 
Retention time = 0.90 
PDA  
λ = 240 nm 
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Figure B3 HRMS of linear biaryl peptoid 106, C25H35N5O3, calculated [M+H]+ = 454.2818, 
observed [M+H]+ = 454.2819. 
 
 
 
 
Figure B4 Analytical HPLC trace of cyclic peptoid 106. Detection at 280 nm. 
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2. Biaryl-Containing Cyclic Peptoid 104 
  
Figure B5 Synthesis of cyclic peptoid 104. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1 and 6.4.3. Cyclisation via Suzuki-Miyaura cross-coupling was carried out on a 
0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried out 
according to procedures 6.7.1 and 6.8.1. 
 
 
 
 
Figure B6 LCMS of crude linear peptoid 103. 
[M+H]+ = 934 
Retention time = 1.73 minutes 
PDA  
λ = 240 nm 
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Figure B7 HRMS of biaryl-containing cyclic peptoid 104, C34H50N8O5, calculated [M+H]+ = 
651.3982, observed [M+H]+ = 651.4004. 
     
 
Figure B8 Analytical HPLC trace of cyclic peptoid 104. Detection at 280 nm. 
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3. Biaryl-Containing Cyclic Peptoid 110 
 
Figure B9 Synthesis of cyclic peptoid 110. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1, 6.4.3 and 6.4.4. Cyclisation via Suzuki-Miyaura cross-coupling was carried 
out on a 0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried 
out according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B10 LCMS of crude linear peptoid 109. 
[M+H]+ = 863 
Retention time = 1.76 minutes 
PDA  
λ = 240 nm 
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Figure B11 HRMS of biaryl-containing cyclic peptoid 110, C30H41N7O5, calculated [M+H]+ = 
580.2347, observed [M+H]+ = 580.3238. 
 
 
Figure B12 Analytical HPLC trace of cyclic peptoid 110. Detection at 280 nm. 
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4. Biaryl-Containing Cyclic Peptoid 119 
 
 
Figure B13: Synthesis of cyclic peptoid 119. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1 and 6.4.3. Cyclisation via Suzuki-Miyaura cross-coupling was carried out on a 
0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried out 
according to procedures 6.7.1 and 6.8.1. 
 
 
Figure B14 LCMS of crude linear peptoid 113. 
[M+H]+ = 934 
Retention time = 1.48 minutes 
PDA  
λ = 240 nm 
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Figure B15 HRMS of biaryl-containing cyclic peptoid 119, C34H50N8O5, calculated [M+H]+ = 
651.3982, observed [M+H]+ = 651.3933. 
 
    
 
Figure B16 Analytical HPLC trace of cyclic peptoid 119. Detection at 280 nm. 
 
0 5 10 15 20 25 30
A
bs
or
ba
nc
e
Retention time /min
Appendix B: Spectra of Biaryl-Containing Peptoids 
 
XXII 
 
5. Biaryl-Containing Cyclic Peptoid 120 
 
 
Figure B17 Synthesis of cyclic peptoid 120. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1, 6.4.3 and 6.4.4. Cyclisation via Suzuki-Miyaura cross-coupling was carried 
out on a 0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried 
out according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B18 LCMS of crude linear peptoid 114. 
[M+H]+ = 863 
Retention time = 1.50 minutes 
PDA  
λ = 240 nm 
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Figure B19 HRMS of biaryl-containing cyclic peptoid 120, C30H41N7O5, calculated [M+H]+ = 
580.2347, observed [M+H]+ = 580.3260. 
       
 
 
Figure B20 Analytical HPLC trace of cyclic peptoid 120. Detection at 280 nm. 
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6. Biaryl-Containing Cyclic Peptoid 121 
 
Figure B21 Synthesis of cyclic peptoid 121. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1 and 6.4.3. Cyclisation via Suzuki-Miyaura cross-coupling was carried out on a 
0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried out 
according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B22 LCMS of crude linear peptoid 115. Peak at 0.925 minutes corresponds to the free 
boronic acid [M+H]+ = 950. 
 
[M+H]+ = 1061 
Retention time = 1.03 minutes 
PDA  
λ = 240 nm 
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Figure B23 HRMS of biaryl-containing cyclic peptoid 121, C40H62N10O6, calculated [M+H]+ = 
779.4932, observed [M+H]+ = 779.4903. 
 
 
 
Figure B24 Analytical HPLC trace of cyclic peptoid 121. Dection at 280 nm. 
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7. Biaryl-Containing Cyclic Peptoid 122 
 
Figure B25 Synthesis of cyclic peptoid 122. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1, 6.4.3 and 6.4.4. Cyclisation via Suzuki-Miyaura cross-coupling was carried 
out on a 0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried 
out according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B26 LCMS of crude linear peptoid 116. 
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Figure B27 HRMS of biaryl-containing cyclic peptoid 122, C36H53N9O6, calculated [M+H]+ = 
708.4197, observed [M+H]+ = 708.4199. 
         
 
Figure B28 Analytical HPLC trace of cyclic peptoid 122. Detection at 280 nm. 
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8. Biaryl-Containing Cyclic Peptoid 123 
 
Figure B29 Synthesis of cyclic peptoid 123. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1 and 6.4.3. Cyclisation via Suzuki-Miyaura cross-coupling was carried out on a 
0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried out 
according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B30 LCMS of crude linear peptoid 117. Peak at 1.08 minutes corresponds to the free 
boronic acid [M+H]+ = 951. 
 
PDA  
λ = 240 nm 
[M+H]+ = 1060 
Retention time = 1.24 minutes 
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Figure B31 HRMS of biaryl-containing cyclic peptoid 123, C40H62N10O6, calculated [M+H]+ = 
779.4932, observed [M+H]+ = 779.4959. 
  
 
Figure B32 Analytical HPLC trace of cyclic peptoid 123. Detection at 280 nm. 
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9. Biaryl-Containing Cyclic Peptoid 124 
 
Figure B33 Synthesis of cyclic peptoid 124. Synthesis of the linear peptoid was carried out on 
Rink Amide resin on a 0.2 mmol scale. Linear peptoid synthesis was carried out according to 
procedures 6.4.1, 6.4.3 and 6.4.4. Cyclisation via Suzuki-Miyaura cross-coupling was carried 
out on a 0.1 mmol scale according to procedure 6.4.5.2. Cleavage and purification was carried 
out according to procedures 6.7.1 and 6.8.1. 
 
 
 
Figure B34 LCMS of crude linear peptoid 118. Peak at 1.08 minutes corresponds to the free 
boronic acid [M+H]+ = 880. 
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Figure B31 HRMS of biaryl-containing cyclic peptoid 124, C36H53N9O6, calculated [M+H]+ = 
708.4197, observed [M+H]+ = 708.4185. 
  
  
Figure B36 Analytical HPLC trace of cyclic peptoid 124.Dection at 280 nm. 
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1. Disulphide-Bridged p15 peptide 126 
 
 
 
 
 
 
 
 
 
Figure C1 Disulphide-bridged p15 peptide. Synthesis of the linear peptide was carried out on 2-
chlorotrityl chloride resin on a 0.2 mmol scale. Linear peptide synthesis was carried out 
according to procedure 6.5.4. Cyclisation via disulphide bridge formation was carried out on a 
0.1 mmol scale according to procedure 6.6.1. Cleavage and purification was carried out 
according to procedures 6.7.2 and 6.8.1. 
 
 
Figure C2 HRMS of disulphide-bridged p15 peptide 126, C54H81N17O14S3, calculated [M+H]+ = 
1288.5389, observed [M+H]+ = 1288.5404. 
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Figure C3 Analytical HPLC trace of p15, 126, detection at 280 nm. 
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2. F-p15 peptide 127 
 
 
Figure C4 F-p15 peptide. Synthesis of the linear peptide was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Linear peptide synthesis was carried out according to 
procedure 6.5.5 and cleaved from the resin according to procedure 6.7.1. Cyclisation via 
hexafluorobenzene stapling was carried out on a 0.1 mmol scale according to procedure 6.6.2. 
Purification was carried out according to procedure 6.8.1. 
 
 
Figure C5 HRMS of F-p15 peptide 127, C60H81F4N17O14S3, calculated [M+H]+ = 1436.5326, 
observed [M+H]+ = 1436.5377. 
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Figure C6 Analytical HPLC trace of F-p15, 127. Detection at 280 nm. 
 
 
Figure C7 19F NMR spectrum of F-p15, 127. Peak at -76.55 ppm arises from TFA.  
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3. C=C p15 peptide 128 
 
 
Figure C8 C=C p15 peptide. Synthesis of the linear peptide was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Linear peptide synthesis was carried out according to 
procedure 6.5.6. Cyclisation via Grubbs’ RCM was carried out on a 0.05 mmol scale according 
to procedure 6.6.3. Cleavage and purification was carried out according to procedures 6.7.2 and 
6.8.1. 
 
 
Figure C9 HRMS of C=C p15 peptide 128, C56H84N18O13S, calculated [M+H]+ = 1249.6265, 
observed [M+H]+ = 1249.6272. 
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Figure C10 Analytical HPLC trace of C=C p15, 128. Detection at 280 nm. 
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4. C-C p15 peptide 129 
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Figure C11 C-C p15 peptide. Peptide 129 was synthesised from C=C p15, 128. Hydrogenation 
of C=C p15 was carried out according to procedure 6.6.4.   
 
 
Figure C12 HRMS of C-C p15 peptide 129, C56H86N18O13S, calculated [M+H]+ = 1251.6421, 
observed [M+H]+ = 1251.6460. 
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Figure C13 Analytical HPLC trace of p15-C-C, 129. Detection at 280 nm. 
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1. D-KLA amide 199 
 
 
H-klakklakklakklak-NH2 
Figure D1 D-KLA amide. Synthesis of the linear peptide was carried out on Rink amide resin. 
Linear peptide synthesis was carried out according to procedure 6.5.1 and 6.5.2. Cleavage and 
purification was carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D2 MALDI-ToF of D-KLA, 199, C72H139N21O14, [M] = 1523.0. 
 
[M+Na]+  
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Figure D3 HRMS of D-KLA, 199, C72H138N21O14, calculated [M+H]+ = 1523.0889, observed 
[M+H]+ = 1523.0907. 
 
 
Figure D4 Analytical HPLC trace of D-KLA, 199. 
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2. KLA-CPPo1 193 
 
 
H-klakklakklakklak-GG-Nlys-Nlys-Npcb-Nlys-NH2 
Figure D5 KLA-CPPo1. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D6 MALDI-ToF of KLA-CPPo1, 193, C103H189ClN30O20, [M] = 2203.3. 
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Figure D7 HRMS of KLA-CPPo1, 193, C103H189ClN30O20, calculated [M+3H]3+ = 735.1549, 
observed [M+3H]3+ = 735.1545. 
 
 
Figure D8 Analytical HPLC trace of KLA-CPPo1, 193. 
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3. KLA-CPPo2 194 
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H-klakklakklakklak-GG-Nlys-Nlys-Nlys-Nphe-NH2 
Figure D9 KLA-CPPo2. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D10 MALDI-ToF of KLA-CPPo2, 194, C103H190N30O20, [M] = 2168.8. 
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Figure D11 HRMS of KLA-CPPo2, 194, C103H190N30O20, calculated [M+2H]2+ = 1085.2479, 
observed [M+2H]2+ = 1085.2368. 
 
 
Figure D12 Analytical HPLC trace of KLA-CPPo2, 194. 
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4. KLA-CPPo3 195 
 
 
H-klakklakklakklak-GG-Npmb-Nlys-Nlys-Nphe-NH2 
Figure D13 KLA-CPPo3. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D14 MALDI-ToF of KLA-CPPo3, 195, C107H189N29O21, [M] = 2217.8. 
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Figure D15 HRMS of KLA-CPPo3, 195, C107H189N29O21, calculated [M+2H]2+ = 1109.7399, 
observed [M+2H]2+ = 1109.7328. 
 
Figure D16 Analytical HPLC trace of KLA-CPPo3, 195.  
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5. KLA-CPPo4 196 
 
H-klakklakklakklak-GG-Npmb-Nlys-Npcb-Nlys-NH2 
Figure D17 KLA-CPPo4. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D18 MALDI-ToF of KLA-CPPo4, 196, C107H188ClN29O21, [M] = 2252.31. 
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Figure D19 HRMS of KLA-CPPo4, 196, C107H188ClN29O21, calculated [M+2H]2+ = 1126.7205, 
observed [M+2H]2+ = 1126.7159. 
 
Figure D20 Analytical HPLC trace of KLA-CPPo4, 196. 
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6. KLA-CPPo5 197 
 
 
H-klakklakklakklak-GG-Nlys-Nlys-Npcb-Nphe-NH2 
Figure D21 KLA-CPPo5. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D22 MALDI-ToF of KLA-CPPo5, 197, C106H186ClN29O20, [M] = 2222.3 
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Figure D23 HRMS of KLA-CPPo5, 197, C106H186ClN29O20, calculated [M+2H]2+ = 1111.7152, 
observed [M+2H]2+ = 1111.7184. 
 
Figure D24 Analytical HPLC trace of KLA-CPPo5, 197. 
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7. KLA-CPPo6 198 
 
H-klakklakklakklak-GG-Npmb-Nlys-Npcb-Nphe-NH2 
Figure D25 KLA-CPPo6. Synthesis of the peptide-peptoid was carried out on Rink amide resin. 
Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Cleavage and purification was 
carried out according to procedures 6.7.1 and 6.8.1. 
 
 
Figure D26 MALDI-ToF of KLA-CPPo6, 198, C110H185ClN28O21, [M] = 2271.3. 
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Figure D27 HRMS of KLA-CPPo6, 198, C110H185ClN28O21, calculated [M+2H]2+ = 1136.2072, 
observed [M+2H]2+ = 1136.2086. 
 
Figure D28 Analytical HPLC trace of KLA-CPPo6, 198. 
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8. Rhod-KLA-CPPo6 201 
 
Rhod-klakklakklakklak-GG-Npmb-Nlys-Npcb-Nphe-NH2 
Figure D29 Rhod-KLA-CPPo6. Synthesis of the peptide-peptoid was carried out on Rink amide 
resin. Peptoid synthesis was first carried out according to procedure 6.4.1 and 6.4.4. Peptide 
synthesis was then carried out according to procedure 6.5.2. Rhodamine was coupled to the 
peptide-peptoid according to procedure 6.5.8. Cleavage and purification was carried out 
according to procedures 6.7.1 and 6.8.1. 
 
Figure D30 MALDI-ToF of Rhod-KLA-CPPo6, 201, C128H214N30O23Cl, [M] = 2695.9.  
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Figure D31 HRMS of Rhod-KLA-CPPo6, 201, C138H213ClN30O23, calculated [M+5H]5+ = 
540.3324, observed [M+5H]5+ = 540.3219. 
 
Figure D32 Analytical HPLC trace of Rhod-KLA-CPPo6, 201 
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1. Hyx-p15-CPPo7 222 (crude) 
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Hyx-CWMSPRHLGTC-GG-Nlys-Nlys-Npcb-Nlys-NH2 
Figure E1 Hyx-p15-CPPo7. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E2 MALDI-ToF of crude Hyx-p15-CPPo7, 222, C97H149ClN28O23S3, [M] = 2207.1. 
[M+H]+  
Appendix E: Spectra of p15-CPPos 
 
LXIII 
 
2. Hyx-p15-CPPo8 223 (crude) 
 
 
Hyx-CWMSPRHLGTC-GG-Nlys-Nlys-Nlys-Nphe-NH2 
Figure E3 Hyx-p15-CPPo8. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E4 MALDI-ToF of crude Hyx-p15-CPPo8, 223, C97H150N28O23S3, [M] = 2172.6. 
[M+H]+  
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3. Hyx-p15-CPPo9 224 (crude) 
 
 
Hyx-CWMSPRHLGTC-GG-Npmb-Nlys-Nlys-Nphe-NH2 
Figure E5 Hyx-p15-CPPo7. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E6 MALDI-ToF of crude Hyx-p15-CPPo9, 224, C101H149N27O24S3, [M] = 2221.7. 
[M+H]+  
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4. Hyx-p15-CPPo10 225 (crude) 
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Hyx-CWMSPRHLGTC-GG-Npmb-Nlys-Npcb-Nlys-NH2 
Figure E7 Hyx-p15-CPPo10. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E8 MALDI-ToF of crude Hyx-p15-CPPo10, 225, C101H148ClN27O24S3, [M] = 2256.1. 
[M+H]+  
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5. Hyx-p15-CPPo11 226 (crude) 
 
 
Hyx-CWMSPRHLGTC-GG-Nlys-Nlys-Npcb-Nphe-NH2 
Figure E9 Hyx-p15-CPPo7. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E10 MALDI-ToF of crude Hyx-p15-CPPo11, 226, C100H146ClN27O23S3, [M] = 2226.1. 
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6. Hyx-p15-CPPo12 227 (crude) 
 
 
Hyx-CWMSPRHLGTC-GG-Npmb-Nlys-Npcb-Nphe-NH2 
Figure E11 Hyx-p15-CPPo7. Synthesis of the peptide-peptoid was carried out on 2-chlorotrityl 
chloride resin on a 0.2 mmol scale. Peptoid synthesis was first carried out according to 
procedure 6.4.2 and 6.4.4. Peptide synthesis was then carried out according to procedure 6.5.2. 
Addition of 5-hexynoic acid was carried out according to procedure 6.5.3. Test cleavages were 
carried out according to procedures 6.7.1 or 6.7.3. 
 
 
Figure E12 MALDI-ToF of crude Hyx-p15-CPPo12, 227, C104H145ClN26O24S3, [M] = 2275.1. 
[M+H]+  
  
 
 
 
 
 
 
 
